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1Version abrégée
Dans le cadre de cette thèse, je présente deux techniques de marquage de protéines par
fluorescence, afin d’étudier in vivo les fonctions du récepteur de la sérotonine 5-HT3 (5-HT3R).
Cette protéine membranaire contient cinq sous-unités formant un canal ionique dont l’ouverture est
induite par la fixation d’un neurotransmetteur spécifique au 5-HT3R.
La première technique, décrite dans la première partie de cette thèse, consiste au marquage du
récepteur par fusion génétique à une protéine fluorescente. J’ai développé des chimères du 5-HT3R
contenant une protéine fluorescente (GFP) par sous-unité, et qui conservent leurs fonctionnalités
biologiques de fixation de ligand et de canal ionique. L’addition d’une dimension visuelle à ce
récepteur permet une grande variété d’expériences, parmi lesquelles je présente la possibilité de
suivre en détail son cycle de vie, de l’assemblage de ses cinq sous-unités dans le réticulum
endoplasmique, sa disposition sur la membrane cellulaire, jusqu’à son internalisation induite par un
ligand. L’imagerie multicolore par microscopie confocale permet en outre de dévoiler l’importance
du cytosquelette pour le transport du récepteur vers la membrane et sa répartition.
La destruction partielle des filaments d’actine engendre la production de fractions de cellules sous
forme de vésicules de diamètres s’échelonnant entre 0.1 et quelques micromètres. La fluorescence
émise par la GFP attachée au 5-HT3R permet d’observer que ces “vésicules natives” contiennent à
leur surface les protéines membranaires originant de la cellule. Je montre que l’activité ionique liée
à ces récepteurs peut être mesurée par fluorescence sur les vésicules, et que ces dernières peuvent
potentiellement remplacer les cellules entières pour analyser les fonctions de base du récepteur.
Je démontre également que la fixation extracellulaire d’un ligand sur le récepteur induit un
changement de conformation transmembranaire du récepteur mesurable par la fluorescence des
protéines de marquage situées dans le domaine intracellulaire du récepteur.
Dans la deuxième partie de cette thèse, j’étudie une technique basée sur l’utilisation d’ARNt
suppresseurs mis-acylés permettant l’incorporation d’acides aminés artificiels fluorescents dans une
protéine. Je parviens à adapter cette technique à une utilisation dans des cellules CHO, et obtiens
une efficacité d’incorporation de l’ordre de 15%. Une méthode originale est également développée
afin de quantifier dans différentes cellules la suppression naturelle, permettant de définir pour
chaque lignée cellulaire la paire codon-anticodon la mieux adaptée à la technique d’ARNt
suppresseur. Finalement, je présente une nouvelle stratégie permettant d’améliorer l’efficacité
d’incorporation d’acides aminés artificiels en diminuant in vivo la quantité d’eRF1 par le biais
d’ARN interférents.
2Summary
In this thesis, two different fluorescent labeling techniques for in vivo investigations on the 5-HT3
receptor (5-HT3R) functions are presented. This plasma membrane protein contains five subunits
surrounding an ion channel that opens after binding of a 5-HT3-specific neurotransmitter.
The first technique, described in the first part of this report, focuses on receptor labeling via genetic
fusion to spectral variants of the green fluorescent protein. I found that the resulting chimeras
containing one fluorescent protein per subunit exhibit preserved ligand binding and channel
activity, opening a wide range of biological research applications. Among these, I present the
possibility to follow the 5-HT3R trafficking and localization during its entire life cycle by
multicolor imaging in live cells, starting with its cytoplasmic biogenesis and ending with its ligand-
induced internalization. The intracellular subunit assembly is shown to occur in the endoplasmic
reticulum, and the importance of the cytoskeleton microtubules for proper membrane targeting is
unraveled.
The utility of bioluminescent 5-HT3R contructs was also demonstrated in another approach using
the chemical disruption of cellular actin filaments to produce vesicular fractions of cells, in the
order of 0.1 to a few micrometers in diameter. These so-called native vesicles, containing the
labeled receptors in their membrane, were shown to be suitable for measurements using
fluorescence confocal microscopy of ligand binding and of ion influx, opening new possibilities for
miniaturized bioanalytics.
In a third approach, I demonstrated that after detergent-solubilization of the receptor, the green
fluorescent protein (GFP) inserted into the receptor sequence permitted to monitor ligand binding
via fluorescence resonance energy transfer (FRET). Furthermore, I could observe a spatial
reorientation of the receptor GFPs upon binding an agonist to the receptor.
In the second part of this thesis, I adapted the mis-acylated suppressor tRNA technology to
mammalian cells, permitting the introduction of unnatural amino acids at specific positions in the
protein of interest. I achieved an efficiency of amino acid incorporation using in vitro
aminoacylated suppressor tRNA in the order of 15% in CHO cells. A novel methodology for the
quantification of background natural nonsense codon readthrough in different cell lines was also
developed, permitting to select the most suitable codon-anticodon pair for this suppressor tRNA
technique in various cell lines. Finally, I present a general strategy to increase the aforementioned
artificial incorporation efficiency by down-regulating the competing eukaryotic release factor 1
(eRF1) using small interfering RNAs.
3Abbreviations
5-HT3R 5-hydroxytryptamine (serotonin) 3 receptor
AARS aminoacyl RNA synthetase
AMA human epithelial amnion cells
C12E9 nonethyleneglycol monodecyl ether
CAT chloramphenicol acetyltransferase
CD circular dichroism
cDNA complementary DNA
CHO Chinese hamster ovary cell
cmc critical micellar concentration
COS1 African green monkey kidney cells
DEPC diethylpyrocarbonate
DHFR dehydrofolate reductase
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
DOTAP N-[1-(2,3-Dioleoyloxy)]-N,N,N-trimethylammonium propane methylsulfate
EC50 half maximal effective concentration
ECFP enhanced cyan fluorescent protein
EDTA ethylenediaminetetraacetic acid
EGFP enhanced green fluorescent protein
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid
ER endoplasmic reticulum
eRF1 eukaryotic release factor 1
EYFP enhanced yellow fluorescent protein
FACS fluorescence activated cell sorting
FCS fetal calf serum
FLASH 4',5'-bis(1,3,2-dithioarsolan-2-yl)fluorescein
FRET fluorescence resonance energy transfer
GABAA γ-aminobutyric acid receptor
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GFP green fluorescent protein
hAGT human O6-alkylguanine-DNA alkyltransferase
HEK293 human embryonic kidney cell
HeLa human cervical carcinoma cells
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
IC50 half maximal inhibitory concentration
Kd dissociation constant
Ki inhibition constant
LGIC ligand-gated ion channel
mCPBG 1-(m-chlorophenyl)-biguanide
mRNA messenger RNA
N1E-115 murine neuroblastoma cell
nAchR nicotinic acetylcholine receptor
NaOAc sodium acetate
NaPi NaH2PO4–Na2HPO4
NMR nuclear magnetic resonance
NTA nitrilotriacetate
PBS phosphate-buffered saline
RNA ribonucleic acid
siRNA short interfering RNA
THF tetrahydrofuran
tRNA transfer RNA
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Thesis  -  General introduction on protein labeling and its applications
0.1.1 Introduction
Understanding the functions and interactions of proteins can be of great benefit for advances in
pharmaceutical research. Indeed, proteins such as ligand-gated ion channels act as important drug
targets by activating or blocking of their channel via the submission of ligands. A complete study of
a specific protein would require deciphering its function and localization in vivo as well as its
structure and activities. However, specific investigations are confronted to the large number of other
molecules present in the living cell. The studied protein would require a specific “tag” to be
distinguishable from the thousands of different endogenous proteins.
Fluorescent labels equip proteins under investigation with a unique property that can be exploited
for both spatial and temporal monitoring of the proteins functions. Such labeling permits the study
of a wide range of intracellular processes – including gene expression [1-4] or cytoskeleton network
visualization [5-7] – by the specific detection of single cellular elements.
Absorption of a photon by a fluorescent molecule causes a transition to an excited state that decays
back to ground state by the emission of a lower energy photon, generating a fluorescent signal. This
entire fluorescence process is cyclical: unless the fluorophore is irreversibly destroyed in the excited
state (photobleaching), the same fluorophore can be repeatedly excited and detected, generating
many thousands of detectable photons. This fluorescence emission can be visualized quantitatively
by various ways. For example fluorescence spectrofluorometers and microplate readers allow to
measure the average signal emitted by molecules in solution, while the use of a confocal
microscope permits in situ detection of fluorescent probes in live cells, producing optical sections
by excluding out-of-focus light.
An evident prerequisite for high detection sensitivity is that the labeled protein must be strongly
fluorescent and distinguishable from the background signals originating from endogenous sample
constituents. A wise selection of the fluorescent label in respect to its extinction coefficient,
quantum yield and resistance to photobleaching, as well as a refinement of the detection specificity
by the use of appropriate filter sets is therefore crucial to proper application of fluorescence
quantification techniques.
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The main objection towards labeling of proteins is the possibility that the tag might interfere with
the function of the investigated protein and that therefore this protein might not reflect anymore the
behavior of its unmodified form. It is hence of utmost importance to probe the basic functions of the
engineered protein under study.
In addition to spatial distribution and colocalization studies, multiple site-specific fluorescent
labeling of proteins permits in some cases the determination of inter- or intramolecular distances by
experiments based on fluorescence resonance energy transfer (FRET). This process of radiationless
energy transfer from a fluorescent donor molecule to a fluorescent acceptor in very close proximity
occurs when the emission spectrum of the donor overlaps that of the acceptor excitation, and results
in the reduction in the donor fluorescence intensity and an increase in the acceptor emission
intensity. The efficiency of this process depends on the inverse sixth power of the distance between
donor and acceptor as described by Förster [8,9]. Hence FRET provides a “molecular ruler” for
determining distances between a donor and an acceptor when they are in the order of 10 to 100 Å
apart, making it ideal for short-range protein interaction studies [10] and a valuable complement to
x-ray diffraction and NMR structure determination.
During the past decade a number of new tools were developed for labeling proteins within cells,
providing high sensitivity and versatility while trying to minimize perturbation of the host cell.
Post-translational fluorescent labeling techniques are based on labeling of the protein itself (using
for instance antibodies [11,12] or ligands [13]), or on the labeling of a peptide genetically fused to
the protein of interest (e.g. bi-arsenic labeling of tetracysteine motifs [14-18], alkyltransferase
labeled with enzymatic substrate derivatives [19], peptide biotinylation by biotin ligases [20-22],
dihydrofolate reductase (DHFR) labeled with fluorescent derivatives of methotrexate [23-25],
metal-ion-chelating nitrilotriacetate (NTA) labeling of oligohistidine sequences [26], semiconductor
nanocrystals (quantum dots) [27-29]).
Another strategy consists on the site-specific labeling of the protein under investigation at an earlier
stage, while it is being translated. This can be achieved via genetic fusion to an autofluorescent
protein [2] or via unnatural fluorescent amino acid incorporation using mis-acylated suppressor
tRNAs [30], techniques approached respectively in the first and second parts of this thesis. The
main advantage of a fluorescent tag integration occurring directly during translation resides in the
fact that it potentially allows for quantitative labeling of the protein under investigation. Also, the
protein can then be observed in live cells without further fixation and labeling procedures,
circumventing any background fluorescence related to unbound or nonspecifically bound probes.
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In this report, different labeling and visualization technologies have been optimized in the prospect
of biological, bioanalytical and biophysical analysis of the pharmacologically important 5-HT3
neurotransmitter receptor (5-HT3R). In that sense and as an initial approach towards fluorescent
labeling at an early stage of the nascent protein I genetically modified its sequence by the insertion
of bioluminescent proteins. The obtained chimeras were probed to be functionally active in terms of
ligand binding and channel activation and offered a wide range of research possibilities, some of
which being presented in the first part of this thesis. In addition, the limitations of this labeling
technique are discussed.
I then focused on a technique permitting the site-specific incorporation of much smaller fluorescent
probes than obtained via protein fusion. This mis-acylated suppressor tRNA method is based on the
integration of unnatural amino acids, which can be autofluorescent or fluorescently-labeled at a
later stage. While technically more challenging, this procedure permits potentially to introduce
small probes at specific positions where protein fusion would structurally or functionally alter the
original protein. However, this technique was originally developed as an in vitro method [31,32],
and later applied in vivo in Xenopus oocytes [30] and Escherichia coli [33]. In the second part of
this thesis, I aimed to expand the suppressor tRNA technology to cultured mammalian cells,
generally more suitable for structural and functional studies of human derived proteins such as the
5-HT3R.
General introduction
9
0.1.2 References
1. Chalfie, M., Tu, Y., Euskirchen, G., Ward, W.W. and Prasher, D.C. (1994) Green
fluorescent protein as a marker for gene expression. Science, 263, 802-805.
2. Kain, S.R., Adams, M., Kondepudi, A., Yang, T.T., Ward, W.W. and Kitts, P. (1995) Green
fluorescent protein as a reporter of gene expression and protein localization. Biotechniques,
19, 650-655.
3. Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C.C. and Kain, S.R. (1998)
Generation of destabilized green fluorescent protein as a transcription reporter. J Biol Chem,
273, 34970-34975.
4. Pick, H.M., Meissner, P., Preuss, A.K., Tromba, P., Vogel, H. and Wurm, F.M. (2002)
Balancing GFP reporter plasmid quantity in large-scale transient transfections for
recombinant anti-human Rhesus-D IgG1 synthesis. Biotechnol Bioeng, 79, 595-601.
5. Presley, J.F., Cole, N.B., Schroer, T.A., Hirschberg, K., Zaal, K.J. and Lippincott-Schwartz,
J. (1997) ER-to-Golgi transport visualized in living cells. Nature, 389, 81-85.
6. Toomre, D., Keller, P., White, J., Olivo, J.C. and Simons, K. (1999) Dual-color
visualization of trans-Golgi network to plasma membrane traffic along microtubules in
living cells. J Cell Sci, 112 ( Pt 1), 21-33.
7. Kimble, M., Kuzmiak, C., McGovern, K.N. and de Hostos, E.L. (2000) Microtubule
organization and the effects of GFP-tubulin expression in dictyostelium discoideum. Cell
Motil Cytoskeleton, 47, 48-62.
8. Forster, T. (1946) Energiewanderung Und Fluoreszenz. Naturwissenschaften, 33, 166-175.
9. Forster, T. (1948) Zwischenmolekulare Energiewanderung Und Fluoreszenz. Annalen Der
Physik, 2, 55-75.
10. Lankiewicz, L., Malicka, J. and Wiczk, W. (1997) Fluorescence resonance energy transfer
in studies of inter-chromophoric distances in biomolecules. Acta Biochim Pol, 44, 477-489.
11. Ng, T., Squire, A., Hansra, G., Bornancin, F., Prevostel, C., Hanby, A., Harris, W., Barnes,
D., Schmidt, S., Mellor, H. et al. (1999) Imaging protein kinase Calpha activation in cells.
Science, 283, 2085-2089.
12. Verveer, P.J., Wouters, F.S., Reynolds, A.R. and Bastiaens, P.I. (2000) Quantitative
imaging of lateral ErbB1 receptor signal propagation in the plasma membrane. Science, 290,
1567-1570.
13. McGrath, J.C., Arribas, S. and Daly, C.J. (1996) Fluorescent ligands for the study of
receptors. Trends Pharmacol Sci, 17, 393-399.
ILEGEMS
10
14. Griffin, B.A., Adams, S.R. and Tsien, R.Y. (1998) Specific covalent labeling of
recombinant protein molecules inside live cells. Science, 281, 269-272.
15. Gaietta, G., Deerinck, T.J., Adams, S.R., Bouwer, J., Tour, O., Laird, D.W., Sosinsky, G.E.,
Tsien, R.Y. and Ellisman, M.H. (2002) Multicolor and electron microscopic imaging of
connexin trafficking. Science, 296, 503-507.
16. Adams, S.R., Campbell, R.E., Gross, L.A., Martin, B.R., Walkup, G.K., Yao, Y., Llopis, J.
and Tsien, R.Y. (2002) New biarsenical ligands and tetracysteine motifs for protein labeling
in vitro and in vivo: synthesis and biological applications. J Am Chem Soc, 124, 6063-6076.
17. Rice, M.C., Czymmek, K. and Kmiec, E.B. (2001) The potential of nucleic acid repair in
functional genomics. Nat Biotechnol, 19, 321-326.
18. Stroffekova, K., Proenza, C. and Beam, K.G. (2001) The protein-labeling reagent FLASH-
EDT2 binds not only to CCXXCC motifs but also non-specifically to endogenous cysteine-
rich proteins. Pflugers Arch, 442, 859-866.
19. Keppler, A., Gendreizig, S., Gronemeyer, T., Pick, H., Vogel, H. and Johnsson, K. (2003) A
general method for the covalent labeling of fusion proteins with small molecules in vivo.
Nat Biotechnol, 21, 86-89.
20. Cronan, J.E., Jr. (1990) Biotination of proteins in vivo. A post-translational modification to
label, purify, and study proteins. J Biol Chem, 265, 10327-10333.
21. Cronan, J.E., Jr. and Reed, K.E. (2000) Biotinylation of proteins in vivo: a useful
posttranslational modification for protein analysis. Methods Enzymol, 326, 440-458.
22. Cull, M.G. and Schatz, P.J. (2000) Biotinylation of proteins in vivo and in vitro using small
peptide tags. Methods Enzymol, 326, 430-440.
23. Israel, D.I. and Kaufman, R.J. (1993) Dexamethasone negatively regulates the activity of a
chimeric dihydrofolate reductase/glucocorticoid receptor protein. Proc Natl Acad Sci U S A,
90, 4290-4294.
24. Remy, I. and Michnick, S.W. (1999) Clonal selection and in vivo quantitation of protein
interactions with protein-fragment complementation assays. Proc Natl Acad Sci U S A, 96,
5394-5399.
25. Remy, I. and Michnick, S.W. (2001) Visualization of biochemical networks in living cells.
Proc Natl Acad Sci U S A, 98, 7678-7683.
26. Guignet, E.G., Hovius, R. and Vogel, H. (2004) Reversible site-selective labeling of
membrane proteins in live cells. Nat Biotechnol.
General introduction
11
27. Wu, X., Liu, H., Liu, J., Haley, K.N., Treadway, J.A., Larson, J.P., Ge, N., Peale, F. and
Bruchez, M.P. (2003) Immunofluorescent labeling of cancer marker Her2 and other cellular
targets with semiconductor quantum dots. Nat Biotechnol, 21, 41-46.
28. Jaiswal, J.K., Mattoussi, H., Mauro, J.M. and Simon, S.M. (2003) Long-term multiple color
imaging of live cells using quantum dot bioconjugates. Nat Biotechnol, 21, 47-51.
29. Dubertret, B., Skourides, P., Norris, D.J., Noireaux, V., Brivanlou, A.H. and Libchaber, A.
(2002) In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science,
298, 1759-1762.
30. Turcatti, G., Nemeth, K., Edgerton, M.D., Meseth, U., Talabot, F., Peitsch, M., Knowles, J.,
Vogel, H. and Chollet, A. (1996) Probing the structure and function of the tachykinin
neurokinin-2 receptor through biosynthetic incorporation of fluorescent amino acids at
specific sites. J Biol Chem, 271, 19991-19998.
31. Kurzchalia, T.V., Wiedmann, M., Breter, H., Zimmermann, W., Bauschke, E. and Rapoport,
T.A. (1988) tRNA-mediated labelling of proteins with biotin. A nonradioactive method for
the detection of cell-free translation products. Eur J Biochem, 172, 663-668.
32. Noren, C.J., Anthony-Cahill, S.J., Suich, D.J., Noren, K.A., Griffith, M.C. and Schultz, P.G.
(1990) In vitro suppression of an amber mutation by a chemically aminoacylated transfer
RNA prepared by runoff transcription. Nucleic Acids Res, 18, 83-88.
33. Liu, D.R., Magliery, T.J., Pastrnak, M. and Schultz, P.G. (1997) Engineering a tRNA and
aminoacyl-tRNA synthetase for the site-specific incorporation of unnatural amino acids into
proteins in vivo. Proc Natl Acad Sci U S A, 94, 10092-10097.

Part I – Chapter I.1
13
Part I Protein labeling via genetic fusion to fluorescent proteins
Chapter I.1
Part I: protein labeling via genetic fusion to fluorescent proteins
ILEGEMS
14
Part I  -  Protein labeling via genetic fusion to fluorescent proteins
I.1.1 Introduction
The advent of genetically encoded dyes began with the discovery of the green fluorescent protein
(GFP), originally isolated from the light-emitting organ of the jellyfish Aequorea victoria in 1962
[1]. About 30 years later its encoding complementary DNA was characterized [2], permitting to
expand the expression of this protein to a wide variety of tissues and organisms, which
revolutionized modern cell biology.
The green light emitted by A. victoria is the result of an energy transfer between the photoprotein
aequorin – producing blue light after calcium binding – and the GFP. Activation of the green
fluorescent protein alone in vitro or in heterologous cells can be achieved via light excitation of its
immanent fluorophore. The GFP structure consists of an 11-stranded β-barrel with a coaxial helix;
its centrally-located chromophore is formed by autocatalytic internal cyclization and oxidation of
the Ser-Tyr-Gly sequence at positions 65-67 within the 238 amino-acid polypeptide [3,4] (Figure
I.1.1).
Figure I.1.1 (A) Structure of the green fluorescent protein (GFP) and (B) interactions between the encaged
fluorophore and its surrounding amino acids and water solvent (“SOL”). Inset in B represents the centrally
located Ser-Tyr-Gly sequence before its cyclization (Figures adapted from Ormö et al. [4]).
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As the GFP is intrinsically fluorescent, chimeric in situ expressed fusion proteins can be monitored
in vivo. Depending on the protein under investigation, its GFP-tagging can be the result of a simple
amino or carboxyl terminus sequence fusion or a more complex genetic incorporation of the GFP.
Functionality of the obtained protein fusion can generally be assessed by proper localization and by
its biochemical activity. In addition to specific protein labeling GFP fusions can be localized to
particular sites within the cell by appropriate targeting signals [5], enlightening the spatial
distribution of all major organelles (see Appendix IV.3).
The engineering of mutated versions of the Aequorea GFP permitted the expansion of the color
repertoire covered by this fluorescent protein. Extensive mutagenesis – mostly near the central
chromophore position – created a number of GFP variants with differing excitation and emission
properties (Appendix IV.2.1). Additionally, the recent discovery of novel GFP-like proteins
originating from other organisms such as Discosoma and Anthozoa have furthermore expanded the
range of available colors, virtually covering the whole visible spectra. As a result, the family of
autofluorescent proteins now includes approximately 30 significantly different members [6,7],
which can be used in conjunction [8] or in combination with other fluorescent molecules for both
multicolor labeling and fluorescent resonance energy transfer experiments.
In the first part of this thesis, I focus on the fluorescent labeling of the 5-HT3 receptor (5-HT3R)
type A via genetic fusion to bioluminescent proteins. This particular ligand-gated ion channel
inducing fast depolarizing neuronal responses after binding of the 5-hydroxytryptamine (5-HT or
serotonin) neurotransmitter secreted from the presynaptic membrane [9] has been shown to be of
medical and pharmaceutical interest by specific ligand administration, in particular for suppression
of the emesis caused by anticancer chemotherapy and radiation [10], or for treating schizophrenia
and other psychiatric disorders [11-14]. An accrued knowledge of cellular trafficking, ligand
binding and channel gating of such neurotransmitter receptors would be beneficial to advances in
drug research.
As an initial step, I found a suitable genetic position for the insertion of GFP-like protein sequences
into that of the receptor under investigation, which resulted in chimeric proteins presenting
preserved ligand binding and channel activity. I first show in chapter I.2 that the autofluorescence
of the resulting receptor permits to monitor its trafficking and membrane organization in vivo after
transient expression. In combination with a spectrally distinguishable variant of the green
fluorescent protein targeted to different specific cytoplasmic organelles and with 5-HT3R-specific
fluorescent ligands, this labeling allows for the determination of subcellular assembly of the
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receptor by multicolor imaging, and permits a better understanding of the cellular cytoskeleton
function for receptor trafficking and localization.
In the two following chapters, I investigate different in vitro techniques to measure ligand binding
as well as channel activation on sub-cellular systems, potentially applicable for multiarray
bioanalytical drug screening methodologies. In chapter I.3, I show that the vesicles protruding from
the plasma membrane after chemical disruption of actin filaments in cells expressing the
fluorescently-labeled 5-HT3R contain the chimera receptor. These so-called “native vesicles” permit
additionally to observe calcium influx after agonist-induced receptor activation, as measured by
confocal fluorescence microscopy using a calcium sensitive dye. In the last chapter of this first part,
I demonstrate that detergent-solubilized labeled receptors – completely separated from their
originating cell – also allow for both ligand binding affinity and channel activation measurements
via fluorescence resonance energy transfer quantification, and we discuss the possibility to obtain
precise resulting structural information using GFP as an energy donor and acceptor.
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I.2 Noninvasive imaging of 5-HT3 receptor trafficking in live cells: from
biosynthesis to endocytosis
I.2.1 Abstract
Sequential stages in the life cycle of the ionotropic 5-HT3 receptor were resolved temporally and
spatially in live cells by multi-color fluorescence confocal microscopy. The insertion of the
enhanced cyan fluorescent protein into the large intracellular loop delivered a fluorescent 5-HT3R,
fully functional in terms of ligand binding specificity and channel activity, which allowed for the
first time to monitor in vivo expression, membrane targeting and ligand mediated endocytosis of a
receptor. The dynamics of subcellular localizations of the fluorescent 5-HT3R were investigated by
imaging simultaneously the receptor and spectrally distinguishable variants of the green fluorescent
protein targeted to particular cytoplasmic organelles. The intracellular delivery of fluorescent 5-
HT3R-specific antagonists allowed the study of ligand binding site formation at an early stage of
receptor expression. After novel protein synthesis was chemically blocked, the 5-HT3 receptor
populations in the endoplasmic reticulum and Golgi cisternae moved quantitatively to the cell
surface, indicating efficient receptor folding and subunit assembly. The intracellular 5-HT3
receptors, which were trafficking in vesicle-like structures along microtubules, inserted into the cell
membrane in a characteristic cluster distribution overlapping with actin-rich domains. Extracellular
agonist application induced rapid internalization of 5-HT3 receptors. The time course of the
disappearence of 5-HT3 receptors from the cell surface was monitored by measuring the binding of
receptor-specific fluorescent ligands at the extracellular membrane surface at different time points
after agonist application.
The results of this chapter have been submitted for publication:
Ilegems, E., Pick, H.M., Deluz, C., Kellenberger, S. and Vogel, H.: Noninvasive imaging of 5-HT3
receptor trafficking in live cells: from biosynthesis to endocytosis.
Part I – Chapter I.2
21
I.2.2 Introduction
A fundamental interest in neurobiology is the study of processes involved in expression, assembly
and subcellular trafficking of neurotransmitter receptors. These receptors are members of a large
molecular family of ligand-gated ion channels (LGIC) that include nicotinic acetylcholine (AChRs),
serotonin (5-HT3R), γ-aminobutyric acid (GABAA), glycine, and ionotropic glutamate receptors
[1,2]. All of them are oligomeric membrane proteins composed of subunits surrounding an ion
channel that opens upon neurotransmitter binding to the receptor. The structural relationship
between the different LGICs suggests that their assembly and trafficking involves similar molecular
events [3]. In general, it is thought that subunit assembly occurs shortly after biosynthesis in the
endoplasmic reticulum (ER) followed by trafficking to the plasma membrane [4-8]. Methodologies
allowing the dynamic observation of these processes have still to be elaborated. In the present
study, we focus on the ionotropic 5-HT3R as a representative member of the LGICs and explore
new strategies for following receptor biogenesis in real time starting with the delivery of their
coding DNA into living cells. We aim at dissecting events, which occur after their “birth” leading to
cell membrane insertion of mature receptors and finally their ligand-induced re-absorption into the
cell reflecting the endpoint of their lifespan. Improved understanding of these processes can be
expected to provide valuable information for the therapeutic targeting of LGICs at specific stages in
their life cycle.
The ionotropic 5-HT3R type A is known to mediate fast signal transduction across synapses in the
nervous system. Homo-pentameric complexes of recombinant 5-HT3A receptors exhibit high cell
surface expression levels in heterologous systems [9] and share substantial pharmacological and
functional properties with native neuronal 5-HT3R [10-12]. To date the direct intracellular analysis
of 5-HT3 receptors has been limited to antibody labeling methods [8]. However these technologies
are not adequate for visualizing receptors in live cells and cannot be used to label intracellular
receptors in non-permeabilized cells.  Here we fuse the enhanced cyan fluorescent protein (ECFP)
to the 5-HT3R to visualize the entire sequence of stages in the life of the receptor. The green
fluorescent protein and its spectral variants are becoming widely used as molecular reporters to
monitor gene expression, localization and intracellular protein trafficking in living cells [13-15].
GFP-tagged proteins often retain their biological activity and have the same trafficking pattern as
native proteins [16-20]. The combination of tagging 5-HT3 receptors with autofluorescent proteins
and the parallel use of fluorescent 5-HT3R specific ligands [21] will be demonstrated as a powerful
tool allowing the multicolor analysis of receptor biosynthesis, trafficking and ligand-dependent
receptor internalization.
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I.2.3 Experimental procedures
Materials
Synthetic oligonucleotides were purchased from MWG-Biotech AG (Ebersberg, Germany), kits for
plasmid and DNA-fragment purification from QIAGEN GmbH (Hilden, Germany), restriction
endonucleases (ClaI, HindIII and NotI) from New England Biolabs (Massachusetts, USA). T !h !e !
!r !a !d !i !o !l !i !g !a !n !d ! !3 !- !( !5 !- !m !e !t !h !y !l !- !1 !H !- !i !m !i !d !a !z !o !l !- !4 !- !y !l !) !- !1 !- !( !1 !- ![ !3 !H !] !m !e !t !h !y !l !- !1 !H !- !i !n !d !o !l !- !3 !- !y !l !) !p !r !o !p !a !n !o !n !e ! !( ![ !3 !H!]!-
!G !R !6 !5 !6 !3 !0 !; ! !85.5 ! !C !i !/ ! !m !m !o !l !) ! !w !a !s ! !f !r !o !m ! !N !E !N !- !D !u !P !o !n !t ! !( !B !o !s !t !o !n !, ! !M !A !); t !h !e ! !a !g !o !n !i !s !t ! ! !s !e !r !o !t !o !n !i !n ! !( !5 !H !T !) ! !w !as !
!o !b !t !a !i !n !e !d ! !f !r !o !m ! !S !i !g !m !a ! !( !B !u !c !h !s !, ! !S !w !i !t !z !e !r !l !a !n !d !) !, ! a !n !d ! !q !u !i !p !a !z !i !n !e ! !a !n !d ! !1 !- !( !m !- !c !h !l !o !r !o !p !h !e !n !y !l !) !b !i !g !u !a !n !i !d !e !
!( !m !C !P !B !G !) ! !f !r !o !m ! !T !o !c !r !i !s !- !C !o !o !k !s !o !n ! !( !L !a !n !g !f !o !r !d !, ! !U !K !) !. ! The fluorescent ligands GR-Cy5 (1,2,3,9-
tetrahydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-9-[3-amino-[N-(Cy5)amido]propyl]-4H-
carbazol-4-one), GR-Flu (1,2,3,9-tetrahydro-3-[(5methyl-1H-imidazol-4-yl)methyl]-9-(3-amino-(N-
fluorescein-thiocarbamoyl)-propyl)-4H-carbazol-4-one) and GR-Rho (1,2,3,9-tetrahydro-3-[(5-
methyl-1H-imidazol-4-yl)methyl]-9-[3-amino-[N-(rhodamineB)thiocarbamoyl]-propyl]-4H-
carbazol-4-one) were prepared as described elsewhere [21,22]. Triton-X100 was from Fluka
(Buchs, Switzerland). The plasmids pEYFP-ER, pEYFP-Golgi, pEYFP-Tub and pEYFP-Actin
were purchased from Clontech (California, USA). Other chemicals were from Sigma-Aldrich
(Missouri, USA).
DNA constructs
All constructs are based on a vector containing the short splicing variant of the murine 5-
hydroxytryptamine type 3A subunit cDNA preceded by the human cytomegalovirus gene promoter,
as described before [9].
The vector p5HT3R-ECFP, containing the ECFP-labeled receptor, was obtained as follows: the
original vector was first mutated using the oligos 5'-CTG ATG ACT GCT CAA TCG ATG CCA
TGG GAA ACC-3' and 5'-GGT TTC CCA TGG CAT CGA TTG AGC AGT CAT CAG-3', adding
a ClaI restriction site in the large cytoplasmic loop sequence between the 3rd and 4th predicted
membrane-spanning domains. The ECFP insert was obtained by PCR amplification on the template
pECFP-N1 (Clontech, California, USA) using the synthetic oligonucleotides 5'- CCA TCG ATA
TGG TGA GCA AGG GCG AGG -3' and 5'- CCA TCG ATC TTG TAC AGC TCG TCC ATG
CCG -3', and ligated into the receptor ClaI restriction site. The restriction sites HindIII and NotI
were added to the 5’ and 3’ ends of the 5-HT3R-EGFP sequence by PCR amplification using the
oligonucleotides 5’- CGA TAA GCT TCA CCA TGC GGC TCT GCA TCC CGC AGG TG -3’
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and 5’- GCT GTG CCC ACG CGG CCG CTC AAG AAT AAT GCC AAA TGG ACC AGAG -3’,
and the purified 2197 bp fragment was sub-cloned into the HindIII/NotI cut vector pEAK8 (Edge
BioSystems, Gaithersburg, MD, USA), giving rise to the vector p5HT3R-ECFP.
The vector p5HT3R was obtained by sub-cloning the non-mutated receptor gene into the plasmid
pEAK8 between HindIII and NotI, using the same oligos as for constructing p5HT3R-ECFP.
The plasmid constructs were confirmed by restriction mapping and DNA sequencing.
Cell culture,  transfections and permeabilization
Adherent human embryonic kidney (HEK293) and N1E-115 cells were grown in DMEM/F12
(Dulbecco’s modified Eagle medium; GIBCO BRL, Rockville, USA) supplemented with 2.2 % and
10 % fetal calf serum (GIBCO BRL) respectively, using plastic flasks from TPP (Trasadingen,
Switzerland).  The cultures were split regularly and kept at 37 °C in a humidified atmosphere with 5
% CO2.
For electrophysiology, confocal microscopy measurements and membrane purification respectively,
cells were seeded in 35 mm cell culture dishes, six-well plates containing 22 mm-diameter glass
cover slips and 150 cm2 flasks at a density of 150’000 cells/ml and transfected using Lipofectamine
2000 reagent (Invitrogen, Carlsbad, California, USA), according to the manufacturer’s instructions.
An amount of 4 g of pelleted cells was used for the membrane solubilization.
Fixation of cells was achieved by 10 minutes incubation at room temperature in a solution
containing 3.7 % formaldehyde in PBS. Subsequent permeabilization was performed by 5 minutes
incubation in presence of 0.1 % Triton-X100 in PBS. Cells were washed three times with PBS
between incubations.
Membrane solubilization
All following manipulations were performed on ice or at 4 ºC, to avoid degradation of the receptor.
The cell pellets were resuspended in 10 ml of a solution containing 10 mM Hepes and 1 mM EDTA
at a pH of 7.4, and homogenized for 90 seconds with an Ultra-Turrax T25 (IKA, Staufen,
Germany). The membrane fraction was collected by centrifugation at 27’000 g for 40 minutes, and
the membrane proteins were solubilized by resuspending and incubating the pellet in 20 ml of 50
mM NaPi (NaH2PO4–Na2HPO4), 300 mM NaCl and 50 cmc C12E9 (Anatrace, Maumee, USA) at
pH 8.0. A final centrifugation at 100’000 g for 60 minutes served to remove the remaining
membrane fraction, and the resulting supernatant was collected and stored at –80 ºC until use.
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Radioactive binding assays
!Receptor concentrations as well as ligand affinities were measured by radioligand binding assay.
100 µl of cells resuspended in 10 mM Hepes pH7.4 were incubated for 30 minutes at room
temperature in solutions of 10 mM Hepes pH7.4 with varying concentrations of the specific
antagonist [3H]-GR65630 in a final volume of 1ml. !A r !a !p !i !d ! !f !i !l !t !r !a !t !i !o !n ! !t !h !r !o !u !g !h ! !W !h !a !t !m !a !n ! !G !F !/ !B ! !f !i !l !t !e !r !s !
!(p !r !e !s !o !a !k !e !d ! !f !o !r ! !1 !5 ! !m !i !n ! !i !n ! !0 !. !5 !% ! !( !w !/ !v !) ! !p !o !l !y !e !t !h !y !l !e !n !i !m !i !n !e !) !f !o !l !l !o !w !e !d ! !b !y ! !t !w !o ! !w !a !s !h !e !s ! !w !i !t !h ! !3 ! !m !L ! !o !f ! !i !c !e !-
!c !o !l !d ! !1 !0 ! !m !M ! !H !epes ! at ! !p !H ! !7 !. !4 ! terminated the incubation. ! !F !i !l !t !e !r !s ! !w !e !r !e ! then !t !r !a !n !s !f !e !r !r !e !d ! !i !n !t !o !
!s !c !i !n !t !i !l !l !a !t !i !o !n ! !v !i !a !l !s ! ! !a !n !d ! !4 ! !m !L ! !o !f ! !U !l !t !i !m !a ! !G !o !l !d ! !( !P !a !c !k !a !r !d !, ! !M !e !r !i !d !a !n !, ! !C !T !) ! !w !a !s ! !a !d !d !e !d !. ! !T !h !e ! !r !a !d !i !o !a !c !t !i !v !i !t !y !
!w !a !s ! !m !e !a !s !u !r !e !d ! !i !n ! !a ! !T !r !i !- !C !a !r !b ! !2 !2 !0 !0 !C !A ! !l !i !q !u !i !d ! !s !c !i !n !t !i !l !l !a !t !i !o !n ! !c !o !u !n !t !e !r ! !( !P !a !c !k !a !r !d !) !. ! !N !o !n !s !p !e !c !i !f !i !c ! !b !i !n !d !i !n !g !
!w!a!s! !d!e!t!e!r!m!i!n!e!d! !i!n! !t!h!e! !p!r !e!s!e!n!c!e! !o!f! !1! µ!M! !q!u!i!p!a!z!i!n!e!.! !A!l!l! !e!x!p!e!r!i !m!e!n!t!s! !w!e!r !e! !p!e!r!f!o!r!m!e!d! !i!n! !t!r!i!p!l !i!c!a!t!e!.!
The dissociation constant Kd of [
3H]-GR65630 and the Hill coefficient n were calculated by fitting
the experimental data to the binding equation:
         
€ 
[GR65630]bound =
[5 −HT3R]
1+ Kd /[GR65630] free( )
n      [I.2.1]
Binding assay on permeablized cells were processed as above, but the cells were pre-treated with
0.1 % saponin in 10 mM Hepes pH 7.4 for 5 minutes at room temperature before radioligand
binding. All experiments were done in triplicate.
Electrophysiology
We used the standard patch-clamp technique in whole-cell voltage-clamp to –60 mV employing an
EPC-9 patch-clamp amplifier (HEKA Elektronik Dr. Schulze GmbH, Lambrecht, Germany). For
data acquisition and storage the software PULSE 8.3 (HEKA) was used. Borosilicate glass pipettes
were heat polished and had resistances of 2-5 MΩ. Pipettes were filled with 140 mM KCl, 5 mM
MgCl2, 10 mM EGTA, 10 mM HEPES-KOH, pH 7.3. The external solution was 147 mM NaCl, 12
mM glucose, 2 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES-NaOH, pH 7.4. Ligands
dissolved in the external solution were applied with a RSC-200 or the MSC-200 perfusion system
(Bio-Logic, Claix, France). During experiments the cells were continuously perfused. All
experiments were performed at room temperature.
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Data were evaluated by fitting to the Hill Equations:
I = Imax/{1+(EC50/[agonist])
n}             [I.2.2]
and
I = I0/{1+(IC50/[antagonist])
-n}  [I.2.3]
where I is the peak current at a certain ligand concentration, Imax is the maximal  peak current
achievable, I0 is the peak current in absence of any antagonist, EC50 and IC50 are the half maximal
effective and inhibitory concentrations, respectively, and n is the Hill coefficient.
For antagonist-agonist competition experiments, cells were perfused with granisetron containing
solutions for three minutes before the addition of serotonin (5-HT) at a concentration of 30 µM.
Laser scanning confocal microscopy and fluorescence measurements
Laser-scanning confocal micographs were recorded using 458 and 488 nm Argon/Krypton and 543
nm HeNe laser lines on a Zeiss LSM 510 microscope (Carl Zeiss AG) equipped with a 63x water
(1.2 numerical aperture) objective. Detection and distinction of fluorescence signals was achieved
by appropriate filter sets using a multitracking mode. Scanning speed and laser intensity were
adjusted to avoid photobleaching of the fluorescent probes, and damage or morphological changes
of the cells. The microscope was equipped with a microcultivation system (Incubator S, CTI
controller 3700 digital, Zeiss) to control temperature, humidity and CO2 for maintaining
physiological conditions during long term experiments.
Fluorescence measurements on detergent-solubilized 5-HT3R-ECFP were performed on a SPEX
Fluorolog II (Instruments S.A., Stanmore, U.K.), using quartz cuvettes of 1x1 cm2 (Hellma,
Müllheim, Germany) and 1.5 nm excitation and emission bandwidths for data acquisition.
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I.2.4 Results
We investigated the time course of 5-HT3R plasma membrane expression by analyzing non-
permeabilized HEK293 cell samples at different time points after transfection via radioligand
binding assay. 5-HT3R cell surface expression increased over time and reached a maximum number
of about 2.6 x 106 receptors per cell 34 hours after transfection (Figure I.2.1).
Figure I.2.1 5-HT3R cell surface expression measured at different time points after transfection via
radioligand binding assays on populations of HEK293 cells. The obtained values were divided by the
number of cells before transfection, which were in the order of 1 x 106 per assay.
When these cells were permeabilized with saponin it was possible to detect in addition to cell
surface receptors also 5-HT3R-specific ligand binding activity inside the cytoplasm, which
accounted to about 40 % of the total ligand binding sites. In N1E-115 cells, which endogenously
express the 5-HT3 receptor, about 60 % of the ligand binding activity was localized inside the cell
(Table I.2.1).
Non-transfected
N1E-115 cells
p5HT3R-transfected
HEK293 cells
Receptor binding sites per cell on membrane 5.0 ± 0.6 x104 2.6 ± 0.2 x106
Total number of receptor binding sites per cell 1.2 ± 0.2 x105 4.4 ± 0.2 x106
Percentage of receptor binding sites localized on membrane 42 ± 12 % 59 ± 7 %
Table I.2.1 Radioactive binding assays to 5-HT3R performed on cell membrane and on saponin-
permeabilized cells. The values represent average number of 5-HT3Rs on populations of 1x10
6 cells as
measured 34 hours after transient transfection of HEK293 cells or on non-transfected N1E-115 cells.
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These results indicate that a substantial fraction of intracellular receptors is capable of binding 5-
HT3R-specific ligands before plasma membrane integration. At this point we decided to analyze
intracellular 5-HT3R formation and trafficking in more detail. In order to observe in real time 5-
HT3R biosynthesis after cell delivery of its coding DNA, we inserted the coding sequence of the
enhanced cyan fluorescent protein (ECFP) into the large cytoplasmic loop between the 3rd and 4th
predicted membrane-spanning domains in the short splicing variant of the receptor, at the position
where in comparison to the large splicing variant six amino acids are missing (homology alignment
in Figure I.2.2A).
Figure I.2.2 Fusion of ECFP to the 5-HT3R. (A) Scheme of the folding of the membrane integrated 5-HT3R
and 5-HT3R-ECFP: the ECFP coding sequence is genetically fused into the large cytoplasmic loop between
the 3rd and 4th transmembrane domains, replacing the amino acids present in the long splicing variant of the
receptor (shown in bold letters in the amino acid homology sequence alignment of the large cytoplasmic
loop). (B) Excitation and fluorescence emission of the detergent-solubilized 5-HT3R-ECFP after transient
expression in human cells, permitting to spectrally differentiate the receptor from EYFP-based subcellular
markers.
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The preserved functionality of the fusion construct was confirmed by radioligand binding assay and
whole cell patch clamp measurements (Table I.2.2).
5HT3R 5HT3R-ECFP
Kd [nM] 0.3 ± 0.1 0.6 ± 0.1Binding assay !![!
3 !H!]!-!GR65630
Hill 0.8 ± 0.2 1.1 ± 0.2
EC50 [µM] 0.97 ± 0.02 0.62 ± 0.06Serotonin
Hill 3.1 ± 0.2 1.8 ± 0.3
EC50 [µM] 0.4 ± 0.1 0.20 ± 0.03mCPBG
Hill 1.0 ± 0.2 1.5 ± 0.3
IC50 [nM] 0.17 ± 0.01 0.26 ± 0.02
Electrophysiology
Granisetron inhibition
Hill 0.92 ± 0.03 1.04 ± 0.05
Table I.2.2 Radioligand binding and electrophysiology on wild-type and ECFP-labeled 5-HT3R revealed the
preserved functionalities of the receptor chimera. For antagonist-agonist competition experiments, cells were
perfused with granisetron containing solutions for three minutes before the addition of serotonin (5-HT) at a
concentration of 30 µM.
Using laser scanning confocal microscopy we found that the ECFP-labeled receptors start to form
in the endoplasmic reticulum about 3 hours after transfection. The receptor-derived fluorescence
signal could be overlapped with a spectrally distinguishable (Figure I.2.2B) enhanced yellow
fluorescent ER marker (Figure I.2.3A), which was transfected together with the ECFP-tagged
receptor DNA. In parallel experiments, we were able to overlap the chimeric receptor
bioluminescence with an EYFP marker targeted to the Golgi apparatus at approximately 4 hours
after transfection (Figure I.2.3B). The complete receptor trafficking from the appearance in the
Golgi and processing to plasma membrane targeting occurred in about 30 minutes (Figure I.2.3C).
The integration of mature receptors into the plasma membrane could be confirmed by binding of a
fluorescent labeled 5-HT3-specific antagonist (Figure I.2.3C inset).
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Figure I.2.3 Trafficking of the 5-HT3R-ECFP followed over time in HEK293 cells by co-transfection with
EYFP-labeled subcellular localization vectors. Images were acquired 3 hours (A), 4 hours (B) and 5 hours
(C) after transfection. The endoplasmic reticulum and Golgi apparatus are labeled by co-transfection with
pEYFP-ER (A) and pEYFP-Golgi (B), respectively. Inset in C shows the membrane integrated receptors by
labeling the non-permeabilized cell with the fluorescent ligand GR-Cy5 (red) [22]. Co-localization of ECFP
(blue) and EYFP (yellow) is indicated in white. Size bar is 10 µm.
Though the fluorescence emitted from the 5-HT3R-ECFP is primarily an indication for ECFP label
folding completion, it allows also to monitor 5-HT3 receptor biogenesis, since the ECFP label is
directly integrated into the receptor sequence. Information about the assembly of 5-HT3R subunits
can be assessed via detection of the formation of the ligand binding sites. Indeed, it has been shown
for the structurally related acetylcholine receptor [23] as well as by amino acid sequence homology
studies on the 5-HT3R [24,25] that the ligand binding sites are located between neighboring
subunits; in consequence, ligand binding can only be observed once the subunits are fully
assembled to a functional pentameric receptor.
After monitoring 5-HT3R biosynthesis in cytoplasmic compartments we started to investigate the
formation of intracellular 5-HT3-specific ligand binding sites indicating the assembly of receptor
subunits. Subcellular receptor ligand binding was assessed by first permeabilizing fixed HEK293
cells at different times after transfection, and subsequently labeling the receptor with 5-HT3-specific
fluorescent ligands. Triton-X100 was used for cell permeabilization because this detergent was
shown not to interfere with ligand binding affinity [12,26].
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ECFP-labeled 5-HT3Rs were localized in the endoplasmic reticulum or Golgi apparatus by overlap
with corresponding EYFP organelle markers as described above. The delivery of a Cy5-labeled 5-
HT3R-specific antagonist (GR-Cy5) into permeabilized cells allowed the detection of ligand
binding activity in ER and Golgi apparatus (Figure I.2.4). This is an indication for receptor
assembly at an early stage of expression in the ER. The GR-Cy5 fluorescence signal located in the
Golgi was stronger than in the ER indicating substantially higher amounts of assembled 5-HT3
receptors in the Golgi.
Figure I.2.4 Study of ligand binding site activity at different stages of receptor expression.
The 5-HT3R-ECFP (cyan) was co-expressed with EYFP (yellow) targeted to the endoplasmic reticulum (A-
C) and Golgi apparatus (D-F). After cell fixation and membrane permeabilization, the overlap with the
fluorescent ligand GR-Cy5 (red) demonstrated the presence of active ligand binding sites of the receptor in
these organelles (C, F).
(G-I): GR-Rho (green) and GR-Cy5 were applied, respectively, before and after permeabilization to
investigate the percentage of membrane as compared to whole cell binding receptors. Size bars = 5 µm.
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The percentage of cell surface receptors as compared to intracellularly formed ligand binding sites
was then evaluated by double ligand labeling (Figure I.2.4, G-I): 2 nM of the fluorescent
rhodamine-labeled antagonist GR-Rho was applied to non-permeabilized 5-HT3R-ECFP expressing
cells 34 hours after transfection to label the receptors located on the plasma membrane. After
fixation and permeabilization of the cells, the antagonist GR-Cy5 was added at a concentration of
12 nM in order to label the receptors inside the cell. Due to particular high affinity of the
fluorescent antagonist GR-Rho to the 5-HT3R, the latter was not replaced by GR-Cy5, as described
before [9], and allowed to visualize the distribution of extra- and intracellular ligand binding
activity. Subsequent image analysis consisting in pixel quantification of Cy5- and rhodamine-
derived fluorescence in consecutive confocal sections covering the whole cell volume revealed that
about 43 ± 14 % of the binding-active receptors were located in the plasma membrane. This mean
value was obtained from analysing 20 different cells, and were in the same range as the values
obtained from radioligand binding assays on cell suspensions.
The specificity of GR-Cy5 ligand binding to 5-HT3 receptors in intracellular compartments was
confirmed by ligand displacement experiments. On fixed and permeabilized HEK293 cells
expressing the 5-HT3R in ER and Golgi, the GR-Cy5 labeling could be replaced by an excess of a
fluorescein-labeled antagonist (GR-Flu), which exhibits a strong affinity for the 5-HT3R (Figure
I.2.5).
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Figure I.2.5 Fluorescent ligands and their specificity for the 5-HT3R in permeabilized cells.
Chemical structures of the fluorescent antagonists: the pharmacophore GR119566 (A) was labeled with Cy5,
fluorescein and rhodamine B, yielding GR-Cy5 (B), GR-Flu (C) and GR-Rho (D) respectively.
HEK293 cells stably expressing the non-labeled 5-HT3R were fixed with 10% formaldehyde and detergent-
permeabilized (E). The receptors were then labeled for 3 minutes with the 5-HT3R-specific ligand GR-Cy5
(F, red) at a concentration of 12 nM, and the excess was washed three times with PBS. This fluorescent
antagonist was then replaced by the ligand GR-Flu, which shows a higher affinity for the receptor (G).
Absence of GR-Cy5 signal after replacement shows the specificity of the ligand in permeabilized cells (H).
Size bar is 5 µm.
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Receptor trafficking from the Golgi apparatus to the plasma membrane was then more precisely
analyzed by imaging 5-HT3R-ECFP expressing HEK293 cells (frame rate of 2 images/s; Figure
I.2.6). The ECFP label allowed us to detect vesicle-like structures carrying 5-HT3 receptors in their
membrane, which moved inside the cytoplasm. The velocity of these carrier vesicles was generally
below 1µm per second, measured as the distance between the pixel coordinates in consecutive
images. The receptor-carrying vesicles seemed to be located in tubulin-rich regions as visualized by
cotransfection with a EYFP-labeled tubulin marker (pEYFP-Tub).
Figure I.2.6 Spatial and temporal resolution in live HEK293 cells of post-Golgi carriers containing the 5-
HT3R-ECFP by confocal microscopy.
(A) average speed as measured by consecutive image acquisition tracking 10 individual receptor carriers. (B)
cotransfection of HEK293 cells with 5-HT3R-ECFP and EYFP-labeled tubulin shows the movement of
carrier vesicles along tubulin-rich domains (white dots in inlet enlargement).
In order to verify whether tubulin filaments are of required for 5-HT3 receptor transport to the
plasma membrane, we studied the influence of colchicine on receptor trafficking, which is known to
inhibit microtubule formation [27-29] (Figure I.2.7). 5 hours after addition of 100 µg/ml
cycloheximide, known to interfere with the translation machinery [30], the receptors were almost
completely located on the cell membrane. However, prior treatment of the cells for 2 hours with 50
µg/ml colchicine did not lead to a complete membrane localization of the receptors, demonstrating
the tubulin requirement for proper receptor trafficking.
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Figure I.2.7 Influence of cycloheximide and colchicine on receptor localization.
(A) 100 µg/ml cycloheximide administrated to the cells 5 hours prior to imaging. (B) Pretreatment with 50
µg/ml colchicine for 2 hours before cycloheximide administration did not lead to complete cell surface
localization of the receptors 5 hours later. Size bars = 5 µm.
We then investigated the effects of agonist application on the subcellular distribution of 5-HT3
receptors. 34 hours after transient 5-HT3R-ECFP expression, HEK293 cells were treated with 100
µg/ml cycloheximide for 5 hours in order to stop new protein synthesis allowing delivery of
intracellular receptors to the cell membrane and thus to avoid intracellular fluorescence background.
Subsequent incubation of non-permeabilized cells with 12 nM GR-Cy5 led to a complete spatial
overlap of the receptors ECFPs and the ligands Cy5 fluorescence signals on the cell surface (Figure
I.2.8, A-E). The fluorescent antagonist was then replaced by adding an excess of the non-
fluorescent 5-HT3R-specific agonist 1-(m-chlorophenyl)-biguanide (mCPBG, 500 nM). After
incubation at room temperature for 30 min, the cells were intensively washed with PBS buffer.
Then we applied the fluorescent antagonist GR-Cy5 for a second time using the same concentration
as before (Figure I.2.8, F-J). The absence of fluorescence labeling on the cell surface was a first
indication that agonist-induced internalization of the 5-HT3R might have occurred. The fact that the
ECFP fluorescence was still located near the plasma membrane might indicate receptor
internalization in early endosomes located closely below the cell surface. This hypothesis was
studied in more detail in the following.
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Figure I.2.8 Internalization of the 5-HT3R visualized by fluorescent antagonist accessibility. (A-E): The 5-
HT3R-ECFP chimera (cyan) was labeled with the fluorescent antagonist GR-Cy5 (red). The cells were then
washed with PBS, and the agonist mCPBG was applied for 30 minutes, leading to the internalization of the
receptors. (F-J): Incubation of internalized receptors with the fluorescent antagonist GR-Cy5 reflected the
inaccessibility of the binding sites. (A, F, D, I): confocal imaging; (B, G, E, J): tridimensional projection of
confocal images; (C, H): transmission channel; 5-HT3R-ECFP and GR-Cy5 fluorescence signals are
represented in cyan and red respectively. Size bar = 10 µm.
Quantification of fluorescence intensities arising from 5-HT3R-ECFP on one hand and from the
receptor-bound antagonist GR-Cy5 on the other, allowed to estimate the number of binding sites on
the cell surface receptors accessible for the ligand. The time-course of receptor internalization was
studied by exposing the cells to 500 nM mCPBG for increasing periods of time at 37ºC. The agonist
was then quickly removed by three washes with PBS buffer. Subsequent labeling with GR-Cy5
allowed to visualize remaining 5-HT3 receptors on the cell surface. We observed that more than half
of the receptors were internalized after 5 minutes constant exposure to the agonist (Figure I.2.9A).
The internalized receptors progressively moved away from the cell surface after endocytosis, and
after 2 hours of constant exposure to the agonist, labeling of the plasma membrane with R18 clearly
revealed no overlap of the ECFP signal with the membrane dye indicating complete internalization
of the receptor (Figure I.2.9, B-D).
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Figure I.2.9 Time-course of agonist-induced decrease in cell-surface binding of GR-Cy5 and internalization
imaged by membrane labeling with R18.
(A) Live HEK293 cells expressing the 5-HT3R-ECFP chimera were exposed to 500 nM mCPBG for the
indicated lengths of time. Subsequent washing with PBS and incubation with 12 nM GR-Cy5 allowed to
quantify non-internalized receptors by comparing ECFP and Cy5 fluorescence intensities. Each bar
represents values measured on one cell and the line shows the average values. (B) After 2 hours constant
exposure to the agonist, the cells were membrane-labeled with R18 (red) and imaged by confocal
microscopy. (C) The receptors fluorescence (cyan) clearly revealed no overlap with the membrane-labeled
dye. (D) The tridimensional projection of confocal images of the ECFP label showed a partial clustered
organization of the internalized receptors. Size bars represent 5 µm.
During receptor internalization we observed a progressive disappearance of its cluster distribution
on the membrane upon agonist binding. By coexpression of 5-HT3R-ECFP together with the actin
marker EYFP-Actin, we could observe that these clusters were colocalized with the actin marker,
suggesting the involvement of actin filaments in the membrane organization of the 5-HT3R (Figure
I.2.10). Image treatment of a 5-HT3R-ECFP-expressing cell over time indicated that its fraction of
receptors in cluster form, which was originally almost 50% of total membrane receptors, dropped
by a factor of two after approximately 4 minutes incubation with 500 nM mCPBG, a time frame
comparable to that of internalization as measured conjointly with the fluorescent antagonist.
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Figure I.2.10 Colocalization of 5-HT3R clusters with actin filaments and cluster disappearance during
agonist-induced desensitization. (A) The 5-HT3R-ECFP chimera has a cluster distribution on the plasma
membrane (arrows). (B) Clusters colocalize with actin-rich domains visualized by co-expression of EYFP-
Actin (arrows). (C) After adding 500 nM of the agonist mCPBG, the percentage of membrane receptors in
cluster form is rapidly decreasing and leads to a more homogeneous distribution of the receptors below the
cell membrane. Size bar = 5 µm.
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I.2.5 Discussion
Receptor labeling by genetic fusion with the enhanced version of the cyan fluorescent protein
(ECFP) allowed monitoring of 5-HT3R expression, trafficking, plasma membrane targeting and
ligand-induced endocytosis in real time in living cells.  The fluorescent receptor retained ligand
binding and channel activity, and permitted in vivo observation of its “birth” after delivery of its
coding DNA into HEK293 cells, used as host system for this trafficking study because these cells
allow efficient cell surface expression of 5HT3 receptors [9].
By colocalization with EYFP-labeled subcellular markers, it was possible to monitor the receptor’s
successive appearance in different organelles over time. Furthermore, the formation of ligand
binding sites was observable in situ at an early step in 5-HT3R synthesis in the endoplasmic
reticulum as visualized by labeling with fluorescent antagonists on permeabilized cells. Recent
studies on the ligand binding domain of nicotinic receptors indicated that the assembly of subunits
was required for proper functioning of its binding site [23]. Homology studies between
acetylcholine receptor and 5-HT3R amino acid sequences point to the fact that the ligand binding
site might be located at the interface between two subunits [24,25,31] indicating that assembly of
the 5-HT3 subunits might be required for proper functioning of the binding site. Thus this present
study indicates that the assembly of the 5-HT3R subunits to a functional receptor is likely to occur
in the endoplasmic reticulum, since the labeling with the 5-HT3R-specific antagonist GR-Cy5
correlates in time and space with the fluorescence signal of the 5-HT3R-ECFP in this subcellular
compartment. Thus, we provide the first evidence obtained in situ on individual live cells that the
first formation of functional 5-HT3R specific binding sites occurs in the ER. So far there were only
indirect indications for 5-HT3AR subunit assembly based on radioligand binding in cell fractions
[12]. For the case of the nAchR assembly the formation of alpha-bungarotoxin binding sites was
also found to occur in the endoplasmic reticulum [32]. The recent discovery of an ER retention
signal in 5-HT3B subunits [33] and the fact that these subunits can only be “rescued” from the ER
and assemble to functional receptors by coexpression of 5-HT3 type A subunits in COS 7 cells [8],
are complementary indirect indications in support of our observations.
We were able to follow receptor trafficking from intracellular compartments up to the plasma
membrane as a microtubule-based transport; receptor-containing vesicles leaving the Golgi
apparatus could not reach the membrane when the microtubule formation was blocked for 2 hours
by colchicine treatment. Another support for this hypothesis was provided by velocity
measurements on these vesicles carrying 5-HT3R-ECFP chimeras inside living cells. We obtained
values of 220 to 1850 nm/s by consecutive fluorescence imaging, which is similar as for the Golgi-
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to-plasma membrane transport via post-Golgi carriers on microtubules measured by others [34-38].
The first appearance of receptors on the plasma membrane occurred about 4-5 hours after
transfection onset and exhibited a cluster distribution, which is in agreement with precedent
experiments on the 5-HT3R [9]. By fluorescent overlap with an actin marker, we observed that these
receptor clusters colocalized with actin-rich membrane domains, suggesting an actin-dependent
membrane localization. Moreover, we could observe high receptor densities on cell-cell interfaces,
corroborating with the large quantity of actin present in these domains [39].
It has been shown for other ligand-gated channels such as nicotinic acetylcholine [40], GABAA
[41], P2X1 [42] receptors that long time-course desensitization provoke internalization by
endocytosis. This property, which could furnish a pathway for receptor down-regulation in response
to tonic levels of agonist, was so far not observed for the 5-HT3R. We could monitor ligand-evoked
endocytosis by concerted imaging of 5-HT3R-ECFP and the antagonist GR-Cy5 after application of
the potent specific agonist mCPBG for different time lapses. We observed that after 5 minutes
incubation the number of receptors present on the plasma membrane diminished by a factor of
three, and in parallel that its cluster organization was consistently overtaken by a more
homogeneous distribution, presumably in endosomes located below the cell membrane. The loss of
cell surface binding of GR-Cy5 was the first indication for 5-HT3R internalization.  The localization
of internalized receptors below the plasma membrane could be confirmed by employing a lipophilic
membrane dye, which did not overlap with the bioluminescence signal of the receptor.
In conclusion, the functionally silent insertion of ECFP into the 5-HT3R proved to be a valuable
tool enabling spatial and temporal examination of the receptor trafficking pattern in single living
cells. We have demonstrated that multicolor imaging could be used to study the receptor
translocation to the plasma membrane after biosynthesis, appearing to follow the microtubule
cytoskeleton in post-Golgi carriers whereas its localization and clustering on the plasma membrane
would involve actin filaments. Furthermore, this is the first report to demonstrate in situ the ER-
localized formation of the 5-HT3R ligand binding sites. We could additionally track dynamic
changes in the receptor localization by direct observation of ligand-induced internalization of the
receptor in response to a 5-HT3R-specific agonist. We believe the same methodology using
multicolor dynamic tracking in living cells could be applied to a variety of other receptors in order
to elucidate number of unraveled cellular mechanisms.
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I.3 Probing the 5-HT3 receptor function in single native vesicles via
fluorescence measurements
I.3.1 Abstract
Cytochalasin induces live biological cells to extrude from their plasma membranes native vesicles.
These (sub-)micrometer-sized vesicles comprise functional cell surface receptors exposing their
originally extracellular ligand binding sites on the outer vesicle surface and retain cytosolic proteins
in the vesicle interior. This was demonstrated coexpressing the ionotropic serotonin 5HT3 receptor
and cytosolic GFP in HEK293 cells from which native vesicles were produced. Agonist application
induced cellular transient calcium signaling in native vesicles proving functional preservation of
both vesicular 5HT3 receptors (calcium ion influx) and ion pumps (restoration of initial calcium
concentration). Such vesicles are the smallest autonomous containers capable of performing cellular
signaling reactions. They open new possibilities for multiple analyses of the functions of single live
cells, which especially in the case of primary cells were hampered by limited availability.
The results of this chapter are part of the submitted publication: Pick, H.M., Schmid, E.L., Tairi,
A.P., Ilegems, E., Preuss, A., Hovius, R. and Vogel, H.: Downscaling bioanalytics to the
submicrometer and attoliter range by probing cellular signaling reactions in single native vesicles
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I.3.2 Introduction
Understanding cellular signaling mediated by cell surface receptors is key to modern biological
research and central to drug development [1,2]. Facing the rapidly growing number of (i) molecular
targets discovered by functional genomics [3] and (ii) potential therapeutic compounds produced by
combinatorial chemical synthesis [4], the need of downscaling assay formats is of utmost
importance for accelerating  functional-screening, and reducing costs and reagent consumption [5].
Cellular responses upon activation of cell surface receptors such as intracellular calcium ion signals
or ion fluxes are typically investigated measuring optical or electrical properties of either single
cells or cell populations in microliter volumes [6]. On the other hand, most bioanalytical approaches
on the micro- and nanometer scale are limited to investigations of selected molecular interactions
under artificially reconstituted, non-physiological conditions [7-14].
In the present study, transmembrane signaling reactions on membrane receptors were monitored in
single (sub-)micrometer sized vesicles derived from biological cells. Such native vesicles are the
smallest autonomous containers capable to perform cellular signaling reactions under physiological
conditions, thus downscaling cellular functions to the micrometer and femtoliter level. This ultimate
miniaturization opens novel routes in functional proteomics such as multiplexing single cell
bioanalytics or investigating receptor mediated signaling in multiarray format.
We describe the production of native vesicles and demonstrate that in these vesicles cell surface
receptors and cytoplasmic proteins retain their original cellular location, orientation and function.
Preserved ligand binding functionality and transmembrane calcium ion flux show that native
vesicles may be used as a universal, efficient and cheap bio-analytical reagent for investigating
cellular signaling reactions in a highly parallel format, replacing live cells within many applications.
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I.3.3 Experimental procedures
Chemicals.
Cytochalasin B and Dulbecco’s PBS containing 1 mM CaCl2 were obtained from Sigma (Buchs,
Switzerland); [3H]-GR65630 from NEN-Dupont (Boston, MA); quipazine and mCPBG from
Tocris-Cookson (Langford, UK); granisetron from the Glaxo Institute for Molecular Biology
(Geneva, Switzerland). All other products were of highest quality available.
5-HT3R constructs
The vector containing the short splice variant of the murine 5-hydroxytryptamine type 3A subunit
cDNA preceded by the human cytomegalovirus gene promoter was described elsewhere [15].
The vector p5HT3R-EGFP, containing the receptor fused to EGFP, was obtained the following
way: the original vector was first mutated using the oligos 5'-CTG ATG ACT GCT CAA TCG
ATG CCA TGG GAA ACC-3' and 5'-GGT TTC CCA TGG CAT CGA TTG AGC AGT CAT
CAG-3', adding a ClaI restriction site in the large cytoplasmic loop sequence between the 3rd and
4th predicted membrane-spanning domains. The EGFP insert was obtained by PCR amplification
on the template pEGFP-N1 (Clontech, California, USA) using the synthetic oligonucleotides 5'-
CCA TCG ATA TGG TGA GCA AGG GCG AGG -3' and 5'- CCA TCG ATC TTG TAC AGC
TCG TCC ATG CCG -3', and ligated into the receptor’s ClaI restriction site. The restriction sites
HindIII and NotI were added to the 5’ and 3’ ends of the 5-HT3R-EGFP sequence by PCR
amplification using the oligonucleotides 5’- CGA TAA GCT TCA CCA TGC GGC TCT GCA
TCC CGC AGG TG -3’ and 5’- GCT GTG CCC ACG CGG CCG CTC AAG AAT AAT GCC
AAA TGG ACC AGA G -3’, and the purified 2197 bp fragment was sub-cloned into the
HindIII/NotI cut vector pEAK8 (Edge BioSystems, Gaithersburg, MD, USA), giving rise to the
vector p5HT3R-EGFP, confirmed by restriction mapping and DNA sequencing.
Cell culture and transfection
Adherent human embryonic kidney HEK293 cells were grown in DMEM/F12 (Dulbecco’s
modified Eagle medium) supplemented with either 2.2 % or 10 % fetal calf serum FCS), using
plastic flasks from TPP (Trasadingen, Switzerland). Cultures were kept at 37 °C in humidified, 5 %
CO2 atmosphere. Exponentially growing HEK293 cells were seeded (10
5 cells/ml) into 6-well
plates, and transfected after 16 - 20 h using Effectene (Qiagen, Hilden, Germany). After 4 h the
transfection solution was replaced by fresh medium. To obtain a stable expression of the receptor,
the growth media of transfected cells was supplemented with 1 µg/ml of puromycin for 3 weeks.
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Vesicle formation
Native vesicles were produced from HEK293 cells expressing either the 5HT3R or the 5-HT3R-
EGFP by a 10-20 min incubation at 37°C with cytochalasin B (10 µg/ml) in serum-free DMEM/F12
medium. Cells were first separated from vesicles by centrifugation at 50 g for 5 minutes (Eppendorf
5810, Hamburg, Germany). Vesicles were then collected by centrifugation at 800 g for 20 min and
resuspended in PBS and either used directly or stored in 10 % DMSO at –80 °C for several weeks
without loss of ligand binding activity.
Calcium signaling in native vesicles
HEK293 cells stably expressing 5-HT3R-EGFP were loaded at 37 °C for 30 min with 10 µM Fura-
Red-AM (Molecular Probes, Oregon, USA) in serum-free DMEM/F12 medium. Cells were washed
with PBS and incubated in DMEM/F12 medium containing 10 % FCS for 30 minutes to allow
complete hydrolysis of intracellular Fura Red-AM. Subsequently, cells were treated with
cytochalasin B as described above. Vesicles containing Fura-Red were transferred to 8-well
chambered coverglass slides (grade 1 thickness, Lab-Tek®, Nalge Nunc International, Naperville,
IL, USA) precoated with 0.1 mg/l poly-L-lysine (Sigma) to ensure electrostatic binding of the
vesicles to the glass surface, and investigated by confocal fluorescence microscopy (LSM 510,
Zeiss, Oberkochen, Germany) using a water immersion objective (Zeiss Achroplan 63 NA 1.2).
Excitation was at 488 nm (Ar+ laser) using either 505-530 nm band pass or 650 nm long pass
emission filters to image EGFP and Fura Red, respectively. Vesicles expressing the 5-HT3R-EGFP
receptor, but not loaded with Fura Red were used as control to ensure that no crosstalk did occur
from the green to the red measuring channel. Generally, individual responses to the 5-HT3R-
specific agonist mCPBG were recorded for 100 s.
Radioligand Binding
The total amount of the radioligand [3H]-GR65630 bound to 5HT3R in native vesicles and in whole
cells was determined as described in chapter I.2.
Binding fluorescent ligands to native vesicles
400 µl of native vesicle preparation was added per well of a 6-well plate in which a coverslide had
been placed at the bottom. After vesicle immobilization, the coverslides were transferred to a
microscope chamber and covered with 200-300 µl PBS buffer. Fluorescence intensity
measurements were performed employing a Zeiss LSM510 confocal microscope and evaluated
from regions of interest (ROI) using the microscope software.
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I.3.4 Results
Formation of native vesicles made from cell membranes
Formation of native vesicles was monitored and characterized using HEK293 cells expressing the
serotonin-gated 5-HT3R-EGFP as a prototypic cell membrane receptor. This chimeric receptor is
genetically identical to the one presented in chapter I.2 (5-HT3R-ECFP), except for the labeling
fluorescent protein. Here, the enhanced version of the green fluorescent protein (EGFP) is preferred
to the cyan version because of its higher quantum yield and extinction coefficient [16], and because
it appeared to be less sensitive to photobleaching, important properties especially when studying
low numbers of receptors in very small spatial regions. Treatment of cells with cytochalasin B leads
to the appearance of tubular extensions, which upon agitation bud off as (sub)micrometer sized
vesicles. When treated cells are expressing the 5-HT3R-EGFP fusion protein, produced vesicles
contain the receptor on their membrane as demonstrated by fluorescence confocal microscopy
(Figure I.3.1A).
Receptor activity and orientation is maintained throughout native vesicle production
Native vesicle production was quantified by measuring binding of radioactive ligands to the 5HT3R.
HEK293 cells transiently expressing 5HT3Rs at average level of 1.2 ± 0.2 x 10
6 receptors on the
surface of live cells were used as starting material. Live cells were incubated with cytochalasin B
and vesicles were released from the cells by agitation. Low speed centrifugation yielded a
homogeneous preparation of 0.5 - 1 µm diameter vesicles (Figure I.3.1B). Typically, a single live
cell delivered 50 ± 10 vesicles. From radioactive ligand binding experiments 15 ± 4  % of the
original average cellular receptor activity was found in vesicles, which corresponds to an average
number of about 3500 receptors per vesicle. If we alternatively compare the average surface area of
the native vesicles (2.0 ± 0.6 µm2, histogram in Figure I.3.1B) with the average surface area of a
live cell (580 ± 20 µm2, see Chapter II.3 for more details), we yield a number of 17 ± 6 % of the
cell membrane transformed to native vesicles, in accord with the number calculated above from
ligand binding experiments.
The topology of the plasma membrane of the originating cells is maintained in native vesicles.
Indeed, after cellular co-transfection with wild-type 5-HT3R and cytosolic GFP DNAs the
fluorescent antagonist GR-Rho binds specifically to native vesicles when added from the bulk
aqueous phase (Figure I.3.1B, inset), indicating that the ligand-binding sites of the 5HT3R are
accessible on the outer vesicle surface. Moreover, cytosolic components are enclosed in vesicles as
demonstrated by the presence of cellular cytosolic GFP. Hence vesicles are formed from live cells
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blistering from the plasma membrane without reorientation, thus enclosing parts of the cellular
cytoplasm in the vesicle lumen. Native vesicles therefore represent miniaturized replications of a
living cell.
These findings are important because only those native vesicles are of interest for bioanalytical
applications, which retain both the membrane topology and cytosolic components.
Figure I.3.1 Formation and characterization of native vesicles from HEK293 cells.
(A) Addition of cytochalasin B to HEK293 cells expressing 5-HT3R-EGFP resulted within a few minutes in
the formation of tubular protrusions, detaching from the plasma membrane to form native vesicles. The
successive confocal images are reflecting the fluorescence emitted by the EGFP label. Scale bar represents 2
µm.
(B) Agitation of cytochalasin-treated cells led to the release of about 50 native vesicles/cell, 80% of which
have a diameter of 0.5-1 µm. The insert shows a vesicle emanating from cells transiently co-expressing
cytosolic GFP (green) and the 5HT3R, and subsequently incubated with 5nM of the fluorescent ligand GR-
Rho (red). The fluorescence intensity profile at the indicated line across this vesicle shows clearly the GFP
inside the lumen of the vesicle (green), and the ligand GR-Rho on the enveloping membrane (red).
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Monitoring 5HT3R-agonist induced calcium influx into single vesicles
Agonist induced activation of recombinant 5HT3R in HEK293 cells increases intracellular calcium
ion concentration resulting from calcium influx across the cell membrane [17]. Based on this
finding, we measured agonist-activated calcium responses in individual native vesicles prepared
from mammalian HEK293 cells stably expressing the 5-HT3R-EGFP.
Changes of calcium ion concentration in individual cells and native vesicles were investigated using
the indicator Fura-Red, which upon binding Ca2+ decreases its fluorescence emission at 650 nm.
Transient calcium signaling was observed after the addition of the 5HT3R-specific agonist 1-(m-
chlorophenyl)-biguanide (mCPBG). Addition of 500 nM mCPBG to either live cells or native
vesicles derived from these cells induced an immediate increase of intracellular calcium ion
concentration, followed by a slower restoration (15-20 s) of resting concentration (Figure I.3.2).
The preservation of the kinetics of the transient cellular calcium response in native vesicles in turn
proves an unaltered function of the 5HT3Rs and of ion pumps, which restore initial transmembrane
calcium ion gradients.
Figure I.3.2 Transient Ca2+ signaling in mammalian cells expressing 5HT3R-EGFP (top trace) and in native
vesicles produced from these cells (lower traces). Changes of the Ca2+ concentration inside cells and vesicles
in response to receptor activation by addition (arrow) of the 5HT3R-specific agonist mCPBG (500 nM) were
recorded with laser scanning confocal microscopy using Fura Red (Ex 488/ Em 650) as a fluorescent Ca2+-
indicator. Decrease of the fluorescence signal corresponds to increase of the Ca2+ concentration.
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I.3.5 Discussion
We have developed an efficient protocol to produce native cell membrane vesicles using
cytochalasin B, which is known as an active agent destabilizing cytoskeleton-membrane
interactions [18]. Vesicle sizes varied from about 0.1 to a few micrometers in diameter depending
on the shear forces during vesicle production. Mechanical shear forces released vesicles from the
cell surface whereas the remaining cell bodies were removed by differential centrifugation or
filtration. In contrast to previous work [19], the controlled vesiculation process induced by
cytochalasin B did not involve any cell homogenizing steps, which would release cytoplasmic
proteins and change membrane protein orientation.
Orientation and functional activity of cell surface receptors as well as the presence of cytosolic
proteins are preserved in native vesicles. These vesicles can be immobilized as functional active
containers on solid supports and therefore offer a number of interesting possibilities for
investigating the function of receptor mediated cellular signaling by surface sensitive techniques.
We provided evidence that native vesicles are the smallest functional units capable of performing
transmembrane signaling at fractions of cellular dimensions. Activation of 5-HT3Rs expressed in
HEK293 was shown to evoke increase in intracellular Ca2+ concentration resulting from calcium
influx across the cellular membrane [17]. Increased cytosolic Ca2+ concentrations as a response of
agonist binding to the 5HT3R-EGFP in cells was also observed in native vesicles. This finding
demonstrates that cellular signaling reactions can be monitored in native vesicles.
The native vesicle approach presented here is not limited to cultured mammalian cells. All
eukaryotic cell types are amenable to cytochalasin B treatment since they possess an actin
cytoskeleton [20]. Of importance would be the use of native vesicles from primary cells for
functional screening, thus providing central biological information at an early stage in drug
discovery. So far such strategies were hampered by the limited availability of primary cells. Native
vesicles allow to perform multiple bioanalytical experiments and tests starting with single live cells
(e.g. cancer cells, stem cells, neuronal cells obtained from living organisms) opening new
possibilities in multiplexing functional single cell bioanalytics.
Because native vesicles can be prepared in large quantities, which can be frozen and stored for
many weeks without loosing ligand binding activity (data not shown), they could serve as
miniaturized artificial cells of constant quality for functional assays replacing time consuming,
expensive analytical procedures based on cell cultures of highly variable quality. Downscaling
functional assays from large numbers and volumes to single native vesicles open the door to new
dimensions of miniaturized bioanalytics.
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Chapter I.4
GFPs at the intracellular side of the 5-HT3 receptor sense transmembrane
mediated conformational changes induced by extracellular binding of agonist
I.4 GFPs at the intracellular side of the 5-HT3 receptor sense transmembrane
mediated conformational changes induced by extracellular binding of agonist
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I.4 GFPs at the intracellular side of the 5-HT3 receptor sense transmembrane
mediated conformational changes induced by extracellular binding of agonist
I.4.1 Abstract
We inserted the enhanced green fluorescent protein (EGFP) into the predicted large intracellular
loop of each subunit of the homopentameric 5-HT3 receptor. FRET measurements between the
receptor EGFPs and a rhodamine-labeled 5-HT3 receptor-specific antagonist allowed for
quantitative saturation binding studies on detergent solubilized receptors. Moreover, the close
proximity of the five EGFPs in the assembled 5-HT3 receptor lead to homo-FRET thus to a certain
degree of fluorescence self-quenching. This effect was reversible by denaturing the receptor
subunits by temperature increase. Binding of an agonist to the extracellular side of the 5-HT3
receptor enhanced the receptor EGFPs fluorescence intensity reflecting conformational changes at
the intracellular side of the receptor i.e. EGFPs sense transmembrane signaling. The thereof
calculated EC50 was identical to that obtained by electrophysiology on living cultured cells. These
results point to a novel fluorescence-based strategy for sensing changes in receptor structure and
open the way to a series of functional and structural investigations using the presented
methodology.
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I.4.2 Introduction
The family of cys-loop ionotropic receptors (IR) comprise structurally related pentameric
membrane proteins like the nicotinic acetylcholine, 5-HT3, GABAA, and glycine receptors [1,2],
which open an ion channel upon binding a particular neurotransmitter. This central transmembrane
signaling event must be mediated by a yet undefined transmembrane conformational change within
the receptor protein.
Electron microscopy provided a low resolution structural model of the nicotinic acetylcholine
receptor (nAchR). In addition, from x-ray diffraction of the acetylcholine binding protein [3],
detailed models of the ligand binding region of the nAch, the GABA and the 5-HT3 receptors were
published [4,5]. The question, how binding of a ligand finally leads to channel opening, i.e.
transmembrane signaling, yet remains to be answered. Here we show for the first time for a ligand-
gated ion channel, that agonist binding at the extracellular side of the receptor, which induces
channel opening, finally transmits a conformational change at the intracellular side of the receptor.
We investigated that for the case of the 5-HT3R using optical detection.
To facilitate their study, ligand-gated receptors can be fused to the green fluorescent protein [6-10].
As a novel strategy we demonstrate the use of GFP tagging for sensing changes in receptor
structure upon its activation.
The murine 5-HT3 receptor, which is known to mediate fast signal transduction across synapses in
the nervous system, consists of five identical subunits each comprising a large extracellular N-
terminal ligand binding domain [5,11-15] followed by four transmembrane segments connected by
three short loops, and a final large intracellular domain [16,17].
We have characterized the functional properties of a bioluminescent version of the 5-HT3R, which
was obtained by insertion of an enhanced green fluorescent protein into the large intracellular loop
of each of its five subunits. The resulting receptor construct exhibited fully preserved functionality
in terms of ligand binding and channel activity and its intrinsic autofluorescent labels allowed for
FRET-based biophysical studies.
In that sense, it was possible to quantify saturation binding of a 5-HT3R specific fluorescent
antagonist. Furthermore, the direct integration of the EGFP labels into the intracellular part of the
receptor allowed for monitoring conformational changes in its quaternary structure induced by
agonist binding.  Finally EGFP tagging and the use of specific fluorescent ligands enabled to
determine molecular details of the 5-HT3R structure by FRET analysis.
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I.4.3 Experimental procedures
Materials
Synthetic oligonucleotides were purchased from MWG-Biotech AG (Ebersberg, Germany). Kits for
plasmid and DNA-fragment purification were obtained from QIAGEN GmbH (Hilden, Germany).
Restriction endonucleases (ClaI, HindIII and NotI) were provided by New England Biolabs
(Massachusetts, USA). Purified rEGFP was purchased from Clontech (California, USA). T !h !e !
!r !a !d !i !o !l !i !g !a !n !d ! !3 !- !( !5 !- !m !e !t !h !y !l !- !1 !H !- !i !m !i !d !a !z !o !l !- !4 !- !y !l !) !- !1 !- !( !1 !- ![ !3 !H !] !m !e !t !h !y !l !- !1 !H !- !i !n !d !o !l !- !3 !- !y !l !) !p !r !o !p !a !n !o !n !e ! !( ![ !3 !H!]!-
!G !R !6 !5 !6 !3 !0 !; ! !85.5 ! !C !i !/ ! !m !m !o !l !) ! !w !a !s ! !f !r !o !m ! !N !E !N !- !D !u !P !o !n !t ! !( !B !o !s !t !o !n !, ! !M !A !) !; q !u !i !p !a !z !i !n !e ! !a !n !d ! !1 !- !( !m !-
!c !h !l !o !r !o !p !h !e !n !y !l !) !b !i !g !u !a !n !i !d !e ! !( !m !C !P !B !G !) ! !f !r !o !m ! !T !o !c !r !i !s !- !C !o !o !k !s !o !n ! !( !L !a !n !g !f !o !r !d !, ! !U !K !) !, and granisetron from
Apin Chemicals (Abingdon, UK).!
All experimental data were treated using the software Igor Pro (Wavemetrics, Oregon, USA).
DNA constructs
All constructs are based on a vector containing the short splicing variant of the murine 5-
hydroxytryptamine type 3A subunit cDNA preceded by the human cytomegalovirus gene promoter,
as described before [18].
For purification purposes, a hexa-histidine tag was added at the N-terminus of the 5-HT3 coding
sequence, directly after the signal sequence. The p5HT3R-N-His vector was obtained by site-
directed mutagenesis (Quickchange kit, Stratagene, California, USA) using the oligonucleotides 5’-
GCC GGA GGA GGG CCA CTA GTC ATC ACC ATC ACC ATC ACC AGG AGG ATA CCA
CCC -3’ and 5’- GGG TGG TAT CCT CCT GGT GAT GGT GAT GGT GAT GAC TAG TGG
CCC TCC TCC GGC -3’. The plasmid construct was confirmed by restriction mapping and DNA
sequencing.
The vector p5HT3R-EGFP, containing the receptor fused to EGFP, was obtained as indicated in
chapter I.3
Cell culture and transfections
Adherent mammalian cells (Human Embryonic Kidney, HEK293) were grown in DMEM/F12
(Dulbecco’s modified Eagle medium; GIBCO BRL, Rockville, USA). The medium was
supplemented with 2.2 % fetal calf serum (GIBCO BRL). The cultures were split regularly and kept
at 37 °C in a humidified atmosphere with 5 % CO2.
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For electrophysiology, confocal microscopy measurements and membrane purification, cells were
seeded in 35 mm cell culture dishes, six-well plates containing 22 mm-diameter glass cover slips
and 150 cm2 flasks at a density of 150’000 cells/ml and transfected using effectene reagent (Qiagen
GmbH, Hilden, Germany). All experiments were performed 48 h after transfection.
Membrane solubilization
All following manipulations were performed on ice or at 4 ºC, to avoid degradation of the receptor.
An amount of 4 g of pelleted cells was used for the membrane solubilization. The cell pellets were
resuspended in 10 ml of a solution containing 10 mM Hepes and 1 mM EDTA at pH 7.4, and
homogenized for 90 seconds with an Ultra-Turrax T25 (IKA, Staufen, Germany). The membrane
fraction was collected by centrifugation at 27’000 g for 40 minutes, and the membrane proteins
were solubilized by resuspending and incubating the pellet in 20 ml of 50 mM NaPi
(NaH2PO4–Na2HPO4), 300 mM NaCl and 50 cmc C12E9 (Anatrace, Maumee, USA) at pH 8.0. A
final centrifugation at 100’000 g for 60 minutes served to remove the remaining membrane fraction,
and the resulting supernatant was collected and stored at –80 ºC until use.
Immobilized metal-ion chromatography purification
5ml of nickel nitrotriacetic acid agarose solution (Qiagen) was used for purification of the 5-HT3R.
The resin was washed 3 times with the membrane solubilization buffer, and incubated at 4 ºC
overnight with the solubilized 5-HT3R-N-His solution. The resine was then packed into a column,
and nonspecifically bound proteins were removed by washing with increasing concentrations of
imidazole in 10 mM NaPi, 500 mM NaCl and 25cmc C12E9 at pH 7.4. Protein elution was followed
by measuring the optical absorption at 280 nm, and the receptor was collected at a concentration of
250 mM imidazole.
The solution was desalted for further analysis of the protein by gel filtration on G-25 columns
(NAP-l0, Pharmacia Biotech, Uppsala, Sweden), using equilibration and elution buffers containing
1 mM Tris and 5 cmc C12E9 at pH 7.4.
Electrophysiology
We used the standard patch-clamp technique in whole-cell voltage-clamp, as described in chapter
I.2.
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Radioactive binding assays
!Receptor concentrations as well as ligand affinities were measured by radioligand binding assay.
100µl of solubilized or purified receptor were incubated for 30 minutes at room temperature in
solutions of 10mM Hepes pH7.4 with varying concentrations of the specific antagonist [3H]-
GR65630 in a final volume of 1ml. !A r !a !p !i !d ! !f !i !l !t !r !a !t !i !o !n ! !t !h !r !o !u !g !h ! !W !h !a !t !m !a !n ! !G !F !/ !B ! !f !i !l !t !e !r !s ! !(p !r !e !s !o !a !k !e !d ! !f !o !r !
!1 !5 ! !m !i !n ! !i !n ! !0 !. !5 !% ! !( !w !/ !v !) ! !p !o !l !y !e !t !h !y !l !e !n !i !m !i !n !e !) !f !o !l !l !o !w !e !d ! !b !y ! !t !w !o ! !w !a !s !h !e !s ! !w !i !t !h ! !3 ! !m !L ! !o !f ! !i !c !e !- !c !o !l !d ! !1 !0 ! !m !M !
!H !E !P !E !S ! at ! !p !H ! !7 !. !4 ! terminated the incubation. ! !F !i !l !t !e !r !s ! !w !e !r !e ! then !t !r !a !n !s !f !e !r !r !e !d ! !i !n !t !o ! !s !c !i !n !t !i !l !l !a !t !i !o !n ! !v !i !a !l !s !, !
!a !n !d ! !4 ! !m !L ! !o !f ! !U !l !t !i !m !a ! !G !o !l !d ! !( !P !a !c !k !a !r !d !, ! !M !e !r !i !d !a !n !, ! !C !T !) ! !w !a !s ! !a !d !d !e !d !. ! !T !h !e ! !r !a !d !i !o !a !c !t !i !v !i !t !y ! !w !a !s ! !m !e !a !s !u !r !e !d ! !i !n ! !a !
!T !r !i !- !C !a !r !b ! !2 !2 !0 !0 !C !A ! !l !i !q !u !i !d ! !s !c !i !n !t !i !l !l !a !t !i !o !n ! !c !o !u !n !t !e !r ! !( !P !a !c !k !a !r !d !) !. ! !N !o !n !s !p !e !c !i !f !i !c ! !b !i !n !d !i !n !g ! !w !a !s ! !d !e !t !e !r !m !i !n !e !d ! !i !n ! !t !h !e !
!p!r!e!s!e!n!c!e! !o!f! !1! µ!M! !q !u!i!p!a!z!i!n!e!.! !A!l!l ! !e!x!p!e!r!i !m!e !n!t !s! !w!e!r!e! !p!e!r!f !o!r!m!e!d! !i !n! !t!r!i!p!l!i !c!a!t!e!.!
The dissociation constant Kd of [
3H]-GR65630 and the Hill coefficient n were calculated by fitting
the experimental data to the binding equation:
         
€ 
[GR65630]bound =
[5 −HT3R]
1+ Kd /[GR65630] free( )
n      [I.4.1]
The binding constant of the rhodamine-labeled ligand GR-Rho[19] has been determined by
competitive radioligand binding assay. The sample containing the receptor was incubated with a
fixed concentration of radioactive [3H]-GR65630 (0.8nM) and increasing concentrations of GR-
Rho. The resulting binding inhibition curve was fitted to:
€ 
y = y0
1+ IC50 /[GR − Rho]( )
−n        [I.4.2]
y and y0 being respectively the fraction of bound [
3H]-GR65630 in the presence and absence of the
competitor GR-Rho. IC50 represents the concentration of GR-Rho that reduced y0 by 50%. The
dissociation constant of GR-Rho was then calculated referring to Cheng and Prusoff [20]:
     
€ 
Kd
GR−Rho =
IC50
1+ [GR65630]/Kd
GR65630       [I.4.3]
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Circular dichroism
The CD spectra of purified 5-HT3R-N-His receptors were obtained on a Model 62DS spectrometer
(Aviv, Lakewood N.J., USA). The protein concentration was 10 nM in 5 cmc C12E9. The spectra
were recorded each nm between 190 and 250 nm, using an averaging time of 10 seconds per
wavelength increment.
For the temperature-dependence experiment, the cuvette chamber was heated at a rate of 1 ºC per
minute, and the sample was measured at 222 nm with an averaging time of 60 seconds. The
ellipticity was recorded at intervals of 2 ºC between 20 and 74 ºC.
The evaluation of protein secondary structure from the CD spectra was performed as described
elsewhere [21,22], based on the method of Hennessey and Johnson [23]. The experimental data
were fitted to a set of 15 protein spectra of known secondary structures.
Fluorescence measurements
Fluorescence measurements on the solubilized 5-HT3R-EGFP and on purified rEGFP (Clontech,
California, USA) were performed on a SPEX Fluorolog II (Instruments S.A., Stanmore, U.K.),
using 1.5 nm excitation and emission bandwidths. Purified rEGFP was dissolved using the same
C12E9 buffer as used for solubilizing the receptor. Quartz cuvettes of 1x1 cm (Hellma, Müllheim,
Germany) were placed in a temperature-controlled holder, and the sample solution was
continuously stirred with a magnetic bar. All experiments were done at 20 ºC, unless otherwise
indicated.
For anisotropy measurements, Glan Taylor polarizers (Halbo Optics, Chelmsford, U.K.) were
placed in the excitation and emission light paths to enable polarized excitation and emission
detection. The excitation and emission wavelengths were 480nm and 512nm respectively, and the
anisotropy r was estimated by
     
€ 
r ⋅ (1−K ⋅OD) = Ivv −
Ihv ⋅ Ivh
Ihh
 
 
 
 
 
 Ivv +
2Ihv ⋅ Ivh
Ihh
 
 
 
 
 
     [I.4.4]
where Ivv and Ivh are respectively the vertically and horizontally polarized fluorescence intensities
measured upon vertical excitation and where Ihv and Ihh are the vertically and horizontally polarized
fluorescence intensities, respectively, measured upon horizontal excitation. OD corresponds to the
optical density of the sample, and the factor (1-K·OD) corrects the effect of light scattering due to
turbidity [24,25]. The proportionality constant K was determined by the anisotropy measurement of
different sample dilutions.
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I.4.4 Results
The two 5-HT3A receptor constructs used are depicted in Figure I.4.1. 5-HT3R-N-His contains an N-
terminal hexa-histidine sequence inserted at the 3’ end of the membrane targeting cDNA sequence.
We used this construct for receptor purification by affinity chromatography. In 5-HT3R-EGFP the
receptor sequence was modified by insertion of the enhanced GFP gene into the large cytoplasmic
loop between the 3rd and 4th predicted membrane-spanning domains of each receptor subunit.
After cellular expression the pentameric 5-HT3R-EGFP receptor contains five green fluorescent
proteins in the intracellular part of the receptor, one per subunit. Radioligand binding and
electrophysiological channel measurement studies confirmed preserved functionality of both
constructs. In the following, we first characterized the pharmacological and optical properties and
then showed how to detect receptor activation by fluorescence.
Figure I.4.1 Coding sequence scheme (left) and subunit topology (right) of the two mutated versions of the
5-HT3 receptor used for this study. The 5-HT3R-N-His construct contains a hexahistidine sequence (“6H”)
between the membrane targeting signal sequence (SS) and the N-terminal extracellular ligand binding
domain. Each subunit of the pentameric 5-HT3R-EGFP mutant protein comprises one EGFP inserted into the
receptor large intracellular loop. “M1”-“M4” are the 4 predicted transmembrane parts.
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Hetero-FRET between the EGFP labels and the fluorescent antagonist GR-Rho
Incubation of solubilized 5-HT3R-EGFP for 3 minutes with increasing concentrations of the
rhodamine-labeled antagonist GR-Rho resulted in saturable quenching of EGFP fluorescence via
FRET between EGFP and rhodamine moieties (Figure I.4.2). No quenching of the EGFP was
observed when the receptor was !pre-incubated with 1 ! µ!M ! !q !u !i !p !a !z !i !n !e, proving that the FRET
observed before is due to specific binding of GR-Rho to the receptor. Evaluation of EGFP
fluorescence intensity versus GR-Rho concentration data of Figure I.4.2 in the framework of a
Langmuir binding equilibrium, yields a dissociation constant of Kd ≈ 1.4 nM for GR-Rho,
comparable to the Kd value obtained via competitive radioligand binding assay (Table I.4.1).
Figure I.4.2 Fluorescence resonance energy transfer between the EGFP label on solubilized 5-HT3R-EGFP
and the rhodamine-labeled antagonist GR-Rho: the EGFP fluorescence is measured after 3 minutes
incubation in presence of increasing concentrations of the ligand.
Table I.4.1 Determination of the dissociation constant of the ligand GR-Rho via radioactive and FRET
binding assays. The GR-Rho EC50 value was obtained by competitive radioactive binding assay, and
represents the concentration of GR-Rho necessary to reduce the binding of 0.8 nM [3H]-GR65630 by 50 %
(see Materials and Methods).
Kd [
3H]-GR65630 [nM] EC50 GR-Rho [nM] Kd GR-Rho [nM]
Radioactive binding assay 0.7 ± 0.2 42 ± 6 1.2 ± 0.5
FRET binding assay – – 1.4 ± 0.3
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Homo-FRET between EGFP-labeled subunits
The close distance between cytoplasmic EGFP labels in the 5-HT3R-EGFP leads to a partial
quenching of their fluorescence. In order to quantify the energy transfer between neighboring EGFP
molecules in the homo-pentamer, we denatured the receptor by temperature increase. Unfolding of
the receptor occurs at a temperature of 57.7 ± 0.3 ºC, as measured by circular dichroism in a parallel
experiment on the purified 5-HT3R-N-His (Figure I.4.3A, Table I.4.2). Subsequent temperature
decrease did not lead to the renaturation of the receptor. This denaturation temperature value will
have no influence on the EGFP fluorescence since it is inferior to the EGFP fluorescence half-loss
temperature of 78 ºC [26,27]. Therefore, receptor unfolding can be monitored by following EGFP
fluorescence properties.
The temperature dependence of the EGFP anisotropy was compared between the solubilized 5-
HT3R-EGFP construct and purified rEGFP dissolved into the same buffer containing an equivalent
C12E9 concentration (Figure I.4.3B).
The relation between 5-HT3R-EGFP and rEGFP volumes can be estimated using the Perrin
equation
€ 
r = r0 1+ (τ /φ)[ ]            [I.4.5]
In this equation τ is the fluorescence lifetime and φ is the rotational correlation time, which can also
be expressed as:
      
€ 
φ =
ηV
RT
           [I.4.6]
η being the viscosity of the sample, V the volume of the fluorescent protein, R the gas constant and
T the absolute temperature. By fitting the anisotropy curves of rEGFP and 5-HT3R-EGFP between
10 and 40 ºC - temperature range in which the receptor was shown by circular dichroism to have a
stable structure - using the water viscosity for η [28] and assuming same fluorescence lifetimes, we
obtain a volume ratio of 1.0 ± 0.4.  However, by presuming a proportionality between volume and
molecular weight, the expected volume of the 5-HT3R-EGFP would be about 17 times superior to
that of the EGFP alone. Indeed the 5-HT3A receptor and each EGFP have molecular masses of
approximately 320 kD [19] and 27 kD [29], respectively. This experimental divergence is due to the
high “local” concentration of the EGFP fluorophores in the 5-HT3R-EGFP that is reflected by a
certain loss in polarization, as explained by Weber [30]. Above the temperature of 40 ºC we can
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observe differing tendencies of the two curves, as the 5-HT3R-EGFP falls apart and its
intramolecular energy transfer disappears.
Figure I.4.3 Temperature dependence of the 5-HT3 receptor structure. (A) Circular dichroism was measured
on purified 5-HT3R-N-His receptor at 222 nm with increasing temperatures. At high temperature the
receptor secondary structure is altered, as shown by the CD spectra in inset. (B) Anisotropy of the
solubilized 5-HT3R-EGFP receptor (filled squares) and of purified rEGFP (empty squares), measured at
excitation and emission wavelengths of 480 nm and 512 nm respectively. (C) Fluorescence intensity of the
EGFP moiety in the solubilized 5-HT3R-EGFP receptor.
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Table I.4.2 Secondary structure of the purified 5-HT3R-N-His receptor at 20 ºC and 75 ºC, as determined by
circular dichroism spectra analysis.
The fluorescence intensity was measured in function of the temperature, and the quenching of the
fluorescent moieties in the 5-HT3R-EGFP can be deducted by the fluorescence increase at a
temperature corresponding to the denaturation of the receptors secondary structure (Figure I.4.3C).
We measured a value of 80 ± 2 % of fluorescence intensity at low temperature in comparison to that
obtained at temperatures higher that 70 ºC. Quantification at room temperature by EGFP
fluorescence intensity measurements using purified rEGFP at known concentrations for calibration
revealed an apparent pentameric receptor concentration of 3.3 ± 0.1 nM. The radioligand binding
assay on the same sample yielded a receptor concentration of 4.0 ± 0.2 nM, giving a similar ratio of
82 ± 7 %.
The transition temperatures measured by these three different methods are summarized in Table
I.4.3 and indicate a reliable correlation between fluorescence measurements and secondary
structure.
Table I.4.3 Transition temperature of the 5-HT3 receptor, measured by circular dichroism on purified 5-
HT3R-N-His, and by anisotropy and fluorescence measurements on solubilized 5-HT3R-EGFP.
α-helix β-sheet β-turn   undefined
20 ºC 51 % 24 % 17 %   8 %
75 ºC 13 % 0 % 0 %   87 %
Circular Dichroism Anisotropy   Fluorescence
Transition temperature 57.7 ± 0.3 ºC 59.5 ± 0.3 ºC   57.3 ± 0.8 ºC
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5-HT3R activation by mCPBG
The solubilized 5-HT3R-EGFP was submitted to different concentrations of the specific receptor
agonist mCPBG [31] to assess any structural change via fluorescence intensity measurement. After
3 minutes incubation, the EGFP autofluorescence intensity of the receptor was recorded and a slight
increase was quantified, reaching a plateau at saturated concentrations of the agonist (Figure I.4.4).
When the solubilized receptor was pre-incubated with excess of the competing antagonist
granisetron (1 µM), the EGFP fluorescence did not increase in presence of mCPBG, proving the
specificity of the fluorescence variation.
The calculated EC50 of 0.5 ± 0.2 µM was in perfect agreement with electrophysiology data,
suggesting an EC50 of 0.66 ± 0.08 µM (Table I.4.4).
Figure I.4.4 Channel activity of the 5-HT3R-EGFP as measured by conventional patch-clamp technique on
whole cells (left) and by EGFP fluorescence of the solubilized receptor. Application of mCPBG to the
receptor results in ion influx (left) and increased fluorescence intensity (right).
Table I.4.4 Activation of the 5-HT3R-EGFP mutant with the agonist mCPBG via electrophysiology and
fluorescence quantification. Electrophysiology was performed on transiently transfected HEK293 cells, and
the EGFP fluorescence measurement was recorded on solubilized labeled receptor.
EC50 [µM] Hill coefficient
Electrophysiology 0.66 ± 0.08 1.4 ± 0.2
EGFP fluorescence 0.5 ± 0.2 0.8 ± 0.3
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Estimation of intramolecular distances in the 5-HT3R-EGFP receptor
The fluorescence quantification in both hetero- and homo-FRET allows us to estimate
intramolecular distances in our fusion receptor, using the relation
€ 
E =
R0 /ri( )
6
i
∑
1+ R0 /ri( )
6
i
∑
[I.4.7]
where E is the energy transfer efficiency depending on the Förster distance R0 and the
intrachromophoric distances ri [32,33].
In the present case, if we arbitrary assume the rhodamine label of the antagonist GR-Rho to be in
the plane formed by one of the green fluorescent proteins and the receptor axis, the GFP cores can
be classified in three groups – G1, G2, G3 – corresponding to three different intrachromophoric
distances due to symmetry (Figure I.4.5).
Figure I.4.5 Scheme of intramolecular distances. Gx represent the EGFP fluorescent cores, Rho the GR-Rho
bound to the receptor, a and b represent the distance Rho~axis and Gx~axis respectively, and h is the
perpendicular distance between the EGFPs plane and GR-Rho. In our approximation, Rho~axis and G1~axis
are in the same plane. Distances in function of a, b and h:
Rho~G1= 
€ 
h2 + (b − a)2 ;
Rho~G2= 
€ 
h2 + (b − (1− 2sin(π /5))a)2 ;
Rho~G3= 
€ 
h2 + (b − (1− 2sin(2π /5))a)2 ;
G1~G2 = 
€ 
2bsin(π /5) ;
G1~G3 = 
€ 
2bsin(2π /5) .
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The energy transfer efficiency for the couple EGFP fluorophores/GR-Rho is then:
€ 
EEGFP~Rho =
R0
EGFP ~Rho
G1 ~ Rho
 
 
 
 
 
 
6
+ 2 R0
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 
 
 
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 
6
+ 2 R0
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6        [I.4.8]
where Gx~Rho are the distances between the GFP cores and the rhodamine label.
The relation between EGFP fluorescence and EEGFP~Rho is:
€ 
Fbound _GRRho
Fno_GRRho
=1− EEGFP~Rho    [I.4.9]
where Fbound_GRRho and Fno_GRRho are the fluorescence intensities of the receptor in presence of a
saturating concentration of GR-Rho and in absence of fluorescent ligand, respectively.
The FRET efficiency between one EGFP fluorophore and its 4 neighbors is:
€ 
EEGFP~EGFP =
2 R0
EGFP~EGFP
G1 ~ G2
 
 
 
 
 
 
6
+ 2 R0
EGFP~EGFP
G1 ~ G3
 
 
 
 
 
 
6
1+ 2 R0
EGFP~EGFP
G1 ~ G2
 
 
 
 
 
 
6
+ 2 R0
EGFP~EGFP
G1 ~ G3
 
 
 
 
 
 
6  [I.4.10]
where G1~Gx are the distances between the GFP donor and its neighboring acceptors.
Because the transferred energy is partially re-emitted by the acceptor, the observed EGFP
fluorescence Fobserved is formulated:
€ 
Fobserved
FnoFRET
= (1− EEGFP~EGFP ) φEGFP ⋅ EEGFP~EGFP( )
i
i= 0
∞
∑ [I.4.11]
where  FnoFRET represents the EGFP fluorescence intensity in absence of homo-FRET and 
€ 
φEGFP  is
its quantum yield.
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The different spectral overlaps (Figure I.4.6A) and Förster distances can be calculated using the
equations:
J = overlap integral =
€ 
FD (λ)∫ εA (λ)λ4dλ [I.4.12]
and
€ 
R0
6 = 8.785 ⋅10−5 κ
2φDJ
n4
[I.4.13]
where FD(λ) is the peak-normalized fluorescence spectrum, εA(λ) the molar absorption coefficient,
κ2 the orientation factor, φD the quantum yield of the donor in absence of acceptor and n the index
of refraction. All wavelengths are expressed in cm.
While the refractive index of the medium between the donor and acceptor is not known precisely, it
is assumed here to be equal to that of water.
Using quenching values of 20 ± 2 % due to homo-FRET, 9 ± 1 % due to FRET between the EGFP
moieties and the rhodamine label, and assuming a κ2 of 2/3 we could estimate 5-HT3R-EGFP
intramolecular distances (Figure I.4.6B, Table I.4.5). We calculated a distance of 78 ± 5 Å between
the EGFP plane and the rhodamine label on the fluorescent antagonist, independently of the
distance “a” between the axis and the rhodamine label, and distances of 40 ± 5 Å and 43 ± 6 Å
between the EGFPs and the 5-HT3R symmetry axis in respectively resting and desensitized states.
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Figure I.4.6 Spectral overlaps of EGFP and GR-Rho absorbance and emission curves (A) and approximation
of the distance between the rhodamine label and the EGFP plane and between each EGFP and the channel
axis. The rhodamine label in the antagonist GR-Rho is represented by a star, and the EGFP cores are
designated by crosses. One subunit is drawn with dashed lines for clarity purposes.
R0 GR-Rho~EGFP plane EGFP~axis (closed state) EGFP~axis (desensitized)
Hetero-FRET 47.7 Å 78 ± 5 Å – –
Homo-FRET 40.6 Å – 40 ± 5 Å 43 ± 6 Å
Table I.4.5 Förster distance of the fluorescent couples EGFP-rhodamine (hetero-FRET) and EGFP-EGFP
(homo-FRET), and estimation of inter-molecular distances. The distances were calculated assuming an
orientation factor κ2 of 2/3.
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I.4.5 Discussion
We generated a bioluminescent version of the murine 5-HT3A receptor by inserting the coding
sequence of the enhanced green fluorescent protein (EGFP) into its large cytoplasmic loop. This
construct exhibited preserved ligand binding and channel properties. The particular position of the
EGFP label – between the 3rd and 4th predicted membrane-spanning domains in each of the five
subunits – allowed for two different types of fluorescence energy transfer measurements. In a first
case, we demonstrated the ability to on-line measure saturation ligand binding on detergent
solubilized receptors by following the EGFP fluorescence diminishment in presence of increasing
concentrations of a 5-HT3R specific antagonist labeled with the acceptor rhodamine. With these
FRET measurements we obtained a binding constant, which was virtually identical to the one
obtained by competitive radioactive binding assay.
The relative proximity of the five EGFP labels in the assembled pentameric receptor causes specific
fluorescence properties, which were shown to be sensitive to changes in the receptor structure. In
the functionally active, detergent-solubilized 5-HT3R the EGFPs are self-quenched due to homo-
FRET. This was demonstrated by changes in both fluorescence intensity and fluorescence
anisotropy denaturating the 5-HT3R-EGFP at higher temperatures. The increase of EGFP
fluorescence intensity after temperature-induced denaturation can be explained by a structural
change mediated separation of the EGFP-labeled subunits. In a parallel experiment, unfolding of the
5-HT3R was monitored by circular dichroism. The transition temperature Tt at which 50 % of the
receptors were denatured corresponded to Tt observed by fluorescence anisotropy and fluorescence
intensity measurements. Because the transition temperature for receptor unfolding at Tt~58 ºC is
distinctly below the cloud point at 88 ºC of the detergent C12E9 [34,35], the fluorescence and CD
experiments were not influenced by structural transitions of the used detergent.
Since changes of the intrinsic EGFP fluorescence intensity were indicative to changes in the
receptor structure, we then considered the possibility of monitoring conformational changes upon
receptor activation directly by fluorescence measurements. By applying increasing concentrations
of a non-fluorescent agonist to the EGFP-labeled receptor we observed an increase in fluorescence
intensity. That intensity reached a plateau at an agonist concentration saturating the receptors’
binding sites. The calculated EC50 was consistent with electrophysiology data on living cells
expressing the EGFP tagged 5-HT3 receptor, suggesting that agonist induced changes in the
receptor conformation might be reflected by changes in the intrinsic EGFP fluorescence intensity.
Moreover, incubation of the receptor with the non-fluorescent antagonist granisetron had no effect
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on the emission intensity, demonstrating the high specificity of our measurements and confirming
the observed effect of agonist binding on receptor conformation.
Studies on the structurally related acetylcholine receptor show that the majority of the receptor
molecules adopt a desensitized structure in presence of an agonist [36,37]. In the case of the 5-
HT3R-EGFP the agonist-induced changes of the EGFP fluorescence are measured under conditions
where the 5-HT3R is supposed to adopt a desensitized state as well. Structural modifications after
receptor activation would then not be restricted to the second transmembrane domain lining the
pore [38] but also to the more distant large intracellular loop between  the 3rd and 4th
transmembrane domains as demonstrated in the present study.
FRET measurements allowed us also to estimate the distance between the plane containing the
EGFP moieties and the rhodamine label on the fluorescent antagonist, as well as between each
EGFP and the axis of the receptor. The values obtained are in agreement with the cylindrical model
of the 5-HT3 receptor having a length of 11 nm and a radius of 4 nm [39]. Additionally, the distance
of 78 ± 5 Å between the rhodamine label on the GR-Rho and the EGFP plane suggests that each
EGFP is spatially localized at about 1 nm below the cell membrane. Indeed, the distance between
the ligand binding site and the micellar plane replacing the original lipid bilayer [40,41] in
solubilized 5-HT3 receptors was shown to be in the order of 5.4 ± 0.9 nm [42], and the membrane
thickness of 3 nm [43].
While it is impossible at this stage to know the exact value of the orientation factor κ2, we used an
approximate value of 2/3, corresponding to fluorophores isotropically distributed. This assumption
is probably worthwhile in the case of the FRET couple EGFP-rhodamine, since it has been shown
by fluorescence anisotropy measurements on the similar fluorescent ligand GR-flu that its
fluoresceine label was highly mobile [44]. However in the case of homo-FRET between subunits,
and due to the high polarization of the EGFP [45], the orientation factor could differ substantially
hence providing a slightly diverging value for the distance between the EGFPs and the central
symmetry axis. Figure I.4.7 provides a relation between the orientation factor κ2 and the calculated
average distances between the EGFPs. We see in that sense that the conformational change in the
desensitized state can either be an opening of approximately 3 Å, an orientation change of the
EGFPs, or a combination of both. Indeed, in the structurally related GABA and acetylcholine
receptors opening of the channel gate was shown to be induced by the rotation of the second
transmembrane domain, meaning that the activated state of the receptor does not necessarily
implicate a dramatic enlargement of its structure, but possibly only twisting of its subunits [46-49].
More precise structural and functional informations might be obtained by analogous experiments
based on the FRET but using smaller fluorophores. While EGFP labeling of the receptor is
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somehow restricted to certain domains due to the sterical hindrance resulting from the fluorophore
size, techniques such as site-specific incorporation of fluorescent unnatural amino acids [50-52] by
nonsense codon suppression would permit a wide variation in the choice of labeling position thus
the possibility to obtain a detailed structural map of the receptor. The suppression methodology is
especially promising for such integral membrane proteins, which are not yet generally amenable to
the methods of high resolution structure determination (e.g., NMR, x-ray crystallography) and
could be a valuable alternative to tedious techniques such as electron microscopy, which is
moreover restricted to fixed incontrovertible conformational states [48,53]. Fluorescent amino acid
incorporation in, or near the 5-HT3 receptor central pore would lead to precious enlightenments
regarding the gating mechanism and spatial modifications over time upon activation by an agonist.
In addition to structural studies the FRET methodology could have another potential application in
drug screening. Using multiarray plates it might be possible to monitor at once and in real time both
ligand binding and channel activation of a wide variety of agonists and antagonists via fluorescence
measurements based on hetero-FRET with a competing fluorescent acceptor ligand and inter-
subunit homo-FRET respectively.
Figure I.4.7 Calculated distance between the EGFP label on one subunit and the channel axis, in relation to
the orientation factor κ2. The two thick lines are representing the position of the EGFP in absence of any
ligand and with a bound agonist (mCPBG). The corresponding fluorescence intensities are expressed in
percentage of the fluorescence of completely separated subunits.
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Part II - Protein labeling using mis-acylated suppressor tRNA technology
II.1.1 Introduction
A relatively new technique, pioneered by the group of P.G. Schultz [1], permits the covalent
labeling of proteins using probes much smaller than reporter proteins such as the green fluorescent
protein [2] or the human alkylguanine transferase (hAGT) [3]. Based on the site-specific
biosynthetic incorporation of artificial amino acids, this approach exhibits minimal interference
with the protein structure and function. Introduction of fluorescent unnatural amino acids is of
special interest for energy transfer measurements that could lead to precise informations regarding
topology, structure and function of membrane proteins. It has already been used with success in the
laboratory of professor Horst Vogel for structural analysis of the tachykinin neurokinin-2 receptor
[4,5]. Indeed, whereas classical site-directed mutagenesis allows for the study of molecular
interactions between ligand molecules and specific amino acids in a receptor protein [6-8], the
suppressor tRNA technology can be used to introduce fluorescent or other chemical groups for
structural investigations as well as for monitoring conformational or functional changes inside a
given protein induced by extremely fine modifications on the atomic level [9,10].
The original strategy was based on the synthesis of a messenger RNA containing an amber codon
(UAG) at the incorporation position, to which an artificial transfer RNA carrying the artificial
amino acid and containing the complementary anti-codon sequence is targeted during in vivo
protein synthesis (Figure II.1.1).
Figure II.1.1: General scheme of the site-specific incorporation of unnatural amino acids in proteins: a mis-
acylated suppressor tRNA and a mRNA containing an amber stop codon at the incorporation position are
applied to the translational machinery, integrating the artificial amino acid in the nascent protein emerging
from the ribosome. Plain circle = natural amino acid, circled star = unnatural amino acid.
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Acylation of the suppressor tRNA can either be carried out in vitro, by enzymatic ligation of a
chemically acylated synthetic short nucleotide together with an in vitro transcribed RNA strand [11-
14], or in vivo, by genetic modification of the host cell [15-24].
In most of the published experiments involving mis-acylated tRNA, the codon/anticodon triplets
were chosen to be one of the three natural stop codons, amber (UAG), ochre (UAA) or opal (UGA),
because none of them is coding for a specific natural amino acid (see Figure II.1.2 left). Preventing
a non-desired incorporation of a competing natural amino acid, this choice of triplet has however
the drawback of being recognized by the prokaryotic or eukaryotic release factors, triggering the
termination of the protein synthesis [25,26]. This obstacle results in a low yield of unnatural amino
acid incorporation. In an attempt to circumvent this impeding competition between the release
factors and the mis-acylated suppressor tRNA, research has been focused to find codons not
recognized by any endogeneous tRNA nor the release factors, but still accepted by the ribosome.
An extension of the genetic code would additionally permit in principle the site-specific
incorporation of several different unnatural amino acids in the same protein, allowing for instance
intramolecular fluorescence energy transfer measurements [27].
Such efforts lead to the synthesis of codons and anticodons containing artificial nucleotide
analogues [28-31], necessitating complicated chemistry on both mRNA and tRNA levels.
Unfortunately, the specificity of base pairing using such unnatural nucleotides is at this time not
sufficient for a reliable incorporation of synthetic amino acids.
In parallel, research initiated by the group of M. Sisido focused on 4- and 5-bases codons [27,32-
40]. By creating a novel tRNA based on a corresponding codon rarely used in the host cell system
and having one or two supplementary bases in the anticodon, they succeeded in obtaining frame-
shift suppression. The fact that the starting triplet is almost not used in the host cell allows for a
minimal competition, whereas the additional base(s) permits the specific incorporation of several
different unnatural amino acids. However, the triplet of choice is highly depending on the species
used for translation, needing a specific customization that is maybe not possible in every case. This
special codon/anticodon pair has also to be sufficiently specific: since the discovery of the genetic
code degeneracy [41], it has been shown that unlike the first two base pairs, the third base pair
between codon and anticodon is not closely monitored by the ribosome, as demonstrated later by x-
ray crystallography [42]. The strongest codon-anticodon interaction is thus required in this
“wobble” position [43-45] to allow for the fourth (and fifth) base to have an adequate specificity.
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Apart from that, a disadvantage of this latter technique is the possible incorporation of natural
amino acids at the position of interest by the natural frameshifting that can occur when the ribosome
is stalled, once the artificial suppressor tRNA is “used-up”. Also, it is potentially possible that the
artificial tRNA can incorporate unnatural amino acids at non-desired positions, using 3 instead of 4-
5 bases.
Even though not universally exploitable, this frameshift suppression technique has already been
applied with success using Escherichia coli in vitro translation systems [27].
For any of these suppressor codons, the rest of the tRNA sequence has also to be considered. While
many tRNAs are recognized by aminoacyl RNA synthetases (AARS) by their anticodon [46,47],
most of them are recognized by other nucleotides [48-53] (see Figure II.1.2 right). The consequence
is that, although the anticodon is designed not to be present in any other tRNA, the suppressor
tRNA could anyway be aminoacylated by endogenous AARS targeting natural tRNAs, leading to
the incorporation of natural amino acids in the protein position of interest. Since the lifetime of an
uncharged tRNA is relatively important as compared to the mis-acylated one [54], this could result
in a large quantity of the unmodified form of the protein under investigation. An adequate tRNA
sequence has hence to be engineered specifically for each cell type utilized.
Figure II.1.2: (left) Codon table (adapted from F.H. Crick [55]). (right) Schematic representation of the
three-dimensional structure of tRNA. Circles indicate the position of nucleotides, the size of which is
proportional to the recognition frequency by AARSs. The acceptor stem is the helical structure formed by
base pairing of bases 1 to 7 with bases 72 to 66. (Figure adapted from McClain & Nicholas [56])
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The second part of the present thesis aims at the extension of this mis-acylated suppressor tRNA
technology to cultured mammalian cells, generally more suitable for structural and functional
studies of membrane proteins such as the 5-HT3 neurotransmitter receptor. Indeed, this technique
has been originally developed as an in vitro method [33,57-61], and later applied in vivo to Xenopus
oocytes  [4,5,9,62,63] and Escherichia coli [16,17,20,21], either unsuited to specific protein
localization and folding or requiring purification to avoid their strong endogenous cellular
autofluorescence when measuring specific fluorescence emitted by unnatural amino acids. An
extension to mammalian cells would permit FRET measurements directly in living cells,
circumventing a possible functional or structural change that can occur during purification.
Firstly, in chapter II.2, I study lipofection as a general tool to guide RNA molecules into cells and
investigate the suitability of this technique for various RNA species through kinetic measurements
of cellular uptake.
In the following chapter, I quantitatively measure specific amino acid incorporation efficiency using
mis-acylated suppressor tRNA in adherent mammalian cells, and propose a general strategy to
assay the adaptability of tRNA sequences to this suppressor technology in any cultured mammalian
cell line.
Using any codon/anticodon pair, a natural suppression can lead to the incorporation of a natural
amino acid in place of the desired unnatural one. This naturally occurring event [64-68] is
depending on the codon sequence [69] and is varying among the cell lines under study. I propose in
chapter II.4 an approach to measure the suitability of different cell lines and of the suppressor codon
sequence, regarding the natural suppression aspect.
Finally, I study in the last chapter the effect of the eRF1 cellular concentration on the artificial
suppression using stop codons, and investigate the possibility to improve incorporation efficiency.
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II.2 mRNA transfection as a mean to achieve homogeneous protein expression:
uptake and expression profiles
II.2.1 Abstract
The delivery of nucleic acids is a primordial step in most experiments based on cultured
mammalian cells, permitting among others functional or structural studies of recombinant proteins.
Transfections of populations of adherent cells generally involve the nuclear delivery of plasmid
DNA using various techniques such as calcium-phosphate, lipofection, or electroporation. These
methods show day-to-day variations in protein expression, notably because the plasmid DNA has to
enter the cell nucleus and is therefore depending on the cell cycle. Furthermore, this fact is reflected
by a lack of homogeneity regarding the protein expression level, impeding proper cell-to-cell
comparisons.
The present chapter deals with the study of mRNA delivery using EGFP as a reporter gene. We
compare protein expression levels between individual cells in cell populations, showing day-to-day
and cell-to-cell homogeneities on the expression level contrarily to plasmid DNA transfection. The
nucleic acid uptake kinetic using lipofection was additionally monitored to discuss the suitability of
this transfection technique for the cellular delivery of degradable molecules such as RNAs.
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II.2.2 Introduction
Biological and medical research is exploiting different transfection techniques for the delivery of
genetic material to a wide variety of cell types. The methods used are either targeting single cells by
microinjection [1,2], or cell population in culture by calcium-phosphate precipitation [3], DEAE-
dextran [4], viral transfection [5], electroporation [6,7] or lipofection [8-10] to mention the most
commonly exploited techniques.
In most cases, the genetic material is transferred to the cell as circular DNA because of its stability,
high levels of expression obtained, and the possibility to generate stably expressing cell lines. This
“nuclear transfection” – because the DNA needs to enter the nucleus in order to express the desired
protein – is however not suitable for experiments depending on reproducibility and on a
homogeneous yield of expression level among individual cells. Indeed it has been shown that
transfections based on nuclear targeted DNA requires mitotic activity, as proven by experiments
based on cell cycle synchronization [11,12]. Therefore non-synchronized cells having individual
differing cell cycles exhibit cell-to-cell variations in levels of protein expression.
In the present study, we investigate transfection efficiencies and protein expression yields on the
single cell level by comparing delivery of DNA and mRNA encoding the enhanced green
fluorescent protein (EGFP) as a reporter. We use DOTAP lipofection [13] for the transfection of
adherent mammalian cells. We also evaluate the lipid-nucleotide complex cellular uptake time to
study the suitability of cytoplasmic lipofection to highly degradation-sensitive molecules such as
mRNA, tRNA or siRNA, taking into account that cationic lipids have protecting properties [14].
ILEGEMS
96
II.2.3 Experimental procedures
Materials
Synthetic oligonucleotides were purchased from MWG-Biotech AG (Ebersberg, Germany). Kits for
plasmid and DNA-fragment purification were obtained from QIAGEN GmbH (Hilden, Germany).
The restriction endonuclease NotI was provided by New England Biolabs (Massachusetts, USA).
Chemicals were purchased from Sigma-Aldrich (Missouri, USA). The MEGAscript kit for in vitro
transcription and the cap analog m7G(5’)ppp(5’)G were from Ambion (Texas, USA). Purified
rEGFP was purchased from Clontech (California, USA), and DOTAP liposomal reagent was
obtained from Boehringer (Mannheim, Germany).
EGFP mRNA transcription
Capped mRNA coding for the EGFP was synthesized from the DNA template pT7PEGFP as
described in details in Chapter II.3, using the MEGAscript kit (Ambion, Texas, USA) and the cap
analog m7G(5’)ppp(5’)G (Ambion).
Cell lines and transfection
HEK293 cells were grown in DMEM/F12 (Dulbecco’s modified Eagle medium; GIBCO BRL,
Rockville, USA) at a density of 150’000 cells/ml. The medium was supplemented with 2.2 % fetal
calf serum (GIBCO BRL). The cultures were split regularly prior to transfection and kept at 37 °C
in a humidified atmosphere with 5 % CO2. The transfection was performed as follows, per milliliter
of cell culture: a mixture containing 2.5 µg of mRNA or DNA and 3.75 µl DOTAP diluted in 50 µl
of 10 mM Hepes buffer at pH 7.4 was incubated for 10 minutes at room temperature, and applied
dropwise to the cell medium. Experiments involving the use of the fluorescently labeled
oligonucleotide were done by replacing 10 % (mass) of the reporter EGFP mRNA with a Cy5-
labeled primer (random sequence: 5’-GTC GTC GTC GTC TGA CCT GGA TGA TCT GTC GTC
GTC GTC-3’). All fluorescent measurements were performed 20 hours after transfection.
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EGFP and Cy5 quantification using a fluorescence plate reader
We used 6-well plates (TPP, Trasadingen, Switzerland) for fluorescence intensity quantifications in
a plate reader. The growth medium was removed and the adherent cells were homogenized for 10
minutes at 37 ºC in 270 µl PBS containing 10 % Triton-X100 (Fluka, Buchs, Switzerland). The
measurements were performed with an Analyst plate reader (LJL Biosystems, California, USA)
using 200 µl per sample in 96-well plates (Greiner, Frickenhausen, Germany).
FACS analysis
Cells were transfected in 25 cm2 flasks 20 hours before analysis, detached using Trypsin-EDTA and
resuspended in PBS. FACS analysis was performed on a PAS III flow cytometer (Partec GmbH,
Münster, Germany), using a 488 nm laser excitation and a 520-560 nm detection filter. Each
experiment was based on the analysis of approximately 30’000 cells per sample at a rate of 100-200
cells/s.
Laser scanning confocal microscopy
The cells were seeded on glass coverslips and imaged using a Zeiss LSM510 (Carl Zeiss AG)
confocal microscope. Detection and distinction of the fluorescence signals of EGFP (excitation at
488 nm) and Cy5 (excitation at 633 nm) was achieved by appropriate filter sets.
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II.2.4 Results
We present here a comparison study between two different transfection pathways by lipofection in
adherent mammalian cells, as depicted in Figure II.2.1.
A
B
   
Figure II.2.1 Comparison of transfection pathways: whereas transfection with mRNA (A) only needs to
traverse the cell plasma membrane for successful expression of the protein of interest, the transfection with
DNA vectors targeting nuclear polymerases (B) additionally requires to pass through the nuclear membrane.
In the present study, the expression level is quantified by the use of nucleotides coding for the EGFP, which
is finally measured by its fluorescence.
Transfections of adherent mammalian cell cultures are generally performed using DNA vectors
containing a eukaryotic promoter (Figure II.2.1B). A successful expression of the gene of interest
requires the vector to pass the plasma membrane, cytoplasm and nuclear membrane to be
recognized and processed by nuclear transcription factors. Direct transfection of in vitro-transcribed
mRNA represents the shortest way between gene and protein by bypassing the need to cross the
nuclear barrier in order to obtain a translation (Figure II.2.1A).
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In order to quantify the expression levels we performed transfections of templates coding for the
enhanced version of the green fluorescent protein (EGFP).
Cells were split 16 hours prior to transfection, and the fluorescence intensities were measured on
the single cell level 24 hours after transfection by FACS analysis (Figure II.2.2). The fluorescence
of blank cells was identical with or without application of the transfection reagent DOTAP (not
shown).
Figure II.2.2 Analysis by flow cytometry of the EGFP fluorescence on individual HEK293 cells, 20 hours
after transfection. (A) non-transfected cells, (B) EGFP coding mRNA-transfected cells, and (C) cells
transfected with pEGFP-N1 plasmid.
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As depicted by the dotted lines, the contribution of non-transfected cells to the expression level
histogram is relatively low in the mRNA transfection case (15 ± 3 %), contrarily to the plasmid
DNA transfection (30 ± 15 %). Furthermore homogeneity in fluorescence levels was observed after
transfection of mRNA coding for the EGFP, whereas plasmid DNA transfection exhibited
extremely various expression levels.
Focusing on the mRNA transfection, we examined whether the average expression level was
depending on the cell cycle by transfecting at different time points after cell splitting. 20 hours after
transfection, the cells were lysed and the EGFP fluorescence was measured using a plate reader.
The results are exposed in Figure II.2.3, showing a transfection efficiency almost unchanged three
days after cell splitting.
Figure II.2.3
EGFP fluorescence emitted 24 hours after mRNA transfection in HEK293 cells. The transfection was
performed at different time points after splitting.
By co-transfecting HEK293 cells with EGFP mRNA and a random Cy5-labeled oligonucleotide at
a ratio of 9:1, we investigated the cellular uptake kinetics of nucleic acids. At various times after
transfection, the medium was exchanged to remove the lipofection reagent, allowing to monitor the
uptake that took place during various incubation times. The cells were kept in the incubator for 20
hours after transfection, and lysed for fluorescence measurement (Figure II.2.4) using a plate reader.
The uptake kinetics were similar for both Cy5 and EGFP, with a half-uptake time of about 45-50
minutes (see Table II.2.1). By measuring the Cy5 fluorescence remaining in the growth medium we
estimated the uptake efficiency as 20 ± 2 % of the original nucleic acid content.
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Figure II.2.4 Monitoring mRNA uptake by liposome-mediated transfection: a complex made of EGFP
mRNA, Cy5-labeled synthetic oligonucleotides and DOTAP lipids was applied to HEK293 cells, and the
uptake efficiency was estimated by changing the medium at several time points after transfection and
measuring both Cy5 fluorescence and EGFP fluorescence 20 hours later. The Cy5 fluorescence reflects the
oligonucleotide uptake kinetics (A), the EGFP fluorescence shows the non-degraded mRNA uptake kinetics
(B). The confocal image shows typical fluorescence emerging from cells 20 hours after transfection for Cy5
(A) and for EGFP (B). The insert of the Cy5 image shows a typical vesicular form of the lipid-nucleic acid
complex, imaged during in the first minutes after transfection (size bar = 2 µm).
Table II.2.1
Study of cellular uptake kinetics by lipofection of a 9:1 mixture containing EGFP mRNA and a Cy5-labeled
oligonucleotide on HEK293 cells. The curves are fitted to the Hill equation
f(time)=1/[1+(HalfTime/time)rate]. The uptake percentage is based on the Cy5 fluorescence measurement in
the cells compared to the fluorescence in the growth medium after an incubation of 24 hours.
Transfection kinetics Rate Half-time [hours] Uptake percentage
Cy5 uptake 1.1 ± 0.1 0.79 ± 0.07 20 ± 2 %
EGFP expression 1.4 ± 0.2 0.84 ± 0.05 -
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II.2.5 Discussion
The cell delivery of a messenger RNA encoding the enhanced green fluorescent protein (EGFP)
resulted in a protein expression of remarkable homogeneity among individual cells, as measured by
flow cytometry. Without any cell cycle synchronization we could achieve similar EGFP
fluorescence intensities throughout cell populations. This demonstrates that cytoplasmic translation
process is not cell cycle dependent, whereas the evident heterogeneity of fluorescence levels in non-
synchronized DNA-transfected cells likely reflects differences in nuclear DNA uptake due to cell-
to-cell variations in cell cycle stages. The transfection efficiency, meaning the number of
transfected cells versus the total cell number, was also notably higher than in the case when the
coding DNA had to enter the nucleus.
We measured the uptake kinetics of mRNA-lipid complexes by cotransfecting EGFP mRNA
together with a Cy5-labeled oligonucleotide.  The fluorescence of both Cy5 and expressed EGFP
was quantified over time by incubating populations of cells with the lipid complexes for increasing
periods of time. By fitting the obtained curve to a Hill equation, we obtained a half-time for uptake
of about 45-50 minutes, at a slightly higher rate for EGFP mRNA than for the Cy5-labeled
oligonucleotide. This can be explained by the fact that the EGFP mRNA is degrading over time,
while the Cy5 label remains stable.
These results lead us to the conclusion that mRNA transfection is apparently independent of cell
cycle processes and can lead to homogeneous protein expression in cell populations, ideal for cell-
to-cell comparison on a large scale. Despite a relatively long uptake time, this technique allows for
mRNA and siRNA transfection, partly relieved by a certain RNA stabilization in lipoplexes [14].
Unfortunately, the very short half-life of an acylated tRNA makes lipofection a non-perfectly suited
technique for experiments such as incorporation of non-natural amino acids in proteins using mis-
acylated suppressor tRNA, where microinjection would be more appropriate.
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II.3 Monitoring mis-acylated tRNA suppression efficiency in mammalian cells
via EGFP fluorescence recovery
II.3.1 Abstract
A reporter assay was developed to detect and quantify nonsense codon suppression by chemically
aminoacylated tRNAs in mammalian cells. It is based on the cellular expression of the enhanced
green fluorescent protein (EGFP) as a reporter for the site-specific amino acid incorporation in its
sequence using an orthogonal suppressor tRNA derived from E.coli. Suppression of an engineered
amber codon at position 64 in the EGFP run-off transcript could be achieved by the incorporation of
a leucine via an in vitro aminoacylated suppressor tRNA. Microinjection of defined amounts of
mutagenized EGFP mRNA and suppressor tRNA into individual cells allowed us to accurately
determine suppression efficiencies by measuring the EGFP fluorescence intensity in individual cells
using laser scanning confocal microscopy. Control experiments showed the absence of natural
suppression or aminoacylation of the synthetic tRNA by endogenous aminoacyl-tRNA synthetases.
This reporter assay opens the way for the optimization of essential experimental parameters for
expanding the scope of the suppressor tRNA technology to different cell types.
The results of this chapter have been published in :
Ilegems, E., Pick, H.M. and Vogel, H. (2002) Monitoring mis-acylated tRNA suppression
efficiency in mammalian cells via EGFP fluorescence recovery. Nucleic Acids Res, 30, e128.
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II.3.2 Introduction
The site-specific incorporation of unnatural amino acids into proteins in living cells is of
importance to analyze in vivo protein structure and function as well as cellular processes using
amino acid analogues comprising probes which are photo-activatable, fluorescent or chemically
reactive [1-6]. This emerging technology relies on the suppression of nonsense codon mutations by
chemically acylated tRNAs and has been originally developed as an in vitro method [7-12].
Meanwhile several reports for its in vivo application in Xenopus oocytes [4-6,13,14], Escherichia
coli [15-18] and COS1 cells [19] appeared in literature. An expansion of this technology to other
cell lines would demand a reporter system permitting the definition of optimal parameters for the
site-specific incorporation of amino acid analogues into proteins.
Here, suppressor tRNA technology was applied to Chinese hamster ovary (CHO) cells which, like
other mammalian cell types, are generally more suitable for structural and functional studies of
human derived proteins if specific post-translational modifications are important. In addition,
certain proteins such as neuro-receptors are optimally expressed only in particular cell lines. We
focused on the enhanced green fluorescent protein (EGFP) as a reporter to assess the efficiency of
nonsense codon suppression directly in living cells. An amber stop codon mutation was site-
specifically introduced in the core position of the EGFP, removing an amino acid essential for the
formation of the fluorophore. The transfer of that mutagenized in vitro transcript into CHO cells
was followed by the expression of an incomplete, non-fluorescent protein. After co-transfer with a
cognate synthetic suppressor tRNA, we could monitor the successful re-incorporation of the
missing amino acid by recovery of the EGFP fluorescence signal, which could be quantified by
using laser scanning confocal microscopy on living cells.
Unlike other fluorescent reporters such as luciferase or β-galactosidase, EGFP does not require the
addition of substrate or cofactors nor cell lysis or fixation. Furthermore, it is stable over a period of
several days and, due to its strong fluorescence allows an accurate and sensitive determination of
suppression efficiencies in individual cells. This strategy could be used to find proper conditions for
an efficient suppression in a number of different mammalian cell lines.
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II.3.3 Experimental procedures
Materials
Synthetic oligonucleotides were purchased from MWG-Biotech AG (Ebersberg, Germany). Kits for
plasmid and DNA-fragment purification were obtained from QIAGEN GmbH (Hilden, Germany).
Restriction endonucleases (BsaI, EcoRI and NotI) were provided by New England Biolabs
(Massachusetts, USA). The MEGAscript kit for in vitro transcription and the cap analog
m7G(5’)ppp(5’)G were from Ambion (Texas, USA). Purified rEGFP was purchased from Clontech
(California, USA). Octadecyl rhodamine B (R18) and Alexa Fluor 546 C5 maleimide were obtained
from Molecular Probes (Oregon, USA). Other chemicals were purchased from Sigma-Aldrich
(Missouri, USA).
Transcription of reporter gene
The coding sequence of the enhanced green fluorescent protein (pEGFP-N1, Clontech) was
modified by the addition of a T7 promoter site and a poly(A) tail using PCR amplification with
synthetic oligonucleotides (Figure II.3.1). The resulting 814 bp fragment was ligated into the
pCR2.1 vector using the TA cloning kit (Invitrogen, California, USA) to obtain the plasmid
pT7PEGFP.
The pT7PEGFPam64L is a mutated version of the pT7PEGFP plasmid.  The CTG codon at position
64 of the EGFP coding sequence was mutated to a nonsense amber (TAG) codon by site-directed
mutagenesis using the Quickchange kit (Stratagene, California, USA). All plasmid constructs were
controlled by restriction mapping and DNA sequencing.
After linearization of the wild type and mutated plasmids by NotI, in vitro transcription was
performed with T7 RNA polymerase using the MEGAscript kit (Ambion, Texas, USA). Capping of
mRNA was achieved during transcription by replacing 80 % of the GTP level with the cap analog
m7G(5’)ppp(5’)G (Ambion). After removing the DNA template by DNaseI treatment, the resulting
mRNAs were purified by successive phenol:chloroform:isoamyl alcohol (25:24:1) and
chloroform:isoamyl alcohol (24:1) extractions, precipitation with an equal volume of isopropanol
for 1 hour at –20 ºC, followed by centrifugation at 0 ºC / 20’800 g for 15 minutes. The mRNA
pellet was dried and redissolved in sterile H2O treated with diethyl pyrocarbonate (DEPC). The
integrity and size of the mRNAs were assayed by agarose gel electrophoresis under denaturating
conditions, and the concentration was determined by measuring the optical density at 260 nm.
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Figure II.3.1 Scheme of the cloning steps for the wild type (pT7PEGFP) and mutant EGFP
(pT7PEGFPam64L) encoding plasmids used for the in vitro transcription. PCR amplification with primers 1
and 2 was performed to add a T7 promoter to the 5’ end and a poly(A) tail to the 3’ end of the EGFP coding
sequence. Primers 3 and 4 were used for replacing the leucine 64 codon by TAG, and providing silent
mutations for clonal selection. All nucleotide sequence modifications are shown in bold letters.
Transcription of suppressor tRNA gene
A 105bp synthetic template fragment encoding the E.coli suppressor tRNAAlaCUA was prepared by
reannealing and ligating two synthetic oligonucletides containing the tRNA gene flanked by a T7
promoter (Figure II.3.2). This blunt-end DNA fragment was cloned into the pCR4 vector using the
TOPO cloning Kit (Invitrogen), following the instructions of the manufacturer. The resulting
plasmid pEcoliAlaCUA was checked by restriction mapping and sequencing.
Plasmid pEcoliAlaCUA was linearized by successive restriction endonuclease digests with EcoRI
and BsaI. After agarose gel purification this DNA fragment was used for the run-off transcription
with T7 RNA polymerase following the protocol of the MegaScript Kit (Ambion). After removing
the template DNA by DNaseI treatment the tRNA was purified by following the protocol described
above for mRNA. The integrity and purity of the tRNA was assayed by polyacrylamide gel
electrophoresis, and the concentration was determined by measuring the optical density at 260 nm.
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Figure II.3.2 Scheme for the in vitro synthesis of the suppressor tRNA from a synthetic DNA template by
T7 run-off transcription. Two synthetic complementary oligonucleotides encoding the E.coli derived
suppressor tRNAAlaCUA were annealed and cloned into the pCR4 vector, leading to pEcoliAlaCUA. T7 RNA
polymerase run-off transcription was performed on the purified EcoRI and BsaI fragment giving rise to a 76-
mer suppressor tRNA.
Deprotection of N-(4-Pentenoyl)-S-leucyl-tRNA
Pentenoyl-protected aminoacylated tRNAAlaCUA was customly synthesized at Cruachem Ltd
(Glasgow, Scotland). 10 µg of lyophilized protected tRNA were resuspended in 10 µl H20.
Deprotection was accomplished by adding 2.5 µl of 25 mM I2 in 1:1 THF-H2O and incubating the
mixture for 10 min at 25 °C. The leucyl-tRNA was precipitated by successive additions of 1.25 µl
of 3 M NaOAc pH 5.3 and 31.25 µl of cold ethanol. After centrifugation at 0 ºC / 20’800 g for 15
minutes the pellet was washed once with 70 % cold ethanol, dried and dissolved in H20 to a final
concentration of 4 µg/µl.
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Cell lines and cell culture
Adherent mammalian cells (Chinese hamster ovary, CHO) were grown in DMEM/F12 (Dulbecco’s
modified Eagle medium; GIBCO BRL, Rockville, USA). The medium was supplemented with 2.2
% fetal calf serum (GIBCO BRL). The cultures were split, distributed in 35 mm Nunc dishes at a
density of 50’000 cells/ml 1 day prior to injection, and kept at 37 °C in a humidified atmosphere
with 5 % CO2.
Injections
Microinjections of CHO cells with mRNA and tRNA mixtures diluted in sterile DEPC-treated H2O
were performed using an InjectMan controller and a Transjector 5246 system (both from
Eppendorf, Hamburg, Germany) mounted on an Axiovert S100TV inverted microscope (Carl Zeiss
AG, Oberkochen, Germany). FemtotipsII capillaries (Eppendorf) were used for all injections.
Laser scanning confocal microscopy
Laser scanning confocal microscopy was performed using a Zeiss LSM510 (Carl Zeiss AG).
Detection and distinction of the fluorescence signals of EGFP (excitation 488 nm / emission 505-
530 nm), Alexa546 and R18 (excitation 543 nm / emission > 560 nm) was achieved by appropriate
filter sets using a multitracking mode. Scanning speed and laser intensity were adjusted to avoid
photobleaching of the fluorophores.
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II.3.4 Results
The general scheme used for in vivo visualization of mis-acylated tRNA suppression is presented in
Figure II.3.3A. The suppression efficiency was determined by measuring the appearance of EGFP
fluorescence in living cells. The EGFP coding sequence was mutated at position 64 by replacing the
CTG (leucine) codon with an amber stop codon in the core of the reporter gene, giving rise to the
EGFPam64L in vitro transcript. A successful suppression by co-injection of this mutated mRNA
with a suppressor tRNA carrying the “removed” amino acid would lead to the completion of the
EGFP translation. Twenty hours after co-injection of suppressor leucyl-tRNA with EGFPam64L
mRNA, we observed the recovery of the EGFP fluorescence in CHO cells by laser scanning
confocal microscopy (see Figure II.3.3B), whereas the co-injection of the mutated mRNA together
with the non-aminoacylated tRNA did not lead to any detectable fluorescence within the cells (data
not shown).
Figure II.3.3 In vivo suppression visualized by EGFP fluorescence recovery:
(A) Schematic view of the assay for the amber suppressor tRNA function: co-injection of a mutated EGFP
mRNA containing an amber codon at position 64 with an amber suppressor leucyl-tRNA. A successful
suppression leads to complete translation of the mRNA transcript thus to the appearance of the EGFP
molecule.
(B) Laser scanning confocal micrograph of CHO cells visualizing EGFP fluorescence 20 hours after co-
injection of the mutated EGFP-mRNA with the amber suppressor tRNA. Size bar is 10 µm.
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Because the injected volume may slightly vary between cells, mostly depending on their intrinsic
viscosity, it was necessary to quantify this parameter in order to validate further comparisons
between different experiments. Therefore, the injections of mRNA and tRNA were performed
together with a known concentration of Alexa546. This dye is non-toxic for the cell and its
excitation and emission wavelengths are well distinguishable from those of EGFP.
Correlation between the fluorescence of the co-loaded dye and the injected volume was obtained by
measuring its dilution in the cell and by calculating individual cell volumes. We first elaborated a
fluorescence intensity calibration curve by measurements on droplets containing known
concentrations of the Alexa546 dye using laser scanning confocal microscopy. A linear relation
between fluorescence intensity versus dye concentration was found. Fluorescence intensity
measurements of the co-injected Alexa546 dye on living cells permitted the determination of the
dye concentration within the cells on the basis of this calibration curve.
The injection volume of the Alexa dye together with mRNA and tRNA mixtures can then be
determined by calculating the cell volume. We therefore detached the adherent cells by addition of
1 mM EDTA and incubation at 37 °C for 10 minutes. Under these conditions the cells became
spherical. They were then membrane-stained with R18 (5 µM / 10 minutes incubation at 37 ºC) to
measure their diameter by laser scanning confocal microscopy, leading to a volume of 1.2 ± 0.1 pl.
The number of EGFP molecules which were expressed during in vivo translation in individual cells
can be estimated by comparison of cell-derived EGFP fluorescence intensities with EGFP
fluorescence intensities measured on droplets of known concentrations of purified rEGFP (Figure
II.3.4).
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Figure II.3.4 Confocal calibration curve established by measurement of signal intensities emerging from
droplets containing known concentrations of rEGFP (I) and Alexa546 (II).
To validate the precision of our injections and concentration calibrations, we also co-injected
variable volumes of a solution containing 500 ng/µl rEGFP and 250 ng/µl Alexa546 in CHO cells.
As seen in Figure II.3.5, there is a linear correlation between injected volume, given by the
Alexa546 fluorescence signal, and the number of EGFP molecules per cell.
Figure II.3.5 Correlation between injection volume and number of EGFP molecules per cell by
microinjection of variable volumes of a solution containing 500 ng/µl rEGFP and 250 ng/µl Alexa546 in
CHO cells. The injected volume is calculated on the basis of the known cell volume (see text for detailed
description) and the final concentration of Alexa546 dye measured directly in the cell (based the calibration
curve in Figure II.3.5).
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On the basis of the presented control experiments we performed all following measurements using
concentrations of 250 ng/µl Alexa546, 2 µg/µl mRNA, and 2 µg/µl leucyl-tRNAAlaCUA. These
concentrations gave best suppression efficiencies, (i) permitting the highest number of RNA
molecules delivery without capillary blocking due to the resulting high solution viscosity, and (ii)
favoring the suppression against competing endogenous termination factors at an excess of 10:1 of
tRNA:mRNA molecules.
The EGFP fluorescence resulting from in vivo suppression was stable between 12 and 24 hours
post-injection. The injected cells were easily identified under the microscope via fluorescence of the
co-injected dye. Thereby we could confirm that every injected cell turned green and could be re-
identified even after 24 h incubation at 37 °C. Using the EGFP and Alexa546 fluorescence intensity
calibration curves, we calculated the number of translated EGFP molecules by confocal microscopy
20 hours after microinjection. Because the variation between injection volumes was 0.05 ± 0.01 pl,
we corrected the number of translated EGFP molecules by extrapolation to an average injection
volume of 0.05 pl (Table II.3.1). We obtained suppression efficiencies of 15 ± 3 % by comparing
EGFP fluorescence signals resulting from in vivo suppression with fluorescence signals derived
from the injection of the identical amounts of non-mutated EGFP mRNA.
Table II.3.1 Number of mRNA and tRNA molecules per cell directly calculated after microinjection by
comparison of the co-injected Alexa dye with the confocal calibration curve on droplets. Expression of
EGFP molecules per cell determined on 50 individual cells, 20 hours after injection of RNA. The values are
corrected for a standard injection volume of 0.05 pl. Co-injections were all processed using concentrations of
2 µg/µl mRNA, 2 µg/µl tRNA and 250 ng/µl Alexa546. ND = not detectable.
0.05pl injection mRNA tRNA EGFP
x103 molecules/cell x103 molecules/cell x103 molecules/cell
EGFPam64L mRNA + tRNACUA 250 ± 20 2500 ± 200 ND
EGFPam64L mRNA + leucyl-tRNACUA 250 ± 20 2500 ± 200   270 ± 30
EGFP mRNA 250 ± 20 - 1800 ± 200
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II.3.5 Discussion
A novel assay has been developed using EGFP as a reporter for direct quantification of termination
codon suppression efficiencies in living mammalian cells. We have shown by fluorescence recovery
that an aminoacylated tRNA derived from E.coli can suppress an amber mutation at codon 64 of the
EGFP mRNA by in vivo translation in CHO cells, whereas the non-aminoacylated form of the same
tRNA cannot. EGFP fluorescence intensities measured in individual cells by laser-scanning
confocal microscopy allowed us to quantify suppression efficiencies. Kohrer et al. [19] have used a
different approach to insert amino acid analogues into the chloramphenicol acetyltransferase (CAT)
by importing a suppressor Tyr-tRNA in COS1 cells using lipofection. These authors measured CAT
activies in cell extracts to determine average levels of termination codon suppression efficiencies in
cell samples, but not in individual cells.
The use of EGFP as a suppression reporter offers advantages compared to other detection
techniques such as those based on luciferase, ß-galactosidase or CAT. In contrast to these
destructive methods, EGFP suppression can be followed in vivo in a single cell without further
chemical or enzymatic treatment, due to the sufficiently high quantum yield of this protein.
To improve the suppression-specific fluorescent signal, we increased the signal-to-noise ratio by
lowering the background signal resulting from possible natural suppressor tRNAs. This was
fulfilled by choosing an amino acid in the protein sequence which plays an important role for the
fluorescence properties of the EGFP. As a consequence, a cell line which comprises a natural
suppressor tRNA aminoacylated with a different amino acid would provide a background signal
reduced to an undetectable value. We selected the leucine at position 64 for its importance in the
fluorescence properties of the EGFP, particularly because it highly improves correct protein folding
[20,21]. Furthermore, due to the fact that it is neither a charged nor a polar amino acid, it is more
quickly accepted and processed by the ribosome, thus better competes with the undesirable effect of
termination factors which could prevent the completion of the full-length protein [22-26].
To determine the contribution of unnatural suppression under investigation, the suppressor tRNA
should also not be recognized by any endogeneous aminoacyl-tRNA synthetases. This natural
aminoacylation of the suppressor tRNA can be minimized by choosing a tRNA from another
organism. In our present study, the tRNA sequence was based on that of E.coli tRNAAlaGGC [27]
mutated to CUA at the anticodon site and modified by two other mutations: A38U improves amber
suppression efficiency [28-30], and C70U, renders the non-aminoacylated tRNA a poor substrate
for E.coli alanyl-tRNA synthetase [31]. This tRNA sequence has been shown by Karginov et al. [9]
to have good suppression properties in in vitro translation systems.
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Our experiments to determine suppression efficiencies by measuring EGFP fluorescence intensities
in cells and to estimate amounts of injected mRNA and tRNA molecules were based on laser
scanning confocal microscopy measurements. Microinjection of defined amounts of fluorescent
dyes in CHO cells demonstrated the suitability of this transfection technique to incorporate in a
controlled way quantifiable molecule amounts, in contrast to saponin permeabilization [32],
electroporation [33] or lipofection [19] of mammalian cells. Furthermore, unlike these other
techniques, control of the transfected amount does not depend on cell type or density, admitting a
more accurate comparison between different cell types. Finally, microinjection requires only low
amounts of material, and prevents the RNA degradation that can take place during delivery in other
transfection techniques.
We were able to observe amber suppression of an amber mutated EGFP mRNA using mis-acylated
tRNA in CHO cells, obtaining 15 ± 3 % of the fluorescence signal obtained by injection of the same
amount of non-mutated EGFP mRNA. After estimation of the RNA molecules and EGFP protein
numbers, we obtained approximately one suppressed translation by mRNA (see Table II.3.1).
Refering to a typical injection volume in CHO cells of 0.05 pl, the number of proteins resulting
from unnatural suppression was in the range of 270’000 ± 30’000.
The general applicability of the presented EGFP-based reporter assay will allow us to extend the
suppressor tRNA technique for many other cell types, and hence permit the selection of suitable
suppressor tRNAs for the site-directed modification of proteins.
In particular interest for applying suppressor tRNA technology are investigations of selective
molecular interactions in live biological cells by fluorescence techniques with high time, spatial and
single molecule resolution to elucidate the complex cellular biochemical networks [34,35].
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II.4 Quantification of natural nonsense codon suppression in mammalian cells
using an EGFP reporter assay
II.4.1 Abstract
A general method for the background detection and quantification of natural nonsense codon
suppression in mammalian cell cultures was developed. It is based on the cellular expression of the
enhanced green fluorescent protein (EGFP) as a reporter carrying engineered termination codons in
the in vitro run-off transcript. Delivery of mutagenized EGFP mRNA into adherently growing cells
was achieved by cationic DOTAP liposomes. EGFP fluorescence recovery allowed us to detect cell
type specific differences in natural nonsense codon suppression efficiencies and quantitative data on
cell populations were obtained by fluorescence measurements on cell lysates. This fluorescence-
based reporter assay allows for the screening of cell types exhibiting low levels of natural nonsense
codon suppression suitable for the suppressor tRNA technology as an emerging tool for in vivo
protein engineering.
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II.4.2 Introduction
Genetically engineered termination codons which interrupt a messenger RNA can be targeted by
chemically acylated nonsense suppressor tRNAs to direct nonnatural amino acid residues to
specified locations in a protein. This emerging technology is currently expanding into mammalian
live cell applications [1-4] (see chapter II.3).
The development of this suppressor technology in various mammalian cell cultures requires cell
type specific optimizations. Indeed, the choice of an optimal termination codon in a specific cellular
background has to be considered, since natural nonsense-codon readthrough [5-9] is a well-
described phenomenon, which potentially competes with the desired unnatural suppression event.
Most of the natural suppression in higher eukaryotic cells seems to involve misreading of
termination codons by normal cytoplasmic aminoacyl-tRNAs by unusual or wobble base pairing
[10], but part of it is also due to natural suppressor tRNAs complementary to one of the three stop
codons carrying a common amino acid [11-15] or a selenocysteine [16-18]. These different types of
natural suppression could also be more specific to one or the other of the three existing stop codons
and its occurrence unequal among the studied organisms, because of a non-homogeneous stop
codon usage in mammalian cells [19].
Depending on the investigated cell type, it has furthermore been shown that these unique
interactions between codons and anticodons in ribosomes could also be affected by the structure of
mRNAs surrounding the nonsense-codon [20-22]. As a matter of fact, these “neighboring” effects
tend to be demonstrated by the natural non-randomness in the codon context in mRNAs [23], and as
an example Phillips-Jones et al. have shown evidence that the codon context effect on UAG
suppressor tRNA is different in Escherichia coli and human cells [24].
We propose here a reporter system based on mutants of the enhanced green fluorescent protein to
assess the efficiency of nonsense codon suppression, in order to define optimal parameters for
future site-specific incorporation of amino acid analogs into proteins in a number of different
mammalian cell lines. The read-through of specifically engineered stop codons in mRNA leads to
the completion of the EGFP translation, which fluorescence is quantified using a convenient plate
reader. By measuring the protein function rather than its size by protein gel electrophoresis we
enumerate only integer proteins completed by natural suppression, and not the random proteins
translated after a frameshift at the stop codon position. As an example we study the suitability of the
amber, ochre and opal stop codons to mis-acylated suppressor tRNA technique in the three cell
lines CHO, HEK293 and N1E-115. In principle, this natural suppression reporter assay could be
extended to other adherent mammalian cell lines, and specific codon contexts could be investigated.
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II.4.3 Experimental procedures
Materials
Synthetic oligonucleotides were purchased from MWG-Biotech AG (Ebersberg, Germany). Kits for
plasmid and DNA-fragment purification were obtained from QIAGEN GmbH (Hilden, Germany).
Restriction endonucleases (BsaI, EcoRI and NotI) were provided by New England Biolabs
(Massachusetts, USA). Chemicals were purchased from Sigma-Aldrich (Missouri, USA). The
MEGAscript kit for in vitro transcription and the cap analog m7G(5’)ppp(5’)G were from Ambion
(Texas, USA). Purified rEGFP was purchased from Clontech (California, USA).
Transcription of EGFP reporter genes
The reporter genes are based on the vector pT7PEGFP, as described in Chapter II.3. This vector
contains the coding sequence of the EGFP preceded by a T7 promoter for in vitro transcription
purposes and ended by a poly(A) tail. The mutated versions comprising nonsense codons after the
Kozak sequence were constructed by site-directed mutagenesis (Quickchange kit, Stratagene,
California, USA) as schemed in Figure II.4.1. The resulting vectors pT7PamEGFP, pT7PocEGFP
and pT7PopEGFP carry respectively the amber, ochre and opal non-sense codons. All plasmid
constructs were controlled by restriction mapping and DNA sequencing.
Figure II.4.1 The synthesis of the mutated EGFP mRNAs was based on the vector pT7PEGFP, containing
the EGFP sequence preceded by a T7 promoter and followed by a poly(A) tail. Amber, ochre and opal
codons were inserted by site-directed mutagenesis right after the Kozac sequence to give rise to the plasmids
pT7PamEGFP, pT7PocEGFP and pT7PopEGFP, respectively. After digestion of these vectors with the
restriction enzyme NotI, purification of the template containing the EGFP sequence, and in vitro
transcription based on a T7 RNA polymerase, we obtained the mRNAs amEGFP, ocEGFP and opEGFP.
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After linearization of the wild type and mutated plasmids by NotI, in vitro transcription was
performed with T7 RNA polymerase using the MEGAscript kit (Ambion, Texas, USA). Capping of
mRNA was achieved during transcription by replacing 80 % of the GTP level with the cap analog
m7G(5’)ppp(5’)G (Ambion). After removing the DNA template by DNaseI treatment, the resulting
mRNAs were purified by successive phenol:chloroform:isoamyl alcohol (25:24:1) and
chloroform:isoamyl alcohol (24:1) extractions, precipitation with an equal volume of isopropanol
for 1 hour at –20 ºC, followed by centrifugation at 0 ºC / 20’800 g for 15 minutes. The mRNA
pellet was dried and redissolved in sterile DEPC-treated H2O. The integrity and size of the mRNAs
were assayed by agarose gel electrophoresis under denaturating conditions, and the concentration
was determined by measuring the optical density at 260 nm.
Transcription of the 5-HT3R gene
The murine 5-HT3R sequence (obtained from H.Pick [25]) was modified by addition of a T7
promoter site and a poly(A) tail using PCR amplification with the synthetic oligonucleotides 5’-
ATA AGA ATG CGG CCG CTA ATA CGA CTC ACT ATA GGG AGG ACC ATG GCC ATG
CGG CTC TGC ATC CCG CAG GTG CTG TTG GCC -3’ and 5’- ATA GTT TAG CGG CCG
CTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TTC AAG AAT AAT GCC AAA TGG ACC
AGA GAG TGA CCA G -3’. The resulting 1524 bp fragment was ligated into the pCR2.1 vector
using the TA cloning kit (Invitrogen, California, USA) to obtain the plasmid pT7P5HT3R. The
construct was controlled by restriction mapping and DNA sequencing, and the corresponding
mRNA was transcribed as described for the EGFP mutants.
Cell lines and transfection
Adherent mammalian cells were grown in DMEM/F12 (Dulbecco’s modified Eagle medium;
GIBCO BRL, Rockville, USA) at 37 °C in a humidified atmosphere with 5 % CO2. The medium
was supplemented with 2.2 % fetal calf serum (GIBCO BRL) for HEK293 and CHO cells, and 10
% for N1E cells. The cultures were split and distributed in 12-well plates at a density of 150’000
cells/ml 12 hours prior to transfection.
Lipofection was performed as follows, per milliliter of cell culture: a mixture containing 2.5 µg of
mRNA and 0.5-6.25 µl DOTAP diluted in 50 µl of 10 mM Hepes buffer at pH 7.4 was incubated
for 10 minutes at room temperature, and applied dropwise to the cell medium. All fluorescence
measurements were performed 20 hours after transfection.
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EGFP quantification using a fluorescence plate reader
We used 6-well plates for the plate reader quantification. The growth medium was removed and the
adherent cells were homogenized for 10 minutes at 37 ºC in 270 µl PBS containing 10 % Triton-
X100 (Fluka, Buchs, Switzerland). The measurements were performed with an Analyst plate reader
(LJL Biosystems, California, USA) using 200 µl per sample in 96-well plates (Greiner,
Frickenhausen, Germany).
Radioactive binding assay
The expression level of cells transfected with 5-HT3R coding mRNA was assayed by binding assay
using the radioactively-labeled specific ligand [3H]-GR65630 (NEN-DuPont, Boston, MA). All
experiments were made in triplicate, using 300’000 cells per measurement. The receptor
quantification was performed as described in chapters I.2, I.3 and I.4.
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II.4.4 Results
In this present study, we use non-sense mutants of the EGFP mRNA to quantify natural suppression
in adherent mammalian cells as depicted in Figure II.4.2. Transfection of the reporter mRNAs
causes an expression level of EGFP proportional to the readthrough properties of the cell system
under investigation. The non-mutated version of the EGFP mRNA serves as a positive reference,
and the level of expression can be conveniently quantified by fluorescence measurements in a plate
reader.
Figure II.4.2 Scheme for the natural suppression measurement in adherent mammalian cells. Transfection of
the mRNA coding for the EGFP induces the expression of the fluorescent protein as shown by the confocal
image, whereas transfection of the mutated EGFP mRNAs will only induce the translation of EGFP when
natural suppression occurs. The intensity of EGFP is measured 20 hours after transfection, and reflects the
natural suppression efficiency as compared to suppression-less translation.
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To probe the validity of comparisons among cell lines and between mRNA constructs, we first
examined the non-dependencies of cellular transfections.
In a first series of experiments, we transfected different cell lines with mRNA coding for the EGFP,
and observed the expression level 20 hours later. By varying the ratio between mRNA and DOTAP
liposomal reagent, we could observe that the same optimal ratio was universally perceived
whatsoever the nature of the cell line (see Figure II.4.3).
Figure II.4.3 Optimization of transfection parameters in three different cell lines, using EGFP mRNA as an
expression reporter: the optimal ratio between mRNA and lipid quantities is independent of the studied cell
line.
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Secondly, HEK293 cells were transfected with mRNA coding for the 5-HT3 receptor. This mRNA
having a size double of that of the EGFP mRNA and a different nucleotide composition, it allows to
demonstrate the full independence of the mRNA properties to the transfection optimizations. As
seen in Figure II.4.4, the optimal ratio between mRNA and DOTAP lipid is unchanged compared to
the same experiment using EGFP mRNA.
Figure II.4.4 Optimization of transfection parameters in HEK293 cells, using mRNA coding for the 5-HT3
receptor as an expression reporter monitored via radioactive binding assay: the optimal ratio between mRNA
and lipid quantities is shown to be identical to that obtained using EGFP mRNA as a reporter, thus revealing
the optimization independency of the transfected mRNA.
The natural suppression was then measured in three different cell lines using the same optimized
lipofection technique and the 4 reporter mRNAs. The mRNA-lipid complexes were applied to the
adherent cells during 20 hours, the cells were lysed by Triton-X100 treatment and the EGFP
fluorescence was recorded using a plate reader. Whereas HEK293 and N1E cell lines had low
natural suppression levels, the CHO cells exhibited a fluorescence signal due to natural suppression
in the order of 20 %, no matter which stop codon was used (Table II.4.1).
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Amber suppression (UAG) Ochre suppression (UAA) Opal suppression (UGA)
CHO 20 ± 8 % 17 ± 9 % 19 ± 8 %
HEK293 2 ± 2 % 4 ± 3 % 10 ± 5 %
N1E-115 5 ± 3 % 6 ± 4 % 5 ± 3 %
Table II.4.1 Natural suppression measurement in three different cell lines. All values are relative to the
fluorescence obtained by transfection of the non-mutated EGFP mRNA. The cells were dissolved using
Triton-X100 20 hours after transfection, and the fluorescence intensities were measured in a plate reader.
Each experiment was made in triplicate, using 150’000 cells per sample.
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II.4.5 Discussion
We elaborated a system permitting an easy measurement of natural suppression in living cells via
lipofection of EGFP mutant mRNAs. The transfection allowed an equal uptake of each mRNA
construct, permitting a proper comparison between nonsense mRNAs and EGFP mRNA. This was
demonstrated by the non-dependence of the mRNA nature to the optimization of lipoplexes
formation and uptake, a fact already established for plasmid DNA [26].
Furthermore, the transfection optimization was shown to be identical whatever the cell line used,
allowing a possible extended use of this technique to several other adherent mammalian cell
cultures.
We based our measures on the EGFP fluorescence: in vitro transcripts containing a stop codon
between the Kozak sequence and the EGFP sequence were used to transfect batches of 150’000
cells per measurement, and the fluorescence emitted from cell lysates was recorded 20 hours later.
We could observe in a quantitative way the fluorescence emitted due to natural suppression. It was
especially high in CHO cells independently on the stop codon triplet, and relatively low for
HEK293 and N1E-115 cells. However, the opal suppression in HEK293 cells appeared stronger
than the almost undetectable natural readthrough of amber and ochre codons. This could be
explained by the discovery of opal suppressor tRNAs contained in human DNA library, however
not proven to be transcribed [27]. Søgaard et al. have also shown via DNA transfections that UGA
codons in HeLa and AMA (human epithelial amnion) cells are subject to readthrough [28],
suggesting that this particular readthrough can be observed in all human cells. We based our
measurements on the more direct RNA rather than DNA transfection because of the cell cycle
independence of this method (chapter II.2). Additionally in the case of DNA transfection the
number of mRNA copies leading to detectable proteins highly depends on the RNA polymerase
activity, which could vary between cells depending on DNA quantity and possibly on the presence
of nonsense codons.
In our system, the fluorescence observed is directly reflecting the percentage of incorporation of a
natural amino acid at the nonsense codon position. Indeed, other phenomenons such as frameshift
suppression [29-33], or bypassing of the Kozac sequence and translation start at the next AUG
which is out of frame would both lead to a non-fluorescent protein, thus not detectable. Even if the
translational mechanism skips the first AUG and moreover makes a frameshift at the second AUG,
repositioning the ribosome in the EGFP sequence correct frame, the translated protein would not be
fluorescent because the second AUG is situated at the amino acid position Nr 37, and it has been
shown that amino acids Nr 7 to 229 are essential for the fluorescence of the EGFP [34].
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We have shown in precedent experiments that CHO cells can in principle be used for the site-
specific incorporation of unnatural amino acids in proteins, and we obtained an incorporation
efficiency of about 15 % using amber codon suppression (chapter II.3). This relatively low
efficiency is due in part to the natural suppression – as measured here – and we can foresee that this
efficiency will most likely not vary dramatically using opal or ochre codons in place of amber
because of the similar levels of natural suppression among the three stop codons. On the contrary,
HEK293 and N1E cells are good candidates for mis-acylated tRNA suppression studies, especially
if the presence of proteins translated without incorporation of the desired unnatural amino acids has
to be avoided. Nevertheless the amber and ochre codons should be preferentially chosen for mis-
acylated suppressor tRNA experiments in HEK293, due to the relatively higher natural opal
suppression in this cell line.
Our present screening strategy can straightforwardly be extended to other cell lines, since mRNA
transfection is generally applicable to a wide range of cells (chapter I.2). This system could help
elucidating complex interactions between the mRNA and the various components of the translation
termination machinery [35,36], and the study of codon context could furthermore be of great use for
the optimization of in vivo unnatural amino acid incorporation technique.
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II.5.1 Abstract
The site-specific incorporation of non-natural amino acids into proteins by nonsense suppression
has been widely used to investigate protein structure and function. Usually this technique exhibits
low incorporation efficiencies of unnatural amino acids into proteins. We describe for the first time
an approach for achieving an increased level of nonsense codon suppression with synthetic
suppressor tRNAs in cultured human cells. We find that the intracellular concentration of the
eukaryotic release factor 1 (eRF1) is a critical parameter influencing the efficiency of amino acid
incorporation by nonsense suppression. Using RNA interference we were able to significantly lower
eRF1 gene expression. We achieved a five times higher level of amino acid incorporation as
compared to non-treated control cells, as demonstrated by EGFP fluorescence recovery after
importing a mutated reporter mRNA together with an artificial amber suppressor tRNA.
The results of this chapter have been submitted for publication:
Ilegems, E., Pick, H.M. and Vogel, H.: RNA interference targeting eRF1 in human cells increases
mis-acylated tRNA suppression efficiency.
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II.5.2 Introduction
The site-specific incorporation of unnatural amino acids into proteins by nonsense suppression
opens novel routes for protein engineering. For example individual proteins can be site-selectively
equipped with fluorescent, photo-activatable or other reactive probes suitable for structural and
functional investigations. Originally developed as an in vitro labeling technique [1-6], nonsense
suppression has been progressively adapted to prokaryotic [7-10] and eukaryotic cells [11-15].
Recently the scope of this technique expanded to mammalian live cells [16,17] yielding levels of
non-natural amino acids incorporation in the order of 15 - 18 % (see Chapter II.3). Here we report
on strategies to increase substantially this level of nonsense suppression efficiency.
The intracellular concentration of the eukaryotic release factor eRF1 is a parameter, which is known
to influence natural nonsense suppression efficiency [18]. Published data point to competitive
actions between natural suppressor tRNAs and eRF1 for stop codon recognition based on their
structural similarity [19-21]. Whereas a suppressor tRNA is required for incorporation of amino
acids and ribosomal read-through, the eRF1 factor triggers the release of the nascent peptide
resulting in termination of translation [18]. Overexpression of eRF1 was shown to increase
termination efficiency [22] whereas a decreased eRF1 activity promoted stop codon read-through in
vitro and in eukaryotic cells [6,18]. Furthermore, it has been shown in recent studies that mRNAs
containing a premature stop codon spatially distant from the 3’ end can be degraded by a Upf1
complex in which the eRF1 is involved [23,24]. These observations point to eRF1 as a factor which
is potentially influencing nonsense codon suppression also in presence of artificial suppressor
tRNAs.
Here we explore the feasibility of post-transcriptional gene silencing of eRF1 to achieve higher
efficiencies of amino acid incorporation by nonsense suppression in HEK293 cells.  The silencing
property of short interfering RNAs [25-28] was used to target eRF1 messenger RNA. Changes in
eRF1 gene expression were quantified by real-time RT-PCR. The effects of eRF1 silencing on
nonsense suppression efficiency were investigated using an EGFP reporter transcript carrying an
amber codon suppression site at an amino acid position, which is essential for fluorophore
formation, as described in Chapter II.3. We found that only the co-injection of the mutated EGFP
reporter messenger RNA together with an artificial suppressor tRNA, which can be amino-acylated
in vivo, gave rise to detectable EGFP fluorescence signals inside HEK293 cells indicating site-
specific nonsense suppression events. The level of EGFP fluorescence recovery reflected the
suppression efficiency and could be quantified in eRF1 silenced cells compared to non-treated cells
using laser-scanning confocal microscopy.
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II.5.3 Experimental procedures
Materials
Synthetic oligonucleotides were purchased from MWG-Biotech AG (Ebersberg, Germany), kits for
plasmid and DNA-fragment purification from QIAGEN GmbH (Hilden, Germany), restriction
endonucleases (BsaI, EcoRI and NotI) from New England Biolabs (Massachusetts, USA),
MEGAscript and MEGAshortscript kits for in vitro transcription as well as the cap analog
m7G(5’)ppp(5’)G from Ambion (Texas, USA), and purified rEGFP from Clontech (California,
USA). All other chemicals were obtained from Sigma-Aldrich (Missouri, USA).
Cell culture
Adherent mammalian cells (Human Embryonic Kidney, HEK293) were grown in DMEM/F12
(Dulbecco’s modified Eagle medium; GIBCO BRL, Rockville, USA). The medium was
supplemented with 2.2 % fetal calf serum (GIBCO BRL). One day prior to injection cells were
transferred to 35/12 mm WillCo-dishes (WPI, Herts, United Kingdom) at a density of 100’000
cells/ml, and kept at 37 °C in a humidified atmosphere with 5 % CO2.
In vitro transcription of reporter genes
The coding sequence of the red fluorescent protein DsRedExpress (pDsRedExpress, Clontech) was
modified by the addition of a T7 promoter site and a poly(A) tail using PCR amplification with
synthetic oligonucleotides. The resulting fragment was ligated into the pCR2.1 vector using the TA
cloning kit (Invitrogen, California, USA) to obtain the plasmid pT7PDsRedExpress, which was
analysed by restriction mapping and DNA sequencing.
We used the plasmid pT7PEGFPam64L, described in Chapter II.3, as the second template. It
contains the coding sequence of the EGFP (Clontech) with an amber mutation at an amino acid
sequence position important for the correct folding of the fluorophore.
After linearization of the plasmids pT7DsRedExpress and pT7EGFPam64L by NotI, in vitro
transcription was performed with T7 RNA polymerase using the MEGAscript kit. Capping of
mRNA was achieved during transcription by replacing 80 % of the GTP level with the cap analog
m7G(5’)ppp(5’)G. After removing the DNA template by DNaseI treatment, the resulting mRNAs
were purified by successive phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform:isoamyl
alcohol (24:1) extractions, precipitation with an equal volume of isopropanol for 1 hour at –20 ºC,
followed by centrifugation at 0 ºC and 20’800 g for 15 minutes. The mRNA pellet was dried and
redissolved in sterile DEPC-treated H2O. The integrity and size of the mRNAs were analysed by
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agarose gel electrophoresis under denaturating conditions, and the concentration was determined by
measuring the optical density at 260 nm.
siRNA synthesis and transfection
The siRNA targeting the eRF1 mRNA was synthesized by annealing in vitro transcripts as depicted
in Figure II.5.1A: for each RNA fragment, two synthetic DNA oligonucleotides were annealed to
obtain templates flanked by a double-stranded T7 promoter [29]. In vitro transcriptions were
performed using the MEGAshortscript kit (Ambion, Texas, USA). After removing the DNA
templates by D N a s e I treatment, the resulting RNAs were purified by successive
phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform:isoamyl alcohol (24:1) extractions.
RNA precipitation was achieved by adding an equal volume of isopropanol and by 1 hour
incubation at –20 ºC, followed by centrifugation at 0 ºC / 20’800 g for 15 minutes. The RNA pellets
were air dried at room temperature and redissolved in sterile DEPC-treated H2O. RNA
concentrations were determined by measuring the optical density at 260 nm. The two
complementary RNA strands were annealed at an equimolar ratio and dissolved in DEPC-treated
water to finally obtain the siRNA at a concentration of 20 µM. The integrity and size of the siRNA
was assayed by polyacrylamide gel electrophoresis under denaturating conditions.
HEK293 cells were transfected with siRNA using the TransMessenger Kit from Qiagen, following
the manufacturer’s instructions. Typically, for a 35 mm Nunc dish, 3.4 µl Enhancer-R, 6 µl siRNA
(20 µM) and 8.5 µl TransMessenger were used. The medium was changed 4 hours after
transfection.
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Figure II.5.1 Scheme of the synthesis of interfering RNAs targeting the eRF1 transcripts. (A) siRNA
obtained by ligation of complementary RNA strands, both in vitro-transcribed from annealed synthetic DNA
oligonucleotides. (B) Hairpin interfering RNA synthesized in vivo after transfection of the vector
pSIRENeRF1. This vector was obtained by annealing and ligating two synthetic oligonucleotides in the
vector pSIREN-RetroQ.
Generation of the stable cell line HEK-seRF1
Complementary DNA nucleotides were annealed and ligated into pSIREN-RetroQ (Clontech,
California, USA), as shown in Figure II.5.1B, giving rise to the plasmid pSIRENeRF1. This vector
leads to the expression of hairpin RNAs containing a 9 nucleotides loop, as described by Yu et al.
[30]. After calcium phosphate transfection of HEK293 cells [31], the expression was maintained by
supplementing 1 µg/ml of puromycin in the growth media. This selection was made during 3 weeks
prior to real-time PCR experiments.
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Transcription of suppressor tRNA gene
A 116 bp synthetic DNA template encoding the artificial human suppressor tRNALeuCUA was
prepared by annealing two oligonucletides containing the tRNA gene flanked by a T7 promoter
(Figure II.5.2). The resulting blunt-end DNA fragment was ligated into pCR4 vector using the
TOPO cloning Kit (Invitrogen). The final plasmid (pHumanLeuCUA) was checked by restriction
mapping and sequencing. This plasmid was linearized by successive restriction endonuclease
digests with EcoRI and BsaI. After agarose gel purification this DNA fragment was used for the
run-off transcription with T7 RNA polymerase following the protocol of the MegaScript Kit. After
removing the template DNA by DNaseI treatment the tRNA was purified by following the protocol
described above for mRNA. The integrity and purity of the tRNA was assayed by polyacrylamide
gel electrophoresis, and the concentration was determined by measuring the optical density at 260
nm.
Figure II.5.2 Scheme for the in vitro synthesis of the suppressor tRNA from a synthetic DNA template by
T7 run-off transcription. Two synthetic complementary oligonucleotides encoding the artificial human
suppressor tRNALeuCUA were annealed and cloned into the pCR4 vector, leading to pHumanLeuCUA. T7
RNA polymerase run-off transcription was performed on the purified EcoRI and BsaI fragment giving rise to
a 87-mer suppressor tRNA.
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cDNA preparation and Real-Time PCR quantification
Total messenger RNA was extracted from approximately 2 million cells per sample using TRIZOL
Reagent (Invitrogen, California, USA). The subsequent eRF1 reverse transcription was achieved
using a TaqMan Gold RT-PCR Kit from Applied Biosystems (California, USA) and random
hexamers. We used the SYBR® Green I kit (Eurogentec, Seraing, Belgium) for quantitative PCR,
together with the eRF1-specific primers 5’- TCACAGACAAAGAGACCGGACA-3’ and 5’-
CGCAAGATACCTCCAATTCCAC-3’. Primers used for the internal reference gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were supplied in the TaqMan Gold RT-PCR
Kit (Applied Biosystems). The ABI Prism 7700 was used as a sequence detection system and data
were treated with the software “Sequence Detection Systems 1.9.1”, both from Applied Biosystems.
The amplification specificities were controlled with dissociation measurements followed by
treatment using “Dissociation Curves 1.0” software (Applied Biosystems). The efficiencies of the
reactions were calculated using “LinRegPCR 7.4” [32], with a minimum of 5 data points for the
determination of each amplification slope.
Injections
Microinjections of HEK293 cells with mRNA and tRNA mixtures diluted in sterile DEPC-treated
H2O were performed using an InjectMan controller and a Transjector 5246 system (both from
Eppendorf, Hamburg, Germany) mounted on an Axiovert S100TV inverted microscope (Carl Zeiss
AG, Oberkochen, Germany). FemtotipsII capillaries (Eppendorf) were used for all injections.
Laser scanning confocal microscopy and fluorescence measurements
Laser scanning confocal microscopy was performed using a Zeiss LSM510 (Carl Zeiss AG).
Detection and distinction of the fluorescence signals of EGFP (excitation at 488 nm) and
DsRedExpress (excitation at 543 nm) was achieved by appropriate filter sets using a multitracking
mode. Scanning speed and laser intensity were adjusted to avoid photobleaching of the fluorophores
and proper comparison between samples of variable fluorescence intensities.
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II.5.4 Results
A schematic view of our strategy to improve mis-acylated tRNA suppression efficiency in human
cells is presented in Figure II.5.3. In a first step the intracellular mRNA level of eRF1 is lowered via
RNA interference and its effect on nonsense suppression is later evaluated by microinjection of
reporter mRNAs. One of the transcripts gives rise to the suppression-dependent expression of a
green fluorescent protein. The other non-mutated, red fluorescent reporter is used as an internal
standard for the amount of injected molecules, allowing the comparison between individual cells.
Lowering of the intrinsic eRF1 messenger concentration has been approached in two different ways
using either a transient siRNA transfection or a stable transcription of a hairpin RNA, both targeting
eRF1 transcripts. The siRNA sequence was designed following Elbashir et al. [27,28] and the
selection of a specific location on the target eRF1 mRNA was made such that both synthesized
RNA strands begin with a guanine, as detailed by Donze et al. [33].
We studied alterations in eRF1 mRNA concentration by real-time PCR, using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as an independent reference gene (Figure II.5.4). Transfection
of siRNA had substantial effect on the eRF1 mRNA concentration, which decreased to
approximately 40 % of its initial value within two days after transfection. The cell line HEK-seRF1
stably expressing the eRF1 targeting hairpin RNA exhibited approximately 60 % of the eRF1
mRNA concentration of non-treated cells. No noticeable difference was observed in the eRF1
mRNA level between non-transfected cells and cells pre-transfected with a control (non-eRF1
targeting) siRNA.
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Figure II.5.3 General representation of the eRF1 silencing effect on the mis-acylated tRNA suppression
efficiency.
Upper line: Interfering RNAs in the cell – obtained by either siRNA or pSIRENeRF1 transfection – lead to a
lower intracellular concentration of eRF1. Subsequently, a solution containing DsRedExpress mRNA,
suppressor tRNA and EGFPam64L mRNA is microinjected into the cell. The tRNA is aminoacylated by
endogenous AARSs and the expression of EGFP reflects the suppression efficiency, whereas the
DsRedExpress expression level serves as a standard for non-suppressed translation (shown by typical
confocal images taken 20 hours after injection). Lower line: Control experiment using non-interfering
siRNA, having no effect on the eRF1 level. In the confocal image on the right, the ratio between the EGFP
and the DsRedExpress expression levels reflects an increase in the suppression efficiency after silencing of
the eRF1.
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Figure II.5.4 Real-time PCR experiments.
(A)-(D): PCR profiles of the amplifications of eRF1 and GAPDH (used as an internal standard). The cDNAs
were produced from (A) non-transfected cells or cells transfected with a non-interfering siRNA, (B) cells
transfected with siRNA 1 day before, (C) cells transfected with siRNA 2 days before, and (D) HEK-seRF1
cells (HEK293 cells stably transfected with pSIRENeRF1).
(E): Comparison of the level of eRF1 mRNA in the different samples, using the GAPDH as an internal
standard.
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To study the correlation between eRF1 concentration and artificial suppression efficiency
microinjection experiments were performed 2 days after siRNA transfection, which we observed
resulted in more homogeneous eRF1 silencing among cells than via DNA transfection, thus
permitting precise cell-to-cell comparisons (see also Chapter II.11). We co-injected DsRedExpress
mRNA, human suppressor tRNALeuCUA, and EGFPam64L mRNA at fixed ratios and controlled
volumes of about 0.05 ± 0.01 pl (as described in Chapter II.3). About 20 hours later, the expression
of both reporter proteins was monitored by laser-scanning confocal microscopy. Whereas the
DsRed fluorescence intensity was shown to be proportional to the number of injected molecules, the
EGFP fluorescence intensity mainly depended on the suppression efficiency. Indeed, the mutated
EGFPam64L mRNA is only translated in a full-length fluorescent EGFP when its amber codon is
suppressed by a specific suppressor tRNA charged with a leucine (for details, see Chapter II.3).
Plotting the fluorescence intensity of the DsRedExpress versus that of EGFP revealed that the
suppression efficiency of the siRNA-transfected cells is increased 5 fold as compared to the non-
treated HEK293 cells (Figure II.5.5, Table II.5.1).
Figure II.5.5 Fluorescence intensities of DsRedExpress and EGFP 20 hours after co-injection of
DsRedExpress mRNA, suppressor tRNA and EGFPam64L mRNA, as measured by confocal microscopy.
Each data point represents a single cell (squares represent non-treated cells, triangles represent cells pre-
transfected with siRNA targeting the eRF1).
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Intracellular eRF1
mRNA concentration
Mis-acylated tRNA
suppression efficiency
Non-treated HEK293 cells 100 % 100 %
HEK transfected with siRNA: 1 day after transfection 83 ± 70 % N.D.
HEK transfected with siRNA: 2 days after transfection 39 ± 33 % 500 ± 100 %
HEK-seRF1 cells 57 ± 60 % N.D.
Table II.5.1 Concentration of eRF1 mRNA as determined by Real-Time PCR, and its effect on mis-acylated
suppression efficiency as deduced from DsRedExpress/EGFP expression level ratios. All samples were
microinjected using concentrations of 2 µg/µl DsRedExpress mRNA, 2 µg/µl EGFPam64L mRNA, 2 µg/µl
tRNA, and imaged 20 hours later. All values are normalized to non-treated HEK293 cells. N.D. = not
determined.
The expression level of the DsRedExpress was controlled to be independent of the siRNA
transfection by co-injecting treated and non-treated cells with DsRedExpress mRNA together with
purified rEGFP as an indicator for injection volume: the DsRedExpress expression level was
identical regardless of the eRF1 concentration, and only depending on the injection volume
reflected by the rEGFP fluorescence intensity (data not shown).
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II.5.5 Discussion
We developed a strategy to enhance the yield of artificial nonsense codon suppression in cultured
human cells. The eukaryotic release factor eRF1, which is known to compete with suppressor
tRNAs for stop codon recognition [21] was down-regulated on the transcript level. Based on the
silencing properties of interfering RNA a substantial decrease in eRF1 mRNA concentration was
achieved. The silencing effect was followed by real-time PCR and increased over time to result in a
two-fold reduction of eRF1 transcripts two days after transfection. A comparable degree of gene
silencing was obtained by stable transfection of HEK293 cells with a vector capable of inducing in
vivo transcription of a hairpin RNA for targeting eRF1 mRNAs.
The effect of eRF1 gene silencing on nonsense codon suppression efficiency was investigated in
individual cells by co-injection of an artificial suppressor tRNA together with in vitro transcripts
encoding two reporter proteins DsRedExpress and EGFPam64L. The suppressor tRNA was
designed in order to obtain a natural aminoacylation by human cells, required for charging it with a
leucine to recover the green fluorescence of the EGFPam64 reporter by amber codon suppression.
The tRNA sequence used in this study was based on the human tRNALeuCAA [34], which anticodon
was mutated to CUA and which was modified by two other mutations A38G/A39U to improve
amber suppression efficiency [35].
Only by co-injecting the amber codon containing EGFP transcript together with the cognate
suppressor tRNA complete translation was achieved as indicated by EGFP fluorescence recovery.
The injection of the EGFPam64L reporter alone did not result in detectable expression of
fluorescent proteins as judged by laser-scanning confocal microscopy (see also Chapter II.3).
DsRedExpress mRNA encoding a red fluorescent protein was co-injected as a standard reflecting
the amount of injected molecules. Since the two reporter mRNAs were always injected at the same
molar ratio the ratio between the resulting EGFP and the DsRedExpress fluorescence intensities
could be used to compare suppression efficiencies in individual cells. Lowering the eRF1 mRNA
concentration by a factor of two resulted in a five-fold increase in suppression efficiency as
compared to non-treated HEK293 cells. Parallel to our present research, Carnes et al. reported a
slight enhancement of natural nonsense read-through after 90 % silencing of eRF1 transcripts in
human cells [36]. These experiments were done in the absence of artificial suppressor tRNAs. On
the basis of our study we are now able to confirm a positive influence of eRF1 silencing also on
artificial nonsense codon suppression.
In general, increased read-through might be problematic for the specific incorporation of unnatural
amino acids when using cell lines exhibiting a strong natural suppression; in such a situation the
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amount of proteins translated without the desired synthetic amino acid incorporation would increase
relatively to the labeled protein. However we determined natural amber codon suppression to be
very low in HEK293 as compared to some other cell lines (Chapter II.4), making them well suited
for labeling experiments. By silencing eRF1 transcripts down to 40 % of the original level we could
achieve an increased artificial amber suppression without enhancing natural read-through.
In our hands, further silencing of eRF1 by using the strong interfering RNA “si1187” [36] lead to
changes in cell morphology as indicated by their detachment from the growth surface, thus
impairing microinjection experiments and subsequent subcellular investigations by fluorescence
confocal microscopy (not shown).
The prospects for suppression of nonsense codons in prokaryotes as well as in eukaryotes might be
influenced by the same strategy involving the downregulation or deactivation of intrinsic translation
termination factors. This was demonstrated in previous in vitro experiments by the group of Sidney
Hecht [6]: partial heat deactivation of a thermosensitive mutant of the prokaryotic release factor 1
(RF1) increased amber codon suppression by chemically misacylated suppressor tRNAs in cell-free
E.coli extracts using dehydropholate reductase (DHFR) as a reporter protein.
Here, we provided a general and efficient method to enhance the yield of artificial nonsense
suppression in live human cells. This finding in combination with the presented EGFP suppression
assay is expected to make the suppressor tRNA labeling technique accessible to a wide range of cell
types, which are more suitable for structural and functional studies than classically used E.coli or
Xenopus oocytes.
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III – Conclusions and outlook
III.1.1 Conclusions and outlook
In the context of this thesis I investigated the versatility of fluorescently-labeled proteins. In the first
part, I showed that the fusion of proteins having completely different original biological functions
could create a chimera exhibiting interesting novel optical properties. The 5-HT3R was fused to
variants of the green fluorescent protein (GFP), without losing its characteristic ligand binding
properties and channel activities. The fluorescent 5-HT3R permitted to follow its trafficking during
an entire biogenesis in live cells, from the assembly of its subunits to cell membrane integration and
finally to its agonist-induced internalization. Moreover, the fluorescence intensity emitted from the
GFP-derived proteins was directly proportional to the number of 5-HT3Rs, permitting to collect
quantitative information about overall spatial organization of the receptors.
In addition, the 5-HT3R was shown to be still functional in both “native vesicles” and detergent-
solubilized form. This finding opens further bioanalytic applications such as functional screening.
The 5-HT3R function could be assessed in both cases via fluorescence: by confocal microscopy
imaging of a calcium-sensitive dye, and by measuring binding of a fluorescent ligand via
fluorescence resonance energy transfer, respectively.
The production of native vesicles from living cells represents a novel approach allowing the
miniaturization of cell-based assays. The exemplary study on the 5-HT3R indicates that plasma
membrane receptors in the native vesicles retain their original cellular location, orientation and
function. Another important finding is that native vesicles preserve cellular signal detection and
transduction processes as demonstrated by 5-HT3R-mediated calcium signaling upon agonist
application. Because a single mammalian cell delivers about 50 native vesicles, which can be
isolated and addressed as individuals, this concept allows multiple analyses of the functions of
single, for example primary cells, which are hampered by limited availability.
Changes in the receptor fluorescence properties upon binding a non-fluorescent agonist could also
be detected, supporting the general idea of a ligand-induced conformational change of the receptor.
The possibility of quantifying agonist-receptor interactions by simple measurements of changes in
receptor-intrinsic GFP fluorescence intensities has the potency for high-throughput applications.
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The structural similarity among ligand-gated ion channels might allow analogous strategies for
other members of this receptor family.
In the second part of this thesis I focused on adapting the mis-acylated tRNA technology to cultured
mammalian cells. In principle, this methodology could lead to the incorporation of much smaller
probes based on single unnatural amino acids, as compared to the large GFP fused to the receptor
protein.
I found that tRNA sequences coming from genetically different cells such as Escherichia coli can
be suitable for unnatural amino acid incorporations in mammalian cells, minimizing the probability
of endogenous acylation by the host cell while still being accepted by the ribosome translational
machinery. Compared to normal translation, we obtained an efficiency of amino acid incorporation
using mis-acylated suppressor tRNA in the order of 15%. I then investigated which cell lines and
codon-anticodon pairs could be more appropriate for this methodology, in respect to the existence
of natural nonsense-codon readthrough [1-5] potentially competing with the unnatural amino acid
incorporation by inserting natural amino acids at the position of interest. Both HEK293 and N1E-
115 cells showed low natural suppression for all three stop codons (UAG, UAA, UGA), with the
exception of the opal codon (UGA) in the case of HEK293 cells. After reduction of background
nonsense codon readthrough by selecting most suited cells and codon-anticodon pair, I elaborated a
general approach for increasing the efficiency of unnatural amino acid mutagenesis. This was
achieved by in vivo siRNA-induced down-regulation of the eRF1, which is the sole release factor in
eukaryotic cells catalyzing translation termination at all three stop codons. I obtained a five-fold
increase of artificial amber codon suppression in cultured human cells, using endogenously
aminoacylated suppressor tRNAs. Due to the inferior stability of in vitro aminoacylated suppressor
tRNA compared to the in vivo aminoacylated suppressor tRNA we used, as well as its “unique”
usage in the ribosome, the efficiency improvement of unnatural amino acid incorporation might not
be multiplied by the same factor of five, but should nevertheless be noticeable.
For each case, I investigated various cell transfection techniques and defined the best adapted one to
transfer the different molecules needed for the mis-acylated suppressor tRNA methodology.
In conclusion, I established the essential basis for efficient site-specific incorporation of unnatural
amino acids in cultured mammalian cells. This technique has the potential to introduce very small
amino acid modifications [6], fluorescent or photoactivatable amino acids [7-10], or even
nonproteinogenic D-amino acids [11], in order to study specific biological processes. Future choice
of an unnatural amino acid should be mainly driven by the research objective, but also by its
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potential acceptance by the ribosomal translational machinery and its stability. Indeed, some
chemical properties of amino acids can affect the stability of aminoacylated tRNAs [12,13], and too
large sizes are a physical limitation for the ribosome processing [14].
Single or multiple unnatural amino acid incorporation using different codon-anticodon pairs [15], or
together with complementary orthogonal labeling methods such as FLASH [16], oligohistidine-
NTA chromophores [17] or the human alkylguanine transferase procedure [18], this approach will
offer many applications to investigate selective molecular interactions allowing the elucidation of
structure-function relationships in live biological cells. More specifically, as I already could observe
ligand-induced structural modifications in the 5-HT3R by fusing EGFP molecules near the channel
opening, it can be foreseen that the introduction of small fluorescent probes into the channel pore
itself could lead to much stronger modifications of the fluorescence signals that could be followed
over time. Although this is a speculative notion, it may be offered as an additional stimulus to
future investigations of the 5-HT3R structure and function.
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IV.1 Murine 5-HT3A receptor cDNA
IV.1 Murine 5-HT3A receptor cDNA
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16
5’- ATG CGG CTC TGC ATC CCG CAG GTG CTG TTG GCC TTG TTC CTT TCC ATG
17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33
CTG ACA GCC CCG GGA GAA GGC AGC CGG AGG AGG GCC ACC CAG GAG GAT ACC
34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50
ACC CAG CCT GCT CTA CTA AGG CTG TCA GAC CAC CTC CTG GCT AAC TAC AAG
51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67
AAG GGG GTG CGG CCT GTG CGG GAC TGG AGG AAG CCT ACT ACT GTC TCC ATT
68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84
GAT GTC ATC ATG TAT GCC ATC CTC AAC GTG GAT GAG AAG AAC CAG GTT CTG
85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100 101
ACC ACC TAC ATA TGG TAC CGG CAG TAC TGG ACT GAT GAG TTT CTG CAG TGG
102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
ACT CCT GAG GAC TTC GAC AAT GTC ACC AAA TTG TCC ATC CCC ACA GAC AGC
119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
ATC TGG GTC CCT GAC ATT CTC ATC AAT GAG TTT GTG GAC GTG GGG AAG TCT
136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152
CCG AAC ATT CCT TAT GTG TAC GTG CAT CAT CGA GGT GAA GTT CAG AAC TAC
153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169
AAG CCC TTG CAA TTG GTG ACC GCC TGT AGC CTT GAC ATC TAC AAC TTC CCC
170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186
TTT GAT GTG CAG AAC TGT TCT CTG ACT TTC ACC AGC TGG CTG CAC ACC ATC
187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203
CAG GAC ATC AAC ATT ACT CTG TGG CGA TCA CCG GAA GAA GTG AGG TCT GAC
204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220
AAG AGC ATC TTC ATA AAT CAG GGC GAG TGG GAG CTG CTG GAG GTG TTC CCC
221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237
CAG TTC AAG GAG TTC AGC ATA GAT ATC AGT AAC AGC TAT GCA GAA ATG AAG
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238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254
TTC TAC GTG ATC ATC CGC CGG AGG CCT TTA TTC TAT GCA GTC AGC CTC TTG
                                1
255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271
CTG CCC AGT ATC TTC CTC ATG GTC GTG GAC ATT GTG GGC TTT TGC CTG CCC
272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288
CCG GAC AGT GGT GAG AGA GTC TCT TTC AAG ATC ACA CTC CTT CTG GGA TAC
                        2
289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305
TCA GTC TTC CTC ATC ATC GTG TCA GAC ACA CTG CCG GCA ACG ATC GGT ACC
306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322
CCC CTC ATT GGT GTC TAC TTT GTG GTG TGC ATG GCT CTG CTA GTG ATA AGC
3
323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339
CTC GCT GAG ACC ATC TTC ATT GTG CGG CTG GTG CAT AAG CAG GAC CTA CAG
340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356
CGG CCA GTA CCT GAC TGG CTG AGG CAC CTG GTC CTA GAC AGA ATA GCC TGG
357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373
ATA CTC TGC CTA GGG GAG CAG CCT ATG GCC CAT AGA CCC CCA GCC ACC TTC
374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
CAA GCC AAC AAG ACT GAT GAC TGC TCA GCC ATG GGA AAC CAC TGC AGC CAT
391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407
GTT GGA GGA CCT CAG GAC TTG GAG AAG ACC CCA AGG GGC AGA GGT AGC CCT
408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424
CTT CCA CCA CCA AGG GAG GCC TCA CTG GCT GTG CGT GGT CTC TTG CAA GAG
425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441
CTA TCC TCC ATC CGC CAC TTC CTG GAG AAG CGG GAT GAG ATG CGG GAG GTG
442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458
GCA AGG GAC TGG CTG CGG GTG GGA TAC GTG CTG GAC AGG CTG CTG TTC CGC
                                                                4
459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475
ATC TAC CTG CTG GCT GTG CTC GCT TAC AGC ATC ACC CTG GTC ACT CTC TGG
476 477 478 479 480 481
TCC ATT TGG CAT TAT TCT TGA –3’
Short splicing variant of the murine 5-HT3A receptor – SwissProt entry p23979.[1] The membrane
targeting signal sequence is indicated in italics, and the four coding regions for the transmembrane
domains are underlined.
ILEGEMS
164
IV.2 Bioluminescent proteins cDNAs
IV.2 Bioluminescent proteins cDNAs
IV.2.1 Fluorescent proteins derived from Aequorea victoria GFP
Enhanced green fluorescent protein (EGFP) sequence:
1       2   3   4   5   6   7   8   9   10  11  12  13  14  15
5’- ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG
16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32
GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG
33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49
GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC
50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66
ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC
67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83
GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG CAG CAC GAC TTC
84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100
TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC TTC
101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117
AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC GAC
118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134
ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC
135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151
AAC ATC CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT
152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168
ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG GTG AAC TTC AAG ATC CGC
169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185
CAC AAC ATC GAG GAC GGC AGC GTG CAG CTC GCC GAC CAC TAC CAG CAG AAC
186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202
ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC
203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219
ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC ATG GTC
220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236
CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG
237 238
TAC AAG TAA –3’
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The usual numbering (as presented here) reflects amino acid positions in the original GFP (before
addition of valine at position 2, modification in all the enhanced versions). The enhanced geen
fluorescent protein (EGFP) encodes the GFPmut1 variant [2], optimized for brighter fluorescence.
The mutations from the original GFP are indicated in bold letters.
Cyan- and yellow-shifted variations are obtained by amino acid substitutions:
Specific ECFP (cyan) mutations [3]: 66 TAC ->CAC
146 AAC->ATC
153 ATG->ACC
163 GTG->GCC
Specific EYFP (yellow) mutations [4]: 64 CTG ->TTC
65 ACC->GGC
68 GTG->CTG
72 AGC->GCC
203 ACC->TAC
The coding sequence of these genes contains additionally hundreds of silent base mutations
corresponding to human codon usage preferences [5], for enhanced expression in mammalian cells.
Figure IV.1 Schematic drawing of the overall fold of the fluorescent proteins derived from the GFP. The 11
strands forming the walls of the β barrel-shaped protein are shown as arrows, and the fluorescent core is
depicted by a black rectangle (adapted from M. Ormö [3] and F. Yang [6]).
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IV.2.2 DsRed Express cDNA derived from Discosoma sp. Red Fluorescent Protein
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16
5’- ATG GCC TCC TCC GAG GAC GTC ATC AAG GAG TTC ATG CGC TTC AAG GTG
17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33
CGC ATG GAG GGC TCC GTG AAC GGC CAC GAG TTC GAG ATC GAG GGC GAG GGC
34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50
GAG GGC CGC CCC TAC GAG GGC ACC CAG ACC GCC AAG CTG AAG GTG ACC AAG
51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67
GGC GGC CCC CTG CCC TTC GCC TGG GAC ATC CTG TCC CCC CAG TTC CAG TAC
68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84
GGC TCC AAG GTG TAC GTG AAG CAC CCC GCC GAC ATC CCC GAC TAC AAG AAG
85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100 101
CTG TCC TTC CCC GAG GGC TTC AAG TGG GAG CGC GTG ATG AAC TTC GAG GAC
102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
GGC GGC GTG GTG ACC GTG ACC CAG GAC TCC TCC CTG CAG GAC GGC TCC TTC
119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
ATC TAC AAG GTG AAG TTC ATC GGC GTG AAC TTC CCC TCC GAC GGC CCC GTA
136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152
ATG CAG AAG AAG ACT ATG GGC TGG GAG GCC TCC ACC GAG CGC CTG TAC CCC
153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169
CGC GAC GGC GTG CTG AAG GGC GAG ATC CAC AAG GCC CTG AAG CTG AAG GAC
170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186
GGC GGC CAC TAC CTG GTG GAG TTC AAG TCC ATC TAC ATG GCC AAG AAG CCC
187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203
GTG CAG CTG CCC GGC TAC TAC TAC GTG GAC TCC AAG CTG GAC ATC ACC TCC
204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220
CAC AAC GAG GAC TAC ACC ATC GTG GAG CAG TAC GAG CGC GCC GAG GGC CGC
221 222 223 224 225
CAC CAC CTG TTC CTG TAG –3’
The nine mutations on the original DsRed sequence [7] are marked in bold letters. Their purpose is
to improve the solubility of the protein, shorten the folding time to that of the EGFP and reduce the
level of green emission [8]. A large number of silent mutations are also present to optimize the
sequence to human codon usage [4].
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IV.3 Subcellular targeting sequences
IV.3 Subcellular targeting sequences
IV.3.1 Nucleus
Tandem repeat of the nuclear localization signal (NLS) to be fused at C-terminus:
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16
5’- GAT CCA AAA AAG AAG AGA AAG GTA GAT CCA AAA AAG AAG AGA AAG GTA
17  18  19  20  21  22  23  24
GAT CCA AAA AAG AAG AGA AAG GTA –3’
The reiteration of the NLS sequence of the simian virus 40 large T-antigen [9,10] significantly
increases the efficiency of translocation into the nucleus of mammalian cells [11].
IV.3.2 Endoplasmic reticulum
Endoplasmic reticulum (ER) targeting sequence of calreticulin [12] to be cloned at the 5' end:
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16
5’- ATG CTG CTA TCC GTG CCG TTG CTG CTC GGC CTC CTC GGC CTG GCC GTC
17
GCC –3’
and the sequence encoding the ER retrieval sequence, KDEL [13,14] (2, 3), cloned at the 3' end:
    1   2   3   4
5’- AAG GAC GAG CTG –3’
IV.3.3 Golgi
Golgi apparatus to be fused at N-terminus:
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16
5’- ATG AGG CTT CGG GAG CCG CTC CTG AGC GGC AGC GCC GCG ATG CCA GGC
17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33
GCG TCC CTA CAG CGG GCC TGC CGC CTG CTC GTG GCC GTC TGC GCT CTG CAC
34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50
CTT GGC GTC ACC CTC GTT TAC TAC CTG GCT GGC CGC GAC CTG AGC CGC CTG
51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67
CCC CAA CTG GTC GGA GTC TCC ACA CCG CTG CAG GGC GGC TCG AAC AGT GCC
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68  69  70  71  72  73  74  75  76  77  78  79  80  81  82
GCC GCC ATC GGG CAG TCC TCC GGG GAG CTC CGG ACC GGA GGG GCC –3’
The sequence encoding the N-terminal 81 amino acids of human beta 1,4-galactosyltransferase
(GT; [15]) contains the membrane-anchoring signal peptide that targets the fusion protein to the
trans-medial region of the Golgi apparatus [16-18].
IV.3.4 Actin
!H!u!m!a!n! !c!y!t!o!p!l!a!s!m !i!c! beta- !a!c!t!i !n! [19,20] to be fused at C-terminus:
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16
5’- ATG GAT GAT GAT ATC GCC GCG CTC GTC GTC GAC AAC GGC TCC GGC ATG
17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33
TGC AAG GCC GGC TTC GCG GGC GAC GAT GCC CCC CGG GCC GTC TTC CCC TCC
34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50
ATC GTG GGG CGC CCC AGG CAC CAG GGC GTG ATG GTG GGC ATG GGT CAG AAG
51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67
GAT TCC TAT GTG GGC GAC GAG GCC CAG AGC AAG AGA GGC ATC CTC ACC CTG
68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84
AAG TAC CCC ATC GAG CAC GGC ATC GTC ACC AAC TGG GAC GAC ATG GAG AAA
85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100 101
ATC TGG CAC CAC ACC TTC TAC AAT GAG CTG CGT GTG GCT CCC GAG GAG CAC
102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
CCC GTG CTG CTG ACC GAG GCC CCC CTG AAC CCC AAG GCC AAC CGC GAG AAG
119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
ATG ACC CAG ATC ATG TTT GAG ACC TTC AAC ACC CCA GCC ATG TAC GTT GCT
136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152
ATC CAG GCT GTG CTA TCC CTG TAC GCC TCT GGC CGT ACC ACT GGC ATC GTG
153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169
ATG GAC TCC GGT GAC GGG GTC ACC CAC ACT GTG CCC ATC TAC GAG GGG TAT
170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186
GCC CTC CCC CAT GCC ATC CTG CGT CTG GAC CTG GCT GGC CGG GAC CTG ACT
187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203
GAC TAC CTC ATG AAG ATC CTC ACC GAG CGC GGC TAC AGC TTC ACC ACC ACG
204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220
GCC GAG CGG GAA ATC GTG CGT GAC ATT AAG GAG AAG CTG TGC TAC GTC GCC
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221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237
CTG GAC TTC GAG CAA GAG ATG GCC ACG GCT GCT TCC AGC TCC TCC CTG GAG
238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254
AAG AGC TAC GAG CTG CCT GAC GGC CAG GTC ATC ACC ATT GGC AAT GAG CGG
255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271
TTC CGC TGC CCT GAG GCA CTC TTC CAG CCT TCC TTC CTG GGC ATG GAG TCC
272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288
TGT GGC ATC CAC GAA ACT ACC TTC AAC TCC ATC ATG AAG TGT GAC GTG GAC
289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305
ATC CGC AAA GAC CTG TAC GCC AAC ACA GTG CTG TCT GGC GGC ACC ACC ATG
306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322
TAC CCT GGC ATT GCC GAC AGG ATG CAG AAG GAG ATC ACT GCC CTG GCA CCC
323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339
AGC ACA ATG AAG ATC AAG ATC ATT GCT CCT CCT GAG CGC AAG TAC TCC GTG
340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356
TGG ATC GGC GGC TCC ATC CTG GCC TCG CTG TCC ACC TTC CAG CAG ATG TGG
357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373
ATC AGC AAG CAG GAG TAT GAC GAG TCC GGC CCC TCC ATC GTC CAC CGC AAA
374 375
TGC TTC TAG –3’
IV.3.5 Tubulin
Human alpha-tubulin [21,22] to be fused at C-terminus:
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16
5’- GTG CGT GAG TGC ATC TCC ATC CAC GTT GGC CAG GCT GGT GTC CAG ATT
17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33
GGC AAT GCC TGC TGG GAG CTC TAC TGC CTG GAA CAC GGC ATC CAG CCC GAT
34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50
GGC CAG ATG CCA AGT GAC AAG ACC ATT GGG GGA GGA GAT GAC TCC TTC AAC
51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67
ACC TTC TTC AGT GAG ACG GGC GCT GGC AAG CAC GTG CCC CGG GCT GTG TTT
68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84
GTA GAC TTG GAA CCC ACA GTC ATT GAT GAA GTT CGC ACT GGC ACC TAC CGC
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85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100 101
CAG CTC TTC CAC CCT GAG CAG CTC ATC ACA GGC AAG GAA GAT GCT GCC AAT
102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
AAC TAT GCC CGA GGG CAC TAC ACC ATT GGC AAG GAG ATC ATT GAC CTT GTG
119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
TTG GAC CGA ATT CGC AAG CTG GCT GAC CAG TGC ACC GGT CTT CAG GGC TTC
136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152
TTG GTT TTC CAC AGC TTT GGT GGG GGA ACT GGT TCT GGG TTC ACC TCC CTG
153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169
CTC ATG GAA CGT CTC TCA GTT GAT TAT GGC AAG AAG TCC AAG CTG GAG TTC
170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186
TCC ATT TAC CCA GCA CCC CAG GTT TCC ACA GCT GTA GTT GAG CCC TAC AAC
187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203
TCC ATC CTC ACC ACC CAC ACC ACC CTG GAG CAC TCT GAT TGT GCC TTC ATG
204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220
GTA GAC AAT GAG GCC ATC TAT GAC ATC TGT CGT AGA AAC CTC GAT ATC GAG
221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237
CGC CCA ACC TAC ACT AAC CTT AAC CGC CTT ATT AGC CAG ATT GTG TCC TCC
238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254
ATC ACT GCT TCC CTG AGA TTT GAT GGA GCC CTG AAT GTT GAC CTG ACA GAA
255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271
TTC CAG ACC AAC CTG GTG CCC TAC CCC CGC ATC CAC TTC CCT CTG GCC ACA
272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288
TAT GCC CCT GTC ATC TCT GCT GAG AAA GCC TAC CAT GAA CAG CTT TCT GTA
289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305
GCA GAG ATC ACC AAT GCT TGC TTT GAG CCA GCC AAC CAG ATG GTG AAA TGT
306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322
GAC CCT CGC CAT GGT AAA TAC ATG GCT TGC TGC CTG TTG TAC CGT GGT GAC
323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339
GTG GTT CCC AAA GAT GTC AAT GCT GCC ATT GCC ACC ATC AAA ACC AAG CGC
340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356
AGC ATC CAG TTT GTG GAT TGG TGC CCC ACT GGC TTC AAG GTT GGC ATC AAC
357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373
TAC CAG CCT CCC ACT GTG GTG CCT GGT GGA GAC CTG GCC AAG GTA CAG AGA
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374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
GCT GTG TGC ATG CTG AGC AAC ACC ACA GCC ATT GCT GAG GCC TGG GCT CGC
391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407
CTG GAC CAC AAG TTT GAC CTG ATG TAT GCC AAG CGT GCC TTT GTT CAC TGG
408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424
TAC GTG GGT GAG GGG ATG GAG GAA GGC GAG TTT TCA GAG GCC CGT GAA GAT
425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441
ATG GCT GCC CTT GAG AAG GAT TAT GAG GAG GTT GGT GTG GAT TCT GTT GAA
442 443 444 445 446 447 448 449 450 451
GGA GAG GGT GAG GAA GAA GGA GAG GAA TAC TAA –3’
IV.3.6 Endosomes
Human rhoB GTPase [23] to be fused at C-terminus:
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16
5’- CGG AAG AAA CTG GTG GTT GTT GGT GAT GGA GCC TGT GGA AAG ACA TGC
17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33
TTG CTC ATA GTC TTC AGC AAG GAC GAG TTC CCA GAG GTG TAT GTG CCC ACA
34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50
GTG TTT GAG AAC TAT GTG GCA GAT ATC GAG GTG GAT GGA AAG CAG GTA GAG
51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67
TTG GCT TTG TGG GAC ACA GCT GGC CAG GAG GAC TAC GAC CGC CTG CGG CCG
68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84
CTC TCC TAC CCG GAC ACC GAC GTC ATT CTC ATG TGC TTC TCG GTG GAC AGC
85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100 101
CCG GAC TCG CTG GAG AAC ATC CCC GAG AAG TGG GTC CCC GAG GTG AAG CAC
102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
TTC TGT CCC AAT GTG CCC ATC ATC CTG GTG GCC AAC AAA AAA GAC CTG CGC
119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
AGC GAC GAG CAT GTC CGC ACA GAG CTG GCC CGC ATG AAG CAG GAA CCC GTT
136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152
CGC ACG GAT GAC GGC CGC GCC ATG GCC GTG CGC ATC CAA GCC TAC GAC TAC
153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168
CTC GAG TGC TCT GCC AAG ACC AAG GAA GGC GTG CGC GAG GTC TTC GAG –3’
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